Back to EveryPatent.com
| United States Patent |
5,288,726
|
|
Koike
, et al.
|
February 22, 1994
|
Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof
and their preparation and uses for inhibiting blood platelet aggregation
Abstract
Compounds of formula (I):
##STR1##
wherein: R.sup.1 is hydrogen, alkyl, halogen, haloalkyl, hydroxy, alkoxy,
haloalkoxy, alkylthio, haloalkylthio, amino, alkanoyl, haloalkanoyl,
carboxy, alkoxycarbonyl, carbamoyl, cyano, nitro, alkanesulfonyl,
haloalkanesulfonyl or sulfamoyl; R.sup.2 is optionally substituted
alkanoyl, optionally substituted alkenoyl, optionally substituted
cycloalkylcarbonyl, substituted benzoyl, or
5,6-dihydro-1,4,2-dioxazin-3-yl; R.sup.3 is hydrogen, hydroxy, optionally
substituted alkoxy, aralkyloxy, alkanoyloxy, alkenoyloxy,
cycloalkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy,
aralkyloxycarbonylxy, phthalidyloxy,
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy,
(5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy, optionally substituted amino or
nitro; Y is --NH-- or oxygen or sulfur; n is 1 to 5; and tautomers and
salts of said compounds of formula (I), have the ability to inhibit blood
platelet aggregation, and can thus be used for treatment and prophylaxis
of thrombosis and embolisms.
| Inventors:
|
Koike; Hiroyuki (Tokyo, JP);
Asai; Fumitoshi (Tokyo, JP);
Sugidachi; Atsuhiro (Tokyo, JP);
Kimura; Tomio (Ube, JP);
Inoue; Teruhiko (Ube, JP);
Nishino; Shigeyoshi (Ube, JP);
Tsuzaki; Yasunori (Ube, JP)
|
| Assignee:
|
Ube Industries Limited (Ube, JP);
Sankyo Company, Limited (Tokyo, JP)
|
| Appl. No.:
|
941676 |
| Filed:
|
September 8, 1992 |
Foreign Application Priority Data
| Sep 09, 1991[JP] | 3-227875 |
| May 29, 1992[JP] | 4-138529 |
| Current U.S. Class: |
514/301; 546/114 |
| Intern'l Class: |
A01K 003/14; C07D 513/04 |
| Field of Search: |
546/114,116
514/301,302
|
References Cited
U.S. Patent Documents
| 4051141 | Sep., 1977 | Castaigne | 260/294.
|
| 4075215 | Feb., 1978 | Castaigne | 260/294.
|
| 4127580 | Nov., 1978 | Braye | 546/114.
|
| 4136186 | Jan., 1979 | Frehel et al. | 546/114.
|
| 4458074 | Jul., 1984 | Bouscuet et al. | 546/114.
|
| 4464377 | Aug., 1984 | Blanchard et al. | 424/256.
|
| 4529596 | Jul., 1985 | Aubert et al. | 514/231.
|
| 4740510 | Apr., 1988 | Badorc et al. | 514/291.
|
| Foreign Patent Documents |
| 421861 | Apr., 1991 | EP | 546/114.
|
Primary Examiner: Rotman; Alan L.
Assistant Examiner: Spivack; Phyllis G.
Attorney, Agent or Firm: Frishauf, Holtz, Goodman & Woodward
Claims
We claim:
1. A compound of formula (I):
##STR11##
wherein R.sup.1 represents a hydrogen atom, an alkyl group having from 1
to 4 carbon atoms, a halogen atom, a haloalkyl group having from 1 to 4
carbon atoms and at least one halogen atom, a hydroxy group, an alkoxy
group having from 1 to 4 carbon atoms, a haloalkoxy group having from 1 to
4 carbon atoms and at least one halogen atom, an alkylthio group having
from 1 to 4 carbon atoms, a haloalkylthio group having from 1 to 4 carbon
atoms and at least one halogen atom, an amino group, an alkanoyl group
having from 1 to 5 carbon atoms, a haloalkanoyl group having from 2 to 5
carbon atoms and at least one halogen atom, a carboxy group, an
alkoxycarbonyl group having from 2 to 5 carbon atoms, a carbamoyl group, a
cyano group, a nitro group, an alkanesulfonyl group having from 1 to 4
carbon atoms, a haloalkanesulfonyl group having from 1 to 4 carbon atoms
and at least one halogen atom, or a sulfamoyl group;
R.sup.2 represents an alkanoyl group having from 1 to 10 carbon atoms; a
substituted alkanoyl group which has from 2 to 10 carbon atoms and which
is substituted by at least one substituent selected from the group
consisting of substituents A, defined below; an alkenoyl group having from
3 to 6 carbon atoms; a substituted alkenoyl group which has from 3 to 6
carbon atoms and which is substituted by at least one substituent selected
from the group consisting of substituents A, defined below; a
cycloalkylcarbonyl group having from 4 to 8 carbon atoms; a substituted
cycloalkylcarbonyl group which has from 4 to 8 carbon atoms and which is
substituted by at least one substituent selected from the group consisting
of substituents A, defined below; or a substituted benzoyl group having at
least one substituent selected from the group consisting of substituents
B, defined below;
R.sup.3 represents a hydrogen atom; a hydroxy group; an alkoxy group having
from 1 to 4 carbon atoms; a substituted alkoxy group which has from 1 to 4
carbon atoms and which is substituted by at least one substituent selected
from the group consisting of substituents C, defined below; an aralkyloxy
group in which the aralkyl part is as defined below; an alkanoyloxy group
having from 1 to 18 carbon atoms; an alkenoyloxy group having from 3 to 6
carbon atoms; a cycloalkylcarbonyloxy group having from 4 to 8 carbon
atoms; an arylcarbonyloxy group in which the aryl part is as defined
below; an alkoxycarbonyloxy group having from 2 to 5 carbon atoms; an
aralkyloxycarbonyloxy group in which the aralkyl part is as defined below;
a phthalidyloxy group; a (5-methyl-2-oxo-1,3-dioxolen-4yl)methoxy group; a
(5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy group; a group of formula
--NR.sup.a R.sup.b : wherein R.sup.a and R.sup.b are independently
selected from the group consisting of hydrogen atoms, alkyl groups having
from 1 to 4 carbon atoms and substituted alkyl groups which have from 1 to
4 carbon atoms and which are substituted by at least one substituent
selected from the group consisting of substituents C, defined below; an
aralkylamino group in which the aralkyl part is as defined below; an
alkanoylamino group having from 1 to 18 carbon atoms; an alkenoylamino
group having from 3 to 6 carbon atoms; a cycloalkylcarbonylamino group
having from 4 to 8 carbon atoms: an arylcarbonylamino group in which the
aryl part is as defined below; an alkoxycarbonylamino group having from 2
to 5 carbon atoms; an aralkyloxycarbonylamino group in which the aralkyl
part is as defined below; a phthalidylamino group; a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methylamino group; a
(5-phenyl-2-oxo-1,3-dioxolen-4-yl)methylamino group, or a nitro group;
Y is a sulfur atom; and
n is an integer from 1 to 5, and, when n is an integer from 2 to 5, the
groups represented by R.sup.1 may be the same as or different from each
other;
said substituents A are selected from the group consisting of halogen
atoms, hydroxy groups, alkoxy groups having from 1 to 4 carbon atoms and
cyano groups;
said substituents B are selected from the group consisting of alkyl groups
having from 1 to 4 carbon atoms, halogen atoms and alkoxy groups having
from 1 to 4 carbon atoms;
said substituents C are selected from the group consisting of alkoxy groups
having from 1 to 4 carbon atoms, alkanoyloxy groups having from 1 to 6
carbon atoms and arylcarbonyloxy groups in which the aryl part is as
defined below;
said aralkyl parts of said aralkyloxy, aralkyloxycarbonyloxy, aralkylamino
and aralkyloxycarbonylamino groups are alkyl groups which have from 1 to 4
carbon atoms and which are substituted by at least one aryl groups as
defined below;
said aryl groups and said aryl parts of said arylcarbonyloxy groups and of
said arylcarbonylamino groups having from 6 to 10 carbon atoms in a
carbocyclic ring which is unsubstituted or is substituted by at least one
substituent selected from the group consisting of substituents D, defined
below; and
said substituents D are selected from the group consisting of the groups
and atoms defined above in relation to R.sup.1, other than said hydrogen
atom;
or a tautomer thereof, or a pharmaceutically acceptable salt of said
compound of formula (I) and of said tautomer.
2. The compound of claim 1, wherein said tautomer has the formula (Ia) or
(Ib):
##STR12##
wherein R.sup.1, R.sup.2, Y and n are as defined above and Z represents
group of formula .dbd.NH or an oxygen atom.
3. The compound of claim 1, wherein R.sup.1 represents a hydrogen atom, an
alkyl group having from 1 to 4 carbon atoms, a halogen atom, a fluoroalkyl
group having from 1 to 4 carbon atoms and at least one fluorine atom, a
hydroxy group, an alkoxy group having from 1 to 4 carbon atoms, a
fluoroalkoxy group having from 1 to 4 carbon atoms and at least one
fluorine atom, an alkylthio group having from 1 to 4 carbon atoms, a
fluoroalkylthio group having from 1 to 4 carbon atoms and at least one
fluorine atom, an amino group, an alkanoyl group having from 1 to 5 carbon
atoms, a fluoroalkanoyl group having from 2 to 5 carbon atoms and at least
one fluorine atom, an alkoxycarbonyl group having from 2 to 5 carbon
atoms, a carbamoyl group, a cyano group, a nitro group, an alkanesulfonyl
group having from 1 to 4 carbon atoms, a fluoroalkanesulfonyl group having
from 1 to 4 carbon atoms and at least one fluorine atom, or a sulfamoyl
group.
4. The compound of claim 1, wherein R.sup.2 represents an alkanoyl group
having from 2 to 6 carbon atoms, a substituted alkanoyl group which has
from 2 to 6 carbon atoms and which is substituted by at least one
substituent selected from the group consisting of substituents A', defined
below, a cycloalkylcarbonyl group having from 4 to 7 carbon atoms, a
substituted cycloalkylcarbonyl group which has from 4 to 7 carbon atoms
and which is substituted by at least one substituent selected from the
group consisting of substituents A', defined below of a substituted
benzoyl group having at least one fluorine substituent; and
said substituents A' are selected from the group consisting of fluorine
atoms, chlorine atoms, hydroxy groups, methoxy groups, ethoxy groups and
cyano groups.
5. The compound of claim 1, wherein:
R.sup.3 represents a hydrogen atom, a hydroxy group, an alkoxy group having
from 1 to 4 carbon atoms, an alkoxymethoxy group in which the alkoxy part
has from 1 to 4 carbon atoms, an alkanoyloxymethoxy group in which the
alkanoyl part has from 1 to 5 carbon atoms, a benzyloxy group which is
unsubstituted or is substituted by at least one substituent selected from
the group consisting of substituents D', defined below, an alkanoyloxy
group having from 1 to 18 carbon atoms, an alkenoyloxy group having 3 or 4
carbon atoms, a cycloalkylcarbonyloxy group having from 4 to 7 carbon
atoms, a benzoyloxy group which is unsubstituted or is substituted by at
least one substituent selected from the group consisting of substituents
D', defined below, an alkoxycarbonyloxy group having from 2 to 5 carbon
atoms, a benzyloxy. carbonyloxy group which is unsubstituted or is
substituted by at least one substituent selected from the group consisting
of substituents D', defined below, a phthalidyloxy group, a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a
(5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a group of formula
--NR.sup.a R.sup.b
wherein R.sup.a and R.sup.b are independently selected from the group
consisting of hydrogen atoms, methyl and ethyl groups or R.sup.a
represents a hydrogen atom and R.sup.b represents an alkanoyloxymethyl
group in which the alkanoyl part has from 1 to 5 carbon atoms,
a benzylamino group, an alkanoylamino group having from 1 to 18 carbon
atoms, an alkenoylamino group having 3 or 4 carbon atoms, a
cycloalkylcarbonylamino group having 6 or 7 carbon atoms, a benzoylamino
group which is unsubstituted or is substituted by at least one substituent
selected from the group consisting of substituents D', defined below, an
alkoxycarbonylamino group having from 2 to 5 carbon atoms or a
benzyloxycarbonylamino group which is unsubstituted or is substituted by
at least one substituent selected from the group consisting of
substituents D', defined below; and
said substituents D' are selected from the group consisting of fluorine
atoms, chlorine atoms, methyl groups and methoxy groups.
6. The compound of claim 1, wherein:
R.sup.1 represents a hydrogen atom, an alkyl group having from I to 4
carbon atoms, a halogen atom, a fluoroalkyl group having from 1 to 4
carbon atoms and at least one fluorine atom, a hydroxy group, an alkoxy
group having from 1 to 4 carbon atoms, a fluoroalkoxy group having from 1
to 4 carbon atoms and at least one fluorine atom, an alkylthio group
having from 1 to 4 carbon atoms, a fluoroalkylthio group having from 1 to
4 carbon atoms and at least one fluorine atom, an amino group, an alkanoyl
group having from 1 to 5 carbon atoms, a fluoroalkanoyl group having from
2 to 5 carbon atoms and at least one fluorine atom, an alkoxycarbonyl
group having from 2 to 5 carbon atoms, a carbamoyl group, a cyano group, a
nitro group, an alkanesulfonyl group having from 1 to 4 carbon atoms, a
fluoroalkanesulfonyl group having from 1 to 4 carbon atoms and at least
one fluorine atom, or a sulfamoyl group;
R.sup.2 represents an alkanoyl group having from 2 to 6 carbon atoms, a
substituted alkanoyl group which has from 2 to 6 carbon atoms and which is
substituted by at least one substituent selected from the group consisting
of substituents A', defined below, a cycloalkylcarbonyl group having from
4 to 7 carbon atoms, a substituted cycloalkylcarbonyl group which has from
4 to 7 carbon atoms and which is substituted by at least one substituent
selected from the group consisting of substituents A', defined below or a
substituted benzoyl group having at least one fluorine substituent;
R.sup.3 represents a hydrogen atom, a hydroxy group, an alkoxy group having
from 1 to 4 carbon atoms, an alkoxymethoxy group in which the alkoxy part
has from 1 to 4 carbon atoms, an alkanoyloxymethoxy group in which the
alkanoyl part has from 1 to 5 carbon atoms, a benzyloxy group which is
unsubstituted or is substituted by at least one substituent selected from
the group consisting of substituents D', defined below, an alkanoyloxy
group having from 1 to 18 carbon atoms, an alkenoyloxy group having 3 or 4
carbon atoms, a cycloalkylcarbonyloxy group having from 4 to 7 carbon
atoms, a benzoyloxy group which is unsubstituted or is substituted by at
least one substituent selected from the group consisting of substituents
D', defined below, an alkoxycarbonyloxy group having from 2 to 5 carbon
atoms, a benzyloxycarbonyloxy group which is unsubstituted or is
substituted by at least one substituent selected from the group consisting
of substituents D', defined below, a phthalidyloxy group, a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a
(5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a group of formula
--NR.sup.a R.sup.b
wherein R.sup.a and R.sup.b are independently selected from the group
consisting of hydrogen atoms, methyl groups and ethyl groups or R.sup.a
represents a hydrogen atom and R.sup.b represents an alkanoyloxymethyl
group in which the alkanoyl part has from 1 to 5 carbon atoms,
a benzylamino group, an alkanoylamino group having from 1 to 18 carbon
atoms, an alkenoylamino group having 3 or 4 carbon atoms, a
cycloalkylcarbonylamino group having 6 or 7 carbon atoms, a benzoylamino
group which is unsubstituted or is substituted by at least one substituent
selected from the group consisting of substituents D', defined below, an
alkoxycarbonylamino group having from 2 to 5 carbon atoms or a
benzyloxycarbonylamino group which is unsubstituted or is substituted by
at least one substituent selected from the group consisting of
substituents D', defined below;
said substituents A' are selected from the group consisting of fluorine
atoms, chlorine atoms, hydroxy groups, methoxy groups, ethoxy groups and
cyano groups; and
said substituents D' are selected from the group consisting of fluorine
atoms, chlorine atoms, methyl groups and methoxy groups.
7. The compound of claim 6, wherein n is from 1 to 3.
8. The compound of claim 6, wherein n is 1.
9. The compound of claim 1, wherein R.sup.1 represents a hydrogen atom, a
methyl group, an ethyl group, a halogen atom, a methyl group substituted
by at least one fluorine atom, a hydroxy group, a methoxy group, an ethoxy
group, a methoxy group substituted by at least one fluorine atom, a
methylthio group, a methylthio group substituted by at least one fluorine
atom, a formyl group, an acetyl group, an acetyl group substituted by at
least one fluorine atom, an alkoxycarbonyl group having from 2 to 4 carbon
atoms, a carbamoyl group, a cyano group, a nitro group, a methanesulfonyl
group, an ethanesulfonyl group, a methanesulfonyl group substituted by at
least one fluorine atom, or a sulfamoyl group.
10. The compound of claim 1, wherein R.sup.2 represents an alkanoyl group
having from 2 to 6 carbon atoms, a substituted alkanoyl group which has
from 2 to 6 carbon atoms and which is substituted by at least one fluorine
atom, a cycloalkylcarbonyl group having from 4 to 7 carbon atoms, or a
substituted cycloalkylcarbonyl group which is substituted by at least one
fluorine atom.
11. The compound of claim 1, wherein R.sup.3 represents a hydrogen atom, a
hydroxy group, a methoxy group, an ethoxy group, a t-butoxy group, a
methoxymethoxy group, an alkanoyloxymethoxy group in which the alkanoyl
part has from 1 to 5 carbon atoms, a benzyloxy group, an alkanoyloxy group
having from 1 to 12 carbon atoms, an alkenoyloxy group having 3 or 4
carbon atoms, a cycloalkylcarbonyloxy group having from 4 to 7 carbon
atoms, a benzoyloxy group, an alkoxycarbonyloxy group having from 2 to 5
carbon atoms, a benzyloxycarbonyloxy group, a phthalidyloxy group, a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a
(5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, an amino group or a
t-butoxycarbonylamino group.
12. The compound of claim 1, wherein:
R.sup.1 represents a hydrogen atom, a methyl group, an ethyl group, a
halogen atom, a methyl group substituted by at least one fluorine atom, a
hydroxy group, a methoxy group, an ethoxy group, a methoxy group
substituted by at least one fluorine atom, a methylthio group, a
methylthio group substituted by at least one fluorine atom, a formyl
group, an acetyl group, an acetyl group substituted by at least one
fluorine atom, an alkoxycarbonyl group having from 2 to 4 carbon atoms, a
carbamoyl group, a cyano group, a nitro group, a methanesulfonyl group, an
ethanesulfonyl group, a methanesulfonyl group substituted by at least one
fluorine atom, or a sulfamoyl group;
R.sup.2 represents an alkanoyl group having from 2 to 6 carbon atoms, a
substituted alkanoyl group which has from 2 to 6 carbon atoms and which is
substituted by at least one fluorine atom, a cycloalkylcarbonyl group
having from 4 to 7 carbon atoms, or a substituted cycloalkylcarbonyl group
which is substituted by at least one fluorine atom; and
R.sup.3 represents a hydrogen atom, a hydroxy group, a methoxy group, an
ethoxy group, a t-butoxy group, a methoxymethoxy group, an
alkanoyloxymethoxy group in which the alkanoyl part has from 1 to 5 carbon
atoms, a benzyloxy group, an alkanoyloxy group having from 1 to 12 carbon
atoms, an alkenoyloxy group having 3 or 4 carbon atoms, a
cycloalkylcarbonyloxy group having from 4 to 7 carbon atoms, a benzoyloxy
group, an alkoxycarbonyloxy group having from 2 to 5 carbon atoms, a
benzyloxycarbonyloxy group, a phthalidyloxy group, a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a
(5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, an amino group or a
t-butoxycarbonylamino group.
13. The compound of claim 12, wherein n is from 1 to 3.
14. The compound of claim 12, wherein n is 1.
15. The compound of claim 1, wherein R.sup.1 represents a halogen atom, a
trifluoromethyl group, a hydroxy group, a difluoromethoxy group, a
trifluoromethoxy group, a difluoromethylthio group, a trifluoromethylthio
group, a formyl group, an acetyl group, a trifluoroacetyl group, a cyano
group or a nitro group.
16. The compound of claim 1, wherein R.sup.3 represents a hydrogen atom, a
hydroxy group, a pivaloyloxymethoxy group, an alkanoyloxy group having
from 2 to 10 carbon atoms, an alkoxycarbonyloxy group having from 2 to 5
carbon atoms or a (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group.
17. The compound of claim 1, wherein:
R.sup.1 represents a halogen atom, a trifluoromethyl group, a hydroxy
group, a difluoromethoxy group, a trifluoromethoxy group, a
difluoromethylthio group, a trifluoromethylthio group, a formyl group, an
acetyl group, a trifluoroacetyl group, a cyano group or a nitro group;
R.sup.2 represents an alkanoyl group having from 2 to 6 carbon atoms, a
substituted alkanoyl group which has from 2 to 6 carbon atoms and which is
substituted by at least one fluorine atom, a cycloalkylcarbonyl group
having from 4 to 7 carbon atoms, or a substituted cycloalkylcarbonyl group
which is substituted by at least one fluorine atom; and
R.sup.3 represents a hydrogen atom, a hydroxy group, a pivaloyloxymethoxy
group, an alkanoyloxy group having from 2 to 10 carbon atoms, an
alkoxycarbonyloxy group having from 2 to 5 carbon atoms or a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group.
18. The compound of claim 17, wherein n is from 1 to 3.
19. The compound of claim 17, wherein n is 1.
20. The compound of claim 1, wherein R.sup.2 represents an acetyl group, a
propionyl group, a substituted acetyl or propionyl group which is
substituted by at least one fluorine atom, a cyclopropylcarbonyl group,
cyclobutylcarbonyl group, or a substituted cyclopropylcarbonyl or
cyclobutylcarbonyl group which is substituted by at least one fluorine
atom.
21. The compound of claim 1, wherein R.sup.3 represents a hydrogen atom, a
hydroxy group, a pivaloyloxymethoxy group, an alkanoyloxy group having
from 2 to 6 carbon atoms or an alkoxycarbonyloxy group having from 2 to 5
carbon atoms.
22. The compound of claim 1, wherein:
R.sup.1 represents a fluorine or chlorine atom;
R.sup.2 represents an acetyl group, a propionyl group, a substituted acetyl
or propionyl group which is substituted by at least one fluorine atom, a
cyclopropylcarbonyl group, cyclobutylcarbonyl group, or a substituted
cyclopropylcarbonyl or cyclobutylcarbonyl group which is substituted by at
least one fluorine atom; and
R.sup.3 represents a hydrogen atom, a hydroxy group, a pivaloyloxymethoxy
group, an alkanoyloxy group having from 2 to 6 carbon atoms or an
alkoxycarbonyloxy group having from 2 to 5 carbon atoms.
23. The compound of claim 22, wherein n is from 1 to 3.
24. The compound of claim 22, wherein n is 1.
25. The compound of claim 1, selected from the group consisting of
5-(2-fluoro-.alpha.-propionylbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridi
ne and pharmaceutically acceptable salts thereof.
26. The compound of claim 1, selected from the group consisting of
5-(.alpha.-cyclopropylcarbonyl-2-fluoro-benzyl)-4,5,6,7-tetrahydrothieno[3
,2-c]pyridine and pharmaceutically acceptable salts thereof.
27. The compound of claim 1, selected from the group consisting of
5-(2-chloro-.alpha.-cyclopropylcarbonylbenzyl)-4,5,6,7-tetrahydrothieno[3,
2-c]pyridine and pharmaceutically acceptable salts thereof.
28. The compound of claim 1, selected from the group consisting of
2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydr
othieno[3,2-c]pyridine and pharmaceutically acceptable salts thereof.
29. The compound of claim 1, selected from the group consisting of
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-propionyloxy-4,5,6,7-tetr
ahydrothieno[3,2-c]pyridine and pharmaceutically acceptable salts thereof.
30. The compound of claim 1, selected from the group consisting of
2-butyryloxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrah
ydrothieno[3,2-c]pyridine and pharmaceutically acceptable salts thereof.
31. The compound of claim 1, selected from the group consisting of
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-pivaloyloxy-4,5,6,7-tetra
hydrothieno[3,2-c]pyridine and pharmaceutically acceptable salts thereof.
32. The compound of claim 1, selected from the group consisting of
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-valeryloxy-4,5,6,7-tetrah
ydrothieno[3,2-c]pyridine and pharmaceutically acceptable salts thereof.
33. The compound of claim 1, selected from the group consisting of
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-hexanoyloxy-4,5,6,7-tetra
hydrothieno[3,2-c]pyridine and pharmaceutically acceptable salts thereof.
34. The compound of claim 1, selected from the group consisting of
2-t-butoxycarbonyloxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6
,7-tetrahydrothieno[3,2-c]pyridine and pharmaceutically acceptable salts
thereof.
35. The compound of claim 1, selected from the group consisting of
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-pivaloyloxymethoxy-4,5,6,
7-tetrahydrothieno-[3,2-c]pyridine and pharmaceutically acceptable salts
thereof.
36. The compound of claim 1, selected from the group consisting of
5-(2-chloro-.alpha.-cyclopropylcarbonylbenzyl)-2-oxo-2,4,5,6,7,7a-hexahydr
othieno[3,2-c]pyridine and its tautomer and pharmaceutically acceptable
salts thereof.
37. The compound of claim 1, selected from the group consisting of
5-(2-fluoro-.alpha.-propionylbenzyl)-2-oxo-2,4,5,6,7,7a-hexahydrothieno[3,
2-c]pyridine and its tautomer and pharmaceutically acceptable salts
thereof.
38. The compound of claim 1, selected from the group consisting of
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7a-hexahydr
othieno[3,2-c]pyridine and its tautomer and pharmaceutically acceptable
salts thereof.
39. The compound of claim 1, selected from the group consisting of
2-acetoxy-5-(2-chloro-.alpha.-cyclopropylcarbonylbenzyl)-4,5,6,7-tetrahydr
othieno[3,2-c]pyridine and pharmaceutically acceptable salts thereof.
40. The compound of claim 1, selected from the group consisting of
5-[.alpha.-(2-fluorocyclopropylcarbonyl-2-fluorobenzyl]-2-oxo-2,4,5,6,7,7a
-hexahydrothieno[3,2-c]pyridine and its tautomer and pharmaceutically
acceptable salts thereof.
41. The compound of claim 1, selected from the group consisting of
2-acetoxy-5-[.alpha.-(2-fluorocyclopropylcarbonyl-2-fluorobenzyl]-4,5,6,7-
tetrahydrothieno[3,2-c]pyridine and pharmaceutically acceptable salts
thereof.
42. A pharmaceutical composition for the treatment and prophylaxis of
thrombosis o embolisms, comprising an effective amount of a blood platelet
aggregation inhibitor in admixture with a pharmaceutically acceptable
carrier or diluent, wherein said inhibitor is at least one compound of
formula (I), or a tautomer or pharmaceutically acceptable salt thereof, as
claimed in claim 1.
43. The composition of claim 42, wherein:
R.sup.1 represents a hydrogen atom, an alkyl group having from 1 to 4
carbon atoms, a halogen atom, a fluoroalkyl group having from 1 to 4
carbon atoms and at least one fluorine atom, a hydroxy group, an alkoxy
group having from 1 to 4 carbon atoms, a fluoroalkoxy group having from 1
to 4 carbon atoms and at least one fluorine atom, an alkylthio group
having from 1 to 4 carbon atoms, a fluoroalkylthio group having from 1 to
4 carbon atoms and at least one fluorine atom, an amino group, an alkanoyl
group having from 1 to 5 carbon atoms, a fluoroalkanoyl group having from
2 to 5 carbon atoms and at least one fluorine atom, an alkoxycarbonyl
group having from 2 to 5 carbon atoms, a carbamoyl group, a cyano group, a
nitro group, an alkanesulfonyl group having from 1 to 4 carbon atoms, a
fluoroalkanesulfonyl group having from 1 to 4 carbon atoms and at least
one fluorine atom, or a sulfamoyl group;
R.sup.2 represents an alkanoyl group having from 2 to 6 carbon atoms, a
substituted alkanoyl group which has from 2 to 6 carbon atoms and which is
substituted by at least one substituent selected from the group consisting
of substituents A', defined below, a cycloalkylcarbonyl group having from
4 to 7 carbon atoms, a substituted cycloalkylcarbonyl group which has from
4 to 7 carbon atoms and which is substituted by at least one substituent
selected from the group consisting of substituents A', defined below, or a
substituted benzoyl group having at least one fluorine substituent, or a;
R.sup.3 represents a hydrogen atom, a hydroxy group, an alkoxy group having
from 1 to 4 carbon atoms, an alkoxymethoxy group in which the alkoxy part
has from 1 to 4 carbon atoms, an alkanoyloxymethoxy group in which the
alkanoyl part has from 1 to 5 carbon atoms, a benzyloxy group which is
unsubstituted or is substituted by at least one substituent selected from
the group consisting of substituents D', defined below, an alkanoyloxy
group having from 1 to 18 carbon atoms, an alkenoyloxy group having 3 or 4
carbon atoms, a cycloalkylcarbonyloxy group having from 4 to 7 carbon
atoms, a benzoyloxy group which is unsubstituted or is substituted by at
least one substituent selected from the group consisting of substituents
D', defined below, an alkoxycarbonyloxy group having from 2 to 5 carbon
atoms, a benzyloxycarbonyloxy group which is unsubstituted or is
substituted by at least one substituent selected from the group consisting
of substituents D', defined below, a phthalidyloxy group, a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a
(5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a group of formula
--NR.sup.a R.sup.b
wherein R.sup.a and R.sup.b are independently selected from the group
consisting of hydrogen atoms, methyl groups and ethyl groups or R.sup.a
represents a hydrogen atom and R.sup.b represents an alkanoyloxymethyl
group in which the alkanoyl part has from 1 to 5 carbon atoms,
a benzylamino group, an alkanoylamino group having from 1 to 18 carbon
atoms, an alkenoylamino group having 3 or 4 carbon atoms, a
cycloalkylcarbonylamino group having 6 or 7 carbon atoms, a benzoylamino
group which is unsubstituted or is substituted by at least one substituent
selected from the group consisting of substituents D', defined below, an
alkoxycarbonylamino group having from 2 to 5 carbon atoms or a
benzyloxycarbonylamino group which is unsubstituted or is substituted by
at least one substituent selected from the group consisting of
substituents D', defined below;
said substituents A' are selected from the group consisting of fluorine
atoms, chlorine atoms, hydroxy groups, methoxy groups, ethoxy groups and
cyano groups; and
said substituents D' are selected from the group consisting of fluorine
atoms, chlorine atoms, methyl groups and methoxy groups.
44. The composition of claim 42, wherein:
R.sup.1 represents a hydrogen atom, a methyl group, an ethyl group, a
halogen atom, a methyl group substituted by at least one fluorine atom, a
hydroxy group, a methoxy group, an ethoxy group, a methoxy group
substituted by at least one fluorine atom, a methylthio group, a
methylthio group substituted by at least one fluorine atom, a formyl
group, an acetyl group, an acetyl group substituted by at least one
fluorine atom, an alkoxycarbonyl group having from 2 to 4 carbon atoms, a
carbamoyl group, a cyano group, a nitro group, a methanesulfonyl group, an
ethanesulfonyl group, a methanesulfonyl group substituted by at least one
fluorine atom, or a sulfamoyl group;
R.sup.2 represents an alkanoyl group having from 2 to 6 carbon atoms, a
substituted alkanoyl group which has from 2 to 6 carbon atoms and which is
substituted by at least one fluorine atom, a cycloalkylcarbonyl group
having from 4 to 7 carbon atoms, or a substituted cycloalkylcarbonyl group
which is substituted by at least one fluorine atom; and
R.sup.3 represents a hydrogen atom, a hydroxy group, a methoxy group, an
ethoxy group, a t-butoxy group, a methoxymethoxy group, an
alkanoyloxymethoxy group in which the alkanoyl part has from 1 to 5 carbon
atoms, a benzyloxy group, an alkanoyloxy group having from 1 to 12 carbon
atoms, an alkenoyloxy group having 3 or 4 carbon atoms, a
cycloalkylcarbonyloxy group having from 4 to 7 carbon atoms, a benzoyloxy
group, an alkoxycarbonyloxy group having from 2 to 5 carbon atoms, a
benzyloxycarbonyloxy group, a phthalidyloxy group, a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a
(5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, an amino group or a
t-butoxycarbonylamino group,
Y represents an oxygen or sulfur atom.
45. The composition of claim 42, wherein:
R.sup.1 represents a halogen atom, a trifluoromethyl group, a hydroxy
group, a difluoromethoxy group, a trifluoromethoxy group, a
difluoromethylthio group, a trifluoromethylthio group, a formyl group, an
acetyl group, a trifluoroacetyl group, a cyano group or a nitro group;
R.sup.2 represents an alkanoyl group having from 2 to 6 carbon atoms, a
substituted alkanoyl group which has from 2 to 6 carbon atoms and which is
substituted by at least one fluorine atom, a cycloalkylcarbonyl group
having from 4 to 7 carbon atoms, or a substituted cycloalkylcarbonyl group
which is substituted by at least one fluorine atom; and
R.sup.3 represents a hydrogen atom, a hydroxy group, a pivaloyloxymethoxy
group, an alkanoyloxy group having from 2 to 10 carbon atoms, an
alkoxycarbonyloxy group having from 2 to 5 carbon atoms or a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group;
46. The composition of claim 42, wherein:
R.sup.1 represents a fluorine or chlorine atom;
R.sup.2 represents an acetyl group, a propionyl group, a substituted acetyl
or propionyl group which is substituted by at least one fluorine atom, a
cyclopropylcarbonyl group, cyclobutylcarbonyl group, or a substituted
cyclopropylcarbonyl or cyclobutylcarbonyl group which is substituted by at
least one fluorine atom; and
R.sup.3 represents a hydrogen atom, a hydroxy group, a pivaloyloxymethoxy
group, an alkanoyloxy group having from 2 to 6 carbon atoms or an
alkoxycarbonyloxy group having from 2 to 5 carbon atoms.
47. The composition of claim 42, wherein said blood platelet aggregation
inhibitor is selected from the group consisting of:
5-(2-fluoro-.alpha.-propionylbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin
e;
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2
-c]pyridine;
5-(2-chloro-.alpha.-cyclopropylcarbonylbenzyl)-4,5,6,7-tetrahydrothieno[3,2
-c]pyridine;
2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydro
thieno[3,2-c]pyridine;
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-propionyloxy-4,5,6,7-tetra
hydrothieno[3,2-c]pyridine;
2-butyryloxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahy
drothieno[3,2-c]pyridine;
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-pivaloyloxy-4,5,6,7-tetrah
ydrothieno[3,2-c]pyridine;
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-valeryloxy-4,5,6,7-tetrahy
drothieno[3,2-c]pyridine;
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-hexanoyloxy-4,5,6,7-tetrah
ydrothieno[3,2-c]pyridine;
2-t-butoxycarbonyloxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,
7-tetrahydrothieno[3,2-c]pyridine;
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-pivaloyloxymethoxy-4,5,6,7
-tetrahydrothieno[3,2-c]pyridine;
5-(2-chloro-.alpha.-cyclopropylcarbonylbenzyl)-2-oxo-2,4,5,6,7,7a-hexahydro
thieno[3,2-c]pyridine and its tautomer;
5-(2-fluoro-.alpha.-propionylbenzyl)-2-oxo-2,4,5,6,7,7a-hexahydrothieno[3,2
-c]pyridine and its tautomer;
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7a-hexahydro
thieno[3,2-c]pyridine and its tautomer;
2-acetoxy-5-(2-chloro-.alpha.-cyclopropylcarbonylbenzyl)-4,5,6,7-tetrahydro
thieno[3,2-c]pyridine;
5[.alpha.-(2-fluorocyclopropylcarbonyl-2-fluorobenzyl]-2-oxo-2,4,5,6,7,7a-h
exahydrothieno[3,2-c]pyridine and its tautomer;
2-acetoxy-5-[.alpha.-(2-fluorocyclopropylcarbonyl-2-fluorobenzyl]-4,5,6,7-t
etrahydrothieno[3,2-c]pyridine;
and pharmaceutically acceptable salts thereof.
48. A method for the treatment or prophylaxis of thrombosis or embolisms,
comprising administering to a mammal an effective amount of a blood
platelet aggregation inhibitor, wherein said inhibitor is at least one
compound of formula (I), or a tautomer or pharmaceutically acceptable salt
thereof, as claimed in claim 1.
49. The method of claim 48, wherein:
R.sup.1 represents a hydrogen atom, an alkyl group having from 1 to 4
carbon atoms, a halogen atom, a fluoroalkyl group having from 1 to 4
carbon atoms and at least one fluorine atom, a hydroxy group, an alkoxy
group having from 1 to 4 carbon atoms, a fluoroalkoxy group having from 1
to 4 carbon atoms and at least one fluorine atom, an alkylthio group
having from 1 to 4 carbon atoms, a fluoroalkylthio group having from 1 to
4 carbon atoms and at least one fluorine atom, an amino group, an alkanoyl
group having from 1 to 5 carbon atoms, a fluoroalkanoyl group having from
2 to 5 carbon atoms and at least one fluorine atom, an alkoxycarbonyl
group having from 2 to 5 carbon atoms, a carbamoyl group, a cyano group, a
nitro group, an alkanesulfonyl group having from 1 to 4 carbon atoms, a
fluoroalkanesulfonyl group having from 1 to 4 carbon atoms and at least
one fluorine atom, or a sulfamoyl group;
R.sup.2 represents an alkanoyl group having from 2 to 6 carbon atoms, a
substituted alkanoyl group which has from 2 to 6 carbon atoms and which is
substituted by at least one substituent selected from the group consisting
of substituents A', defined below, a cycloalkylcarbonyl group having from
4 to 7 carbon atoms, a substituted cycloalkylcarbonyl group which has from
4 to 7 carbon atoms and which is substituted by at least one substituent
selected from the group consisting of substituents A', defined below, of a
substituted benzoyl group having at least one fluorine substituent;
R.sup.3 represents a hydrogen atom, a hydroxy group, an alkoxy group having
from 1 to 4 carbon atoms, an alkoxymethoxy group in which the alkoxy part
has from 1 to 4 carbon atoms, an alkanoyloxymethoxy group in which the
alkanoyl part has from 1 to 5 carbon atoms, a benzyloxy group which is
unsubstituted or is substituted by at least one substituent selected from
the group consisting of substituents D', defined below, an alkanoyloxy
group having from 1 to 18 carbon atoms, an alkenoyloxy group having 3 or 4
carbon atoms, a cycloalkylcarbonyloxy group having from 4 to 7 carbon
atoms, a benzoyloxy group which is unsubstituted or is substituted by at
least one substituent selected from the group consisting of substituents
D', defined below, an alkoxycarbonyloxy group having from 2 to 5 carbon
atoms, a benzyloxycarbonyloxy group which is unsubstituted or is
substituted by at least one substituent selected from the group consisting
of substituents D', defined below, a phthalidyloxy group, a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a
(5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a group of formula
--NR.sup.a R.sup.b
wherein R.sup.a and R.sup.b are independently selected from the group
consisting of hydrogen atoms, methyl groups and ethyl groups or R.sup.a
represents a hydrogen atom and R.sup.b represents an alkanoyloxymethyl
group in which the alkanoyl part has from 1 to 5 carbon atoms,
a benzylamino group, an alkanoylamino group having from 1 to 18 carbon
atoms, an alkenoylamino group having 3 or 4 carbon atoms, a
cycloalkylcarbonylamino group having 6 or 7 carbon atoms, a benzoylamino
group which is unsubstituted or is substituted by at least one substituent
selected from the group consisting of substituents D', defined below, an
alkoxycarbonylamino group having from 2 to 5 carbon atoms or a
benzyloxycarbonylamino group which is unsubstituted or is substituted by
at least one substituent selected from the group consisting of
substituents D', defined below;
said substituents A' are selected from the group consisting of fluorine
atoms, chlorine atoms, hydroxy groups, methoxy groups, ethoxy groups and
cyano groups; and
said substituents D' are selected from the group consisting of fluorine
atoms, chlorine atoms, methyl groups and methoxy groups.
50. The method of claim 48, wherein:
R.sup.1 represents a hydrogen atom, a methyl group, an ethyl group, a
halogen atom, a methyl group substituted by at least one fluorine atom, a
hydroxy group, a methoxy group, an ethoxy group, a methoxy group
substituted by at least one fluorine atom, a methylthio group, a
methylthio group substituted by at least one fluorine atom, a formyl
group, an acetyl group, an acetyl group substituted by at least one
fluorine atom, an alkoxycarbonyl group having from 2 to 4 carbon atoms, a
carbamoyl group, a cyano group, a nitro group, a methanesulfonyl group, an
ethanesulfonyl group, a methanesulfonyl group substituted by at least one
fluorine atom, or a sulfamoyl group;
R.sup.2 represents an alkanoyl group having from 2 to 6 carbon atoms, a
substituted alkanoyl group which has from 2 to 6 carbon atoms and which is
substituted by at least one fluorine atom, a cycloalkylcarbonyl group
having from 4 to 7 carbon atoms, or a substituted cycloalkylcarbonyl group
which is substituted by at least one fluorine atom; and
R.sup.3 represents a hydrogen atom, a hydroxy group, a methoxy group, an
ethoxy group, a t-butoxy group, a methoxymethoxy group, an
alkanoyloxymethoxy group in which the alkanoyl part has from 1 to 5 carbon
atoms, a benzyloxy group, an alkanoyloxy group having from 1 to 12 carbon
atoms, an alkenoyloxy group having 3 or 4 carbon atoms, a
cycloalkylcarbonyloxy group having from to 7 carbon atoms, a benzoyloxy
group, an alkoxycarbonyloxy group having from 2 to 5 carbon atoms, a
benzyloxycarbonyloxy group, a phthalidyloxy group, a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a
(5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, an amino group or a
t-butoxycarbonylamino group.
51. The method of claim 48, wherein:
R.sup.1 represents a halogen atom, a trifluoromethyl group, a hydroxy
group, a difluoromethoxy group, a trifluoromethoxy group, a
difluoromethylthio group, a trifluoromethylthio group, a formyl group, an
acetyl group, a trifluoroacetyl group, a cyano group or a nitro group;
R.sup.2 represents an alkanoyl group having from 2 to 6 carbon atoms, a
substituted alkanoyl group which has from 2 to 6 carbon atoms and which is
substituted by at least one fluorine atom, a cycloalkylcarbonyl group
having from 4 to 7 carbon atoms, or a substituted cycloalkylcarbonyl group
which is substituted by at least one fluorine atom; and
R.sup.3 represents a hydrogen atom, a hydroxy group, a pivaloyloxymethoxy
group, an alkanoyloxy group having from 2 to 10 carbon atoms, an
alkoxycarbonyloxy group having from 2 to 5 carbon atoms or a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group.
52. The method of claim 48, wherein:
R.sup.1 represents a fluorine or chlorine atom;
R.sup.2 represents an acetyl group, a propionyl group, a substituted acetyl
or propionyl group which is substituted by at least one fluorine atom, a
cyclopropylcarbonyl group, cyclobutylcarbonyl group, or a substituted
cyclopropylcarbonyl or cyclobutylcarbonyl group which is substituted by at
least one fluorine atom;
R.sup.3 represents a hydrogen atom, a hydroxy group, a pivaloyloxymethoxy
group, an alkanoyloxy group having from 2 to 6 carbon atoms or an
alkoxycarbonyloxy group having from 2 to 5 carbon atoms; and
Y represents a sulfur atom.
53. The method of claim 48, wherein said blood platelet aggregation
inhibitor is selected from the group consisting of:
5-(2-fluoro-.alpha.-propionylbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin
e;
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2
-c]pyridine;
5-(2-chloro-.alpha.-cyclopropylcarbonylbenzyl)-4,5,6,7-tetrahydrothieno[3,2
-c]pyridine;
2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydro
thieno[3,2-c]pyridine;
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-propionyloxy-4,5,6,7-tetra
hydrothieno[3,2-c]pyridine;
2-butyryloxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahy
drothieno[3,2-c]pyridine;
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-pivaloyloxy-4,5,6,7-tetrah
ydrothieno[3,2-c]pyridine;
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-valeryloxy-4,5,6,7-tetrahy
drothieno[3,2-c]pyridine;
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-hexanoyloxy-4,5,6,7-tetrah
ydrothieno[3,2-c]pyridine;
2-t-butoxycarbonyloxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,
7-tetrahydrothieno[3,2-c]pyridine;
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-pivaloyloxymethoxy-4,5,6,7
-tetrahydrothieno[3,2-c]pyridine;
5-(2-chloro-.alpha.-cyclopropylcarbonylbenzyl)-2-oxo-2,4,5,6,7,7a-hexahydro
thieno[3,2-c]pyridine and its tautomer;
5-(2-fluoro-.alpha.-propionylbenzyl)-2-oxo-2,4,5,6,7,7a-hexahydrothieno[3,2
-c]pyridine and its tautomer;
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7a-hexahydro
thieno[3,2-c]pyridine and its tautomer;
2-acetoxy
-5-(2-chloro-.alpha.-cyclopropylcarbonylbenzyl)-4,5,6,7-tetrahydrothieno[3
,2-c]pyridine;
5-[.alpha.-(2-fluorocyclopropylcarbonyl-2-fluorobenzyl]-2-oxo-2,4,5,6,7,7a-
hexahydrothieno[3,2-c]pyridine and its tautomer;
2-acetoxy-5-[.alpha.-(2-fluorocyclopropylcarbonyl-2-fluorobenzyl]-4,5,6,7-t
etrahydrothieno[3,2-c]pyridine;
and pharmaceutically acceptable salts thereof.
54. The compound of claim 1, wherein R.sup.1 represents a fluorine atom.
55. The compound of claim 1, wherein R.sup.1 represents a chlorine atom.
56. The compound of claim 1, wherein
R.sup.1 represents a fluorine atom;
R.sup.2 represents an acetyl group, a propionyl group, a substituted acetyl
or propionyl group which is substituted by at least one fluorine atom, a
cyclopropylcarbonyl group, cyclobutylcarbonyl group, or a substituted
cyclopropylcarbonyl or cyclobutylcarbonyl group which is substituted by at
least one fluorine atom;
R.sup.3 represents a hydrogen atom, a hydroxy group, a privaloyloxymethoxy
group, an alkanoyloxy group having from 2 to 6 carbon atoms or an
alkoxycarbonyloxy group having from 2 to 5 carbon atoms; and
Y represents a sulfur atom.
Description
BACKGROUND OF THE INVENTION
The present invention relates to a series of new
tetrahydrothieno[3,2-c]pyridine derivatives and furo and pyrrolo analogs
of these derivatives, and provides processes for preparing these
derivatives as well as methods and compositions using them for inhibiting
blood platelet aggregation.
A number of tetrahydrothienopyridine and tetrahydrofuropyridine derivatives
is known, and some of these have been disclosed to have the ability to
inhibit blood platelet aggregation. For example, U.S. Pat. Nos. 4,051,141,
4,075,215, 4,127,580, 4,464,377 and 4,529,596 all disclose compounds of
this type, although not all disclose them for the inhibition of blood
platelet aggregation. The closest prior art is believed to be U.S. Pat.
No. 4,051,141, which discloses, inter alia,
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and U.S Pat.
No. 4,529,596, which discloses, inter alia,
5-(2-chloro-.alpha.-methoxycarbonylbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]
pyridine.
However, there are problems with the prior art compounds referred to above,
especially in that many of them require a long time after administration
before they manifest their activity. Accordingly, there is a need for new
compounds of this type having improved activity and the ability to act
faster.
We have now discovered a series of new tetrahydrothieno[3,2-c]pyridine
derivatives and furo and pyrrolo analogs of these derivatives which have
an improved ability to inhibit the aggregation of blood platelets.
BRIEF SUMMARY OF INVENTION
It is, therefore, an object of the present invention to provide a series of
new compounds of this type.
It is a further, and more specific object of the present invention to
provide such compounds having valuable inhibitory activity against
platelet aggregation.
Other objects and advantages of the present invention will become apparent
as the description proceeds.
The compounds of the present invention are those compounds of formula (I):
##STR2##
wherein: R.sup.1 represents a hydrogen atom, an alkyl group having from 1
to 4 carbon atoms, a halogen atom, a haloalkyl group having from 1 to 4
carbon atoms and at least one halogen atom, a hydroxy group, an alkoxy
group having from 1 to 4 carbon atoms, a haloalkoxy group having from 1 to
4 carbon atoms and at least one halogen atom, an alkylthio group having
from 1 to 4 carbon atoms, a haloalkylthio group having from 1 to 4 carbon
atoms and at least one halogen atom, an amino group, an alkanoyl group
having from 1 to 5 carbon atoms, a haloalkanoyl group having from 2 to 5
carbon atoms and at least one halogen atom, a carboxy group, an
alkoxycarbonyl group having from 2 to 5 carbon atoms, a carbamoyl group, a
cyano group, a nitro group, an alkanesulfonyl group having from 1 to 4
carbon atoms, a haloalkanesulfonyl group having from 1 to 4 carbon atoms
and at least one halogen atom, or a sulfamoyl group;
R.sup.2 represents an alkanoyl group having from 1 to 10 carbon atoms, a
substituted alkanoyl group which has from 2 to 10 carbon atoms and which
is substituted by at least one substituent selected from the group
consisting of substituents A, defined below, an alkenoyl group having from
3 to 6 carbon atoms, a substituted alkenoyl group which has from 3 to 6
carbon atoms and which is substituted by at least one substituent selected
from the group consisting of substituents A, defined below, a
cycloalkylcarbonyl group having from 4 to 8 carbon atoms, a substituted
cycloalkylcarbonyl group which has from 4 to 8 carbon atoms and which is
substituted by at least one substituent selected from the group consisting
of substituents A, defined below, a substituted benzoyl group having at
least one substituent selected from the group consisting of substituents
B, defined below, or a 5,6-dihydro 1,4,2-dioxazin-3-yl group;
R.sup.3 represents a hydrogen atom, a hydroxy group, an alkoxy group having
from 1 to 4 carbon atoms, a substituted alkoxy group which has from 1 to 4
carbon atoms and which is substituted by at least one substituent selected
from the group consisting of substituents C, defined below, an aralkyloxy
group in which the aralkyl part is as defined below, an alkanoyloxy group
having from 1 to 18 carbon atoms, an alkenoyloxy group having from 3 to 6
carbon atoms, a cycloalkyl carbonyloxy group having from 4 to 8 carbon
atom, an arylcarbonyloxy group in which the aryl part is as defined below,
an alkoxycarbonyloxy group having from 2 to 5 carbon atoms, an
aralkyloxycarbonyloxy group in which the aralkyl part is as defined below,
a phthalidyloxy group, a (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group,
a (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a group of formula
--NR.sup.a R.sup.b
wherein R.sup.a and R.sup.b are independently selected from the group
consisting of hydrogen atoms, alkyl groups having from 1 to 4 carbon atoms
and substituted alkyl groups which have from 1 to 4 carbon atoms and which
are substituted by at least one substituent selected from the group
consisting of substituents C, defined below,
an aralkylamino group in which the aralkyl part is as defined below, an
alkanoylamino group having from 1 to 18 carbon atoms, an alkenoylamin
group having from 3 to 6 carbon atoms, a cycloalkylcarbonylamino group
having from 4 to 8 carbon atoms, an arylcarbonylamino group in which the
aryl part is as defined below, an alkoxycarbonylamino group having from 2
to 5 carbon atoms, an aralkyloxycarbonylamino group in which the aralkyl
part is as defined below, a phthalidylamino group, a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methylamino group, a
(5-phenyl-2-oxo-1,3-dioxolen-4-yl)methylamino group or a nitro group;
Y represents a group of formula --NH-- or an oxygen or sulfur atom; and
n is an integer from 1 to 5, and, when n is an integer from 2 to 5, the
groups represented by R.sup.1 may be the same as or different from each
other;
said substituents A are selected from the group consisting of halogen
atoms, hydroxy groups, alkoxy groups having from 1 to 4 carbon atoms and
cyano groups;
said substituents B are selected from the group consisting of alkyl groups
having from 1 to 4 carbon atoms, halogen atoms and alkoxy groups having
from 1 to 4 carbon atoms;
said substituents C are selected from the group consisting of alkoxy groups
having from 1 to 4 carbon atoms, alkanoyloxy groups having from 1 to 6
carbon atoms and arylcarbonyloxy groups in which the aryl part is as
defined below;
said aralkyl parts of said aralkyloxy, aralkyloxy. carbonyloxy,
aralkylamino and aralkyloxycarbonylamino groups are alkyl groups which
have from 1 to 4 carbon atoms and which are substituted by at least one
aryl group as defined below;
said aryl groups and said aryl parts of said arylcarbonyloxy groups and of
said arylcarbonylamino groups have from 6 to 10 carbon atoms in a
carbocyclic ring which is unsubstituted or is substituted by at least one
substituent selected from the group consisting of substituents D, defined
below; and
said substituents D are selected from the group consisting of the groups
and atoms defined above in relation to R.sup.1, other than said hydrogen
atom;
and tautomers thereof and pharmaceutically acceptable salts of said
compounds of formula (I) and of said tautomers.
The invention also provides a pharmaceutical composition for the treatment
and prophylaxis of thrombosis or embolisms, comprising an effective amount
of a blood platelet aggregation inhibitor in admixture with a
pharmaceutically acceptable carrier or diluent, wherein said inhibitor is
at least one compound of formula (I), or a tautomer or pharmaceutically
acceptable salt thereof.
The invention still further provides a method for the treatment or
prophylaxis of thrombosis or embolisms, comprising administering to a
mammal, which may be human, an effective amount of a blood platelet
aggregation inhibitor, wherein said inhibitor is at least one compound of
formula (I), or a tautomer or pharmaceutically acceptable salt thereof.
The invention also provides processes for preparing these compounds, which
are described in greater detail hereafter.
DETAILED DESCRIPTION OF INVENTION
When the compounds of the present invention have an amino or hydroxy group
at the 2- or 3- position (i.e. R.sup.3 represents an amino or hydroxy
group at the 2- or 3- position), they can exist as keto-enol tautomers,
that is:
##STR3##
wherein Y, R.sup.1, R.sup.2 and n are as defined above, and Z represents a
group of formula .dbd.NH or an oxygen tom. These tautomers may or may not
be readily separable, and, if separable, may be separated by methods well
known in the art. In any event, the present invention embraces both the
individual isolated tautomers, as well as mixtures thereof, and both the
isolated tautomers and such mixtures may be used in the compositions and
methods of the present invention. In particular, the tautomers of formula
(Ia) are preferred.
In the compounds of the present invention, where R.sup.1 represents an
alkyl group, this may be a straight or branched chain alkyl group having
from 1 to 4 carbon atoms, and examples include the methyl, ethyl, propyl,
isopropyl, butyl, isobutyl, sec-butyl and t-butyl groups. Of these, we
prefer those alkyl groups having from 1 to 3 carbon atoms, more preferably
the methyl and ethyl groups.
Where R.sup.1 represents a halogen atom, this may be, for example, a
fluorine, chlorine, iodine or bromine atom, and is preferably a fluorine
or chlorine atom.
Where R.sup.1 represents a haloalkyl group, the alkyl part may be any one
of the alkyl groups exemplified above and may be substituted by one or
more halogen (for example fluorine, chlorine, bromine or iodine) atoms.
There is, in principle, no restriction on the number of halogen
substituents on the alkyl group, this being limited only by the number of
substitutable atoms. In general, however, from 1 to 5 halogen substituents
are preferred, from 1 to 3 substituents being more preferred. Specific
examples of such groups include the fluoromethyl, difluoromethyl,
trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl,
2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2-iodoethyl,
2,2,2-trichloroethyl, 2,2,2-trifluoroethyl, 2-fluoropropyl,
3-fluoropropyl, 3-chloropropyl, 2-fluorobutyl, 3-fluorobutyl,
4-chlorobutyl and 4-fluorobutyl groups. The fluorine-substituted and
chlorine-substituted groups are preferred, the fluorine-substituted groups
being more preferred. The fluoromethyl, difluoromethyl and trifluoromethyl
groups are most preferred, especially the trifluoromethyl group.
Where R.sup.1 represents an alkoxy group, this may be a straight or
branched chain alkoxy group having from 1 to 4 carbon atoms, and examples
include the methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy,
sec-butoxy and t-butoxy groups. Of these, we prefer those alkoxy groups
having from 1 to 3 carbon atoms, more preferably the methoxy and ethoxy
groups.
Where R.sup.1 represents a haloalkoxy group, the alkoxy part may be any one
of the alkoxy groups exemplified above and may be substituted by one or
more halogen (for example fluorine, chlorine, bromine or iodine) atoms.
There is, in principle, no restriction on the number of halogen
substituents on the alkoxy group, this being limited only by the number of
substitutable atoms. In general, however, from 1 to 5 halogen substituents
are preferred, from 1 to 3 substituents being more preferred. Specific
examples of such groups include the fluoromethoxy, difluoromethoxy,
trifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy,
2-iodoethoxy, 2,2,2-trichloroethoxy, 2,2,2-trifluoroethoxy,
2-fluoropropoxy, 3-fluoropropoxy, 3-chloropropoxy, 2-fluorobutoxy,
3-fluorobutoxy, 4-chlorobutoxy and 4-fluorobutoxy groups. The fluoroalkoxy
groups are preferred. The fluoromethoxy, difluoromethoxy and
trifluoromethoxy groups are most preferred, especially the
trifluoromethoxy group.
Where R.sup.1 represents an alkylthio group, this may be a straight or
branched chain alkylthio group having from 1 to 4 carbon atoms, and
examples include the methylthio, ethylthio, propylthio, isopropylthio,
butylthio, isobutylthio, sec-butylthio and t-butylthio groups. Of these,
we prefer those alkylthio groups having from 1 to 3 carbon atoms, more
preferably the methylthio and ethylthio groups.
Where R.sup.1 represents a haloalkylthio group, the alkylthio part may be
any one of the alkylthio groups exemplified above and may be substituted
by one or more halogen (for example fluorine, chlorine, bromine or iodine)
atoms. There is, in principle, no restriction on the number of halogen
substituents on the alkylthio group, this being limited only by the number
of substitutable atoms. In general, however, from 1 to 5 halogen
substituents are preferred, from 1 to 3 substituents being more preferred.
Specific examples of such groups include the fluoromethylthio,
difluoromethio, trifluoromethylthio, 2-fluoroethylthio, 2-chloroethylthio,
2-bromoethylthio, 2-iodoethylthio, 2,2,2-trichloroethylthio,
2,2,2-trifluoroethylthio, 2-fluoropropylthio, 3-fluoropropylthio,
3-chloropropylthio, 2-fluorobutylthio, 3-fluorobutylthio,
4-chlorobutylthio and 4-fluorobutylthio groups. The fluorine substituted
groups are preferred. The fluoromethylthio, difluoromethylthio and
trifluoromethylthio groups are most preferred, especially the
trifluoromethylthio group.
Where R.sup.1 represents an alkanoyl group, this has from 1 to 5 carbon
atoms and may be a straight or branched chain group. Examples include the
formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl and
pivaloyl groups, of which the formyl and acetyl groups are preferred.
Where R.sup.1 represents a haloalkanoyl group, this has from 2 to 5 carbon
atoms and may be a straight or branched chain group. Examples include the
fluoroacetyl, difluoroacetyl, trifluoroacetyl, chloroacetyl,
trichloroacetyl, bromoacetyl, iodoacetyl, 3-fluoropropionyl,
4-fluorobutyryl and 5-fluorovaleryl groups. Of these, the fluorine
substituted alkanoyl groups are preferred, the fluoroacetyl,
difluoroacetyl and trifluoroacetyl groups being more preferred and the
trifluoroacetyl group being most preferred.
Where R.sup.1 represents an alkoxycarbonyl group, this may be a straight or
branched chain alkoxycarbonyl group having from 2 to 5 carbon atoms, that
is the alkoxy part has from 1 to 4 carbon atoms, and examples include the
methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl,
butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl and t-butoxycarbonyl
groups. Of these, we prefer those alkoxycarbonyl groups having from 1 to 3
carbon atoms, more preferably the methoxycarbonyl and ethoxycarbonyl
groups.
Where R.sup.1 represents an alkanesulfonyl group, this may be a straight or
branched chain alkanesulfonyl group having from 1 to 4 carbon atoms, and
examples include the methanesulfonyl, ethanesulfonyl, propanesulfonyl,
isopropanesulfonyl, butanesulfonyl, isobutanesulfonyl, sec butanesulfonyl
and t-butanesulfonyl groups. Of these, we prefer those alkanesulfonyl
groups having from 1 to 3 carbon atoms, more preferably the
methanesulfonyl and ethanesulfonyl groups.
Where R.sup.1 represents a haloalkanesulfonyl group, the alkanesulfonyl
part may be any one of the alkanesulfonyl groups exemplified above and may
be substituted by one or more halogen (for example fluorine, chlorine,
bromine or iodine) atoms. There is, in principle, no restriction on the
number of halogen substituents on the alkanesulfonyl group, this being
limited only by the number of substitutable atoms. In general, however,
from 1 to 5 halogen substituents are preferred, from 1 to 3 substituents
being more preferred. Specific examples of such groups include the
fluoromethanesulfonyl, difluoromethanesulfonyl, trifluoromethanesulfonyl,
dichloromethanesulfonyl, trichloromethanesulfonyl, 2-fluoroethanesulfonyl,
2-chloroethanesulfonyl 2-bromoethanesulfonyl, 2-iodoethanesulfonyl,
2,2,2-trichloroethanesulfonyl, 2,2,2-trifluoroethanesulfonyl,
2-fluoropropanesulfonyl, 3-fluoropropanesulfonyl, 3-chloropropanesulfonyl,
2-fluorobutanesulfonyl, 3-fluorobutanesulfonyl, 4-chlorobutanesulfonyl and
4-fluorobutanesulfonyl groups. The fluorine-substituted alkanesulfonyl and
chlorine substituted alkanesulfonyl groups are preferred, the
fluorine-substituted alkanesulfonyl groups being more preferred. The
fluoromethanesulfonyl, difluoromethanesulfonyl and
trifluoromethanesulfonyl groups are most preferred, especially the
trifluoromethanesulfonyl group.
Of the above groups and atoms, we especially prefer that R.sup.1 should
represent: a hydrogen atom; an alkyl group having from 1 to 4 carbon
atoms; a halogen atom; a fluorine substituted alkyl group having from 1 to
4 carbon atoms; a hydroxy group; an alkoxy group having from 1 to 4 carbon
atoms; a fluorine-substituted alkoxy group having from 1 to 4 carbon
atoms; an alkylthio group having from 1 to 4 carbon atoms; a
fluorine-substituted alkylthio group having from 1 to 4 carbon atoms; an
amino group; an alkanoyl group having from 1 to 5 carbon atoms; a
fluorine-substituted alkanoyl group having from 2 to 5 carbon atoms; an
alkoxycarbonyl group having from 2 to 5 carbon atoms; a carbamoyl group; a
cyano group; a nitro group; an alkanesulfonyl group having from 1 to 4
carbon atoms; a fluorine-substituted alkanesulfonyl group having from 1 to
4 carbon atoms; or a sulfamoyl group.
More preferably R.sup.1 represents: a hydrogen atom; a methyl group; an
ethyl group; a halogen atom; a fluorine-substituted methyl group; a
hydroxy group; a methoxy group; an ethoxy group; a fluorine-substituted
methoxy group; a methylthio group; a fluorine-substituted methylthio
group; a formyl group; an acetyl group; a fluorine-substituted acetyl
group; a methoxycarbonyl group; an ethoxycarbonyl group; a propoxycarbonyl
group; a carbamoyl group; a cyano group; a nitro group; a methanesulfonyl
group; an ethanesulfonyl group; a fluorine-substituted methanesulfonyl
group; or a sulfamoyl group.
Still more preferably R.sup.1 represents: a halogen atom; a trifluoromethyl
group; a hydroxy group; a difluoromethoxy group; a trifluoromethoxy group;
a difluoromethylthio group; a trifluoromethylthio group; a formyl group;
an acetyl group; a trifluoroacetyl group; a cyano group or a nitro group.
Most preferably R.sup.1 represents: a fluorine atom, a chlorine atom or a
trifluoromethyl group; especially a fluorine atom or a chlorine atom.
The number of the substituents, n, represented by R.sup.1 is from 1 to 5,
although the maximum may be lower than 5 in some cases if there is a
problem of steric hindrance. Preferably n is from 1 to 3, and more
preferably 1 or 2. The position of substitution by R.sup.1 on the phenyl
group is preferably para or ortho, more preferably ortho.
Where R.sup.2 represents an alkanoyl group having from 1 to 10 carbon
atoms, this may be a straight or branched chain group, and examples
include the formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl,
isovaleryl, pivaloyl, hexanoyl, heptanoyl, octanoyl, nonanoyl and decanoyl
groups, of which those groups having from 2 to 6 carbon atoms are
preferred, especially the acetyl, propionyl and isobutyryl groups, of
which the acetyl and propionyl groups are most preferred.
Those alkanoyl groups represented by R.sup.2 and having from 2 to 10 carbon
atoms may be substituted by one or more of substituents A, defined above.
Examples of such substituents A include:
halogen atoms, such as the fluorine, chlorine, bromine and iodine atoms;
hydroxy groups;
alkoxy groups having from 1 to 4 carbon atoms, such as those exemplified
above in relation to R.sup.1 ; and
cyano groups.
In the case of these substituted groups, and all substituted groups
referred to herein, there is no specific limitation on the number of the
substituents, except such as may be imposed by the number of substitutable
positions and possibly also by steric constraints. However, in general,
from 1 to 3 such substituents are preferred.
Specific examples of such substituted alkanoyl groups include the
fluoroacetyl, difluoroacetyl, trifluoroacetyl, chloroacetyl,
trichloroacetyl, bromoacetyl, iodoacetyl, 3-fluoropropionyl,
3-cloropropionyl, 3-bromopropionyl, 3-iodopropionyl, 4-fluorobutyryl,
4-chlorobutyryl, 5-fluorovaleryl, hydroxyacetyl, 3-hydroxypropionyl,
4-hydroxybutyryl, 5-hydroxyvaleryl, methoxyacetyl, 3-methoxypropionyl,
4-methoxybutyryl, 5-methoxyvaleryl, ethoxyacetyl, 3-ethoxypropionyl,
4-ethoxybutyryl, 5-ethoxyvaleryl, cyanoacetyl, 3-cyanopropionyl,
4-cyanobutyryl and 5-cyanovaleryl groups, of which the fluoroacetyl,
difluoroacetyl, trifluoroacetyl, chloroacetyl, 3-fluoropropionyl,
3-chloropropionyl, hydroxyacetyl, 3-hydroxypropionyl, methoxyacetyl,
3-methoxypropionyl, ethoxyacetyl, cyanoacetyl and 3-cyanopropionyl groups
are more preferred. Still more preferred are the fluoroacetyl,
difluoroacetyl, trifluoroacetyl, chloroacetyl, 3-fluoropropionyl,
hydroxyacetyl, methoxyacetyl, ethoxyacetyl and cyanoacetyl groups. The
most preferred groups are the fluoroacetyl, difluoroacetyl,
trifluoroacetyl, chloroacetyl, 3-fluoropropionyl, hydroxyacetyl,
methoxyacetyl and cyanoacetyl groups, especially the fluoroacetyl,
difluoroacetyl and trifluoroacetyl groups.
Where R.sup.2 represents an alkenoyl group having from 3 to 6 carbon atoms,
this may be a straight or branched chain group, and examples include the
acryloyl, methacryloyl, 2-butenoyl, 2-pentenoyl and 2-hexenoyl groups, of
which the acryloyl and methacryloyl groups are preferred.
These alkenoyl groups may also be substituted by one or more of
substituents A, defined and exemplified above. Specific examples of such
substituted groups include the 3-fluoroacryloyl, 3-chloroacryloyl and
3-cyanoacryloyl groups, of which the 3-fluoroacryloyl group is
particularly preferred.
Where R.sup.2 represents a cycloalkylcarbonyl group, this has from 4 to 8
carbon atoms, that is the cycloalkyl group itself has from 3 to 7 ring
carbon atoms. Examples of such groups include the cyclopropylcarbonyl,
cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexyl carbonyl and
cycloheptylcarbonyl groups, of which the cyclopropylcarbonyl and
cyclobutylcarbonyl groups are particularly preferred.
These cycloalkylcarbonyl groups may also be substituted by one or more of
substituents A, defined and exemplified above. Specific examples of such
substituted groups include the 2-fluorocyclopropylcarbonyl,
2,2-difluorocyclopropylcarbonyl, 2-chlorocyclopropylcarbonyl,
2-bromocyclopropylcarbonyl, 2-fluorocyclobutylcarbonyl,
2-chlorocyclobutylcarbonyl, 2-fluorocyclopentylcarbonyl,
2-chlorocyclopentyl carbonyl, 2-fluorocyclohexylcarbonyl,
2-chlorocyclohexylcarbonyl, 2-hydroxycyclopropylcarbonyl,
2-hydroxycyclobutylcarbonyl, 2-hydroxycyclopentylcarbonyl,
2-hydroxycyclohexylcarbonyl, 2-methoxycyclopropylcarbonyl,
2-methoxycyclobutylcarbonyl, 2-methoxycyclopentylcarbonyl,
2-methoxycyclohexylcarbonyl, 2-ethoxycyclopropylcarbonyl,
2-ethoxycyclobutylcarbonyl, 2-ethoxycyclopentylcarbonyl,
2-ethoxycyclohexylcarbonyl, 2-cyanocyclopropylcarbonyl,
2-cyanocyclobutylcarbonyl, 2-cyanocyclopentylcarbonyl and
2-cyanocyclohexylcarbonyl groups, of which the
2-fluorocyclopropylcarbonyl, 2,2-difluorocyclopropylcarbonyl,
2-chlorocyclopropylcarbonyl, 2-fluorocyclobutylcarbonyl,
2-chlorocyclobutylcarbonyl, 2 fluorocyclopentylcarbonyl,
2-fluorocyclohexylcarbony, 2-hydroxycyclopropylcarbonyl,
2-methoxycyclopropylcarbonyl, 2-ethoxycyclopropyl. carbonyl and
2-cyanocyclopropylcarbonyl groups are preferred. More preferred groups are
the 2-fluorocyclopropylcarbonyl, 2-chlorocyclopropylcarbonyl,
2-fluorocyclobutylcarbonyl and 2-methoxycyclopropyl carbonyl groups, and
the most preferred is the 2-fluorocyclopropylcarbonyl group.
Where R.sup.2 represents a substituted benzoyl group, this is substituted
by at least one of substituents B, which are selected from the group
consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms
and alkoxy groups having from 1 to 4 carbon atoms, all of which may be as
exemplified in relation to the same groups and atoms represented by
R.sup.1. The number of the substituents may be from 1 to 5, provided that
there is no problem of steric hindrance; preferably, however, are from 1
to 3 substituents, more preferably 1 or Specific examples of such
substituted benzoyl groups include the 2-fluorobenzoyl, 3-fluorobenzoyl,
4-fluorobenzoyl, 2,4-difluorobenzoyl, 2,4,6-trifluorobenzoyl,
2,3,4,5,6-pentafluorobenzoyl, 4-chlorobenzoyl, 2,4-dichlorobenzoyl,
4-methylbenzoyl, 2,4-dimethylbenzoyl, 4-ethylbenzoyl, 2,4-diethylbenzoyl,
4-methoxybenzoyl, 2,4-dimethoxybenzoyl, 4-ethoxybenzoyl and
2,4-diethoxybenzoyl groups, of which the 4-fluorobenzoyl and
2,4-difluorobenzoyl groups are preferred.
Where R.sup.3 represents an alkoxy group, this may be a straight or
branched chain group having from 1 to 4 carbon atoms and may be any of the
alkoxy groups exemplified above in relation to R.sup.1. Such a group may
be unsubstituted or it may have one or more substituents selected from the
group consisting of substituents C, defined above, and examples of which
are as follows:
alkoxy groups having from 1 to 4 carbon atoms, such as those exemplified
above in relation to R.sup.1 ;
alkanoyloxy groups having from 1 to 6 carbon atoms, which may be a straight
or branched chain group, for example the formyloxy, acetoxy, propionyloxy,
butyryloxy, isobutyryloxy, valeryloxy, isovaleryloxy, pivaloyloxy or
hexanoyloxy groups, of which those groups having from 1 to 5 carbon atoms
are preferred, and the acetoxy, propionyloxy, butyryloxy and pivaloyloxy
groups are most preferred; and
arylcarbonyloxy groups in which the aryl part is as defined above, for
example the arylcarbonyloxy groups exemplified below in relation to
R.sup.3.
Specific examples of such substituted alkoxy groups include the
methoxymethoxy, ethoxymethoxy, propoxymethoxy, butoxymethoxy,
2-methoxyethoxy, 2-ethoxyethoxy, formyloxymethoxy, acetoxymethoxy,
propionyloxymethoxy, 2-formyloxyethoxy, 2-acetoxyethoxy,
2-propionyloxyethoxy, 3-acetoxypropoxy, 4-acetoxybutoxy,
valeryloxymethoxy, pivaloyloxymethoxy, benzoyloxymethoxy,
naphthoyloxymethoxy, p-toluoyloxymethoxy, p-chlorobenzoyloxymethoxy,
2-benzoyloxyethoxy, 3-benzoyloxypropoxy and 4-benzoyloxybutoxy groups, of
which the pivaloyloxymethoxy group is most preferred.
Where R3 represents an aralkyloxy group, the alkoxy part is an alkoxy group
having from 1 to 4, preferably from 1 to 3, carbon atoms, such as those
exemplified above in relation to R.sup.1, especially the methoxy, ethoxy,
propoxy or isopropoxy groups. The aryl part is as defined above and has
from 6 to 10, preferably 6 or 10, ring carbon atoms. Examples of such aryl
groups include the phenyl, 1-naphthyl and 2-naphthyl groups and such
groups which are substituted by one or more of substituents D, defined
above and examples of which have been given in relation to the same groups
and atoms which may be represented by R.sup.1. The alkoxy part may be
substituted by one or more aryl groups, the maximum being dictated only by
the number of substitutable positions and possibly also by steric
constraints; however, from 1 to 3 aryl groups are normally preferred, 1 or
2 being more preferred and 1 being most preferred. Specific examples of
the aralkyloxy groups include the benzyloxy, 1-naphthylmethoxy,
2-naphthylmethoxy, phenethyloxy, .alpha.-methylbenzyloxy, 3-phenylpropoxy,
2-phenylpropoxy, 1-phenylpropoxy, 4-phenylbutoxy, benzhydryloxy (i.e.
diphenylmethoxy) and trityloxy (i.e. triphenylmethoxy) groups (of these,
the benzyloxy and phenethyloxy groups are preferred), and such groups
which are substituted by one or more of substituents D.
Where R.sup.3 represents an alkanoyloxy group, this may be a straight or
branched chain group and has from 1 to 18 carbon atoms. Examples of such
groups include the formyloxy, acetoxy, propionyloxy, butyryloxy,
isobutyryloxy, valeryloxy, isovaleryloxy, pivaloyloxy, hexanoyloxy,
heptanoyloxy, octanoyloxy, nonanoyloxy, decanoyloxy, lauroyloxy,
myristoyloxy, palmitoyloxy and stearoyloxy groups, of which those groups
having from 1 to 12 carbon atoms are preferred, those having from 2 to 10
carbon atoms are more preferred, and those having from 2 to 5 carbon atoms
are most preferred, especially the acetoxy, propionyloxy, butyryloxy,
pivaloyloxy, nonanoyloxy and decanoyloxy groups, of which the acetoxy,
propionyloxy, butyryloxy and pivaloyloxy groups are most preferred.
Where R.sup.3 represents an alkenoyloxy group, this may be a straight or
branched chain group and has from 3 to 6, more preferably 3 or 4, carbon
atoms. Examples of such groups include the acryloyloxy, methacryloyloxy,
2-butenoyloxy, 2-pentenoyloxy and 2-hexenoyloxy groups, of which the
acryloyloxy and methacryloyloxy groups are preferred.
Where R.sup.3 represents a cycloalkylcarbonyloxy group, this has from 4 to
8, more preferably from 4 to 7, carbon atoms, that is the cycloalkyl group
itself has from 3 to 7 ring carbon atoms. Examples of such groups include
the cyclopropylcarbonyloxy, cyclobutylcarbonyloxy, cyclopentylcarbonyloxy,
cyclohexylcabonyloxy and cycloheptylcarbonyloxy groups, of which the
cyclopropylcarbonyloxy and cyclobutylcarbonyloxy groups are particularly
preferred.
Where R.sup.3 represents arylcarbonyloxy group, the aryl part is as defined
above, and examples of such groups include the benzoyloxy, 1-naphthoyloxy,
2-naphthoyloxy, o-, m- and p-toluoyloxy, o-, m- and p-chlorobenzoyloxy,
o-, m- and p-fluorobenzoyloxy, o-, m- and p-methoxybenzoyloxy, 2,3-, 2,4-,
2,5-, 2,6-, 3,4- and 3,5-dichlorobenzoyloxy, 2,4-difluorobenzoyloxy and
2,4,6-trifluorobenzoyloxy groups, preferably the benzoyloxy group.
Where R.sup.3 represents an alkoxycarbonyloxy group, this may be a straight
or branched chain alkoxycarbonyloxy group having from 2 to 5 carbon atoms,
that is the alkoxy part has from 1 to 4 carbon atoms, and examples include
the methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy,
isopropoxycarbonyloxy, butoxycarbonyloxy, isobutoxycarbonyloxy,
sec-butoxycarbonyloxy and t-butoxycarbonyloxy groups. Of these, we prefer
those alkoxycarbonyloxy groups having from 1 to 3 carbon atoms in the
alkoxy part and the t-butoxycarbonyloxy group, more preferably the
methoxycarbonyloxy, ethoxycarbonyloxy and t-butoxycarbonyloxy groups.
Where R.sup.3 represents an aralkyloxycarbonyloxy group, the alkoxy part is
an alkoxy group having from 1 to 4, preferably from 1 to 3, carbon atoms,
such as those exemplified above in relation to R.sup.1, especially the
methoxy, ethoxy, propoxy or isopropoxy groups. The aryl part is as defined
above and has from 6 to 10, preferably 6 or 10, ring carbon atoms.
Examples of such aryl groups include the phenyl, 1-naphthyl and 2-naphthyl
groups and such groups which are substituted by one or more of
substituents D, defined above and examples of which have been given in
relation to the same groups and atoms which may be represented by R.sup.1.
The alkoxy part may be substituted by one or more aryl groups, the maximum
being dictated only by the number of substitutable positions and possibly
also by steric constraints; however, from 1 to 3 aryl groups are normally
preferred, 1 or 2 being more preferred and 1 being most preferred.
Specific examples of the aralkyloxycarbonyloxy groups include the
benzyloxycarbonyloxy, 1-naphthylmethoxycarbonyloxy,
2-naphthylmethoxycarbonyloxy, phenethyloxycarbonyloxy,
.alpha.-methylbenzyloxy. carbonyloxy, 3-phenylpropoxycarbonyloxy,
2-phenylpropoxycarbonyloxy, 1-phenylpropoxycarbonyloxy,
4-phenylbutoxycarbonyloxy, benzhydryloxycarbonyloxy and
trityloxycarbonyloxy groups (of these, the benzyloxycarbonyloxy group is
preferred), and such groups which are substituted by one or more of
substituents D.
Where R.sup.3 represents a group of formula --NR.sup.a R.sup.b, R.sup.a and
R.sup.b are independently selected from the group consisting of hydrogen
atoms, alkyl groups having from 1 to 4 carbon atoms and substituted alkyl
groups which have from 1 to 4 carbon atoms and which are substituted by at
least one substituent selected from the group consisting of substituents
C, defined above. Examples of the alkyl groups which may be represented by
R.sup.a and R.sup.b are as given above in relation to R.sup.1, and
examples of the substituted alkyl groups which may be represented by
R.sup.a and R.sup.b are the substituted alkyl groups corresponding to the
substituted alkoxy groups, as given above in relation to R.sup.3. Specific
examples of these groups of formula --NR.sup.a R.sup.b include amino,
methylamino, ethylamino, propylamino, isopropylamino, butylamino,
isobutyamino, sec-butylamino, t-butylamino, dimethylamino, diethylamino,
dipropylamino, diisopropylamino, dibutylamino, methylethylamino,
methylpropylamino, N-(methoxymethyl)amino, N-(2-methoxyethyl)amino,
N-(acetoxymethyl)amino, N-(pivaloyloxymethyl)amino,
N-(benzoylmethyl)amino, N-(2-acetoxyethyl)amino,
N-(2-pivaloyloxyethyl)amino and N-(2-benzoylethyl)amino groups, preferably
the amino, methylamino, ethylamino, N-(acetoxymethyl)amino and
N-(pivaloyloxymethyl)amino groups.
Where R.sup.3 represents an aralkylamino group, the alkyl part is an alkyl
group having from 1 to 4, preferably from 1 to 3, carbon atoms, such as
those exemplified above in relation to R.sup.1, especially the methyl,
ethyl, propyl or isopropyl groups. The aryl part is as defined above and
has from 6 to 10, preferably 6 or 10, ring carbon atoms. Examples of such
aryl groups include the phenyl, 1-naphthyl and 2-naphthyl groups and such
groups which are substituted by one or more of substituents D, defined
above and examples of which have been given in relation to the same groups
and atoms which may be represented by R.sup.1. The alkyl part may be
substituted by one or more aryl groups, the maximum being dictated only by
the number of substitutable positions and possibly also by steric
constraints; however, from 1 to 3 aryl groups are normally preferred, 1 or
2 being more preferred and 1 being most preferred. Specific examples of
the aralkyl amino groups include the benzylamino,
N-(1-naphthylmethyl)amino, N-(2-naphthylmethyl)amino, phenethylamino,
N-(.alpha.-methylbenzyl)amino, N-(3-phenylpropyl)amino,
N-(2-phenylpropyl)amino, N-(1-phenylpropyl)amino, N-(4-phenylbutyl)amino,
benzhydrylamino and tritylamino groups (of these, the benzylamino group is
preferred), and such groups which are substituted by one or more of
substituents D.
Where R.sup.3 represents an alkanoylamino group, this may be a straight or
branched chain group and has from 1 to 18 carbon atoms. Examples of such
groups include the formamido, acetamido, propionamido, butyramido,
isobutyramido, valerylamino, isovalerylamino, pivaloylamino,
hexanoylamino, heptanoylamino, octanoylamino, nonanoylamino,
decanoylamino, lauroylamino, myristoylamino, palmitoylamino and
stearoylamino groups, of which those groups having from 1 to 12 carbon
atoms are preferred, those having from 2 to 10 carbon atoms are more
preferred, and those having from 2 to 5 carbon atoms are most preferred,
especially the acetamido, propionamido, butyramido, pivaloylamino,
nonanoylamino and decanoylamino groups, of which the acetamido,
propionamido, butyramido and pivaloylamino groups are most preferred.
Where R.sup.3 represents an alkenoylamino group, this may be a straight or
branched chain group and has from 3 to 6 carbon atoms. Examples of such
groups include the acryloylamino, methacryloylamino, 2-butenoylamino,
2-pentenoylamino and 2-hexenoylamino groups, of which the acryloylamino
and methacryloylamino groups are preferred.
Where R.sup.3 represents a cycloalkylcarbonylamino group, this has from 4
to 8 carbon atoms, that is the cycloalkyl group itself has from 3 to 7
ring carbon atoms. Examples of such groups include the
cyclopropylcarbonylamino, cyclobutylcarbonylamino,
cyclopentylcarbonylamino, cyclohexylcarbonylamino and
cycloheptylcarbonylamino groups, of which the cyclopropylcarbonylamino and
cyclobutylcarbonylamino groups are particularly preferred.
Where R.sup.3 represents arylcarbonylamino group, the aryl part is as
defined above, and examples of such groups include the benzamido,
1-naphthoylamino, 2-naphthoylamino, o-, m- and p-toluoylamino, o-, m- and
p-chlorobenzamido, o-, m- and p-fluorobenzamido, o-, m- and
p-methoxybenzamido, 2,4-dichlorobenzamido, 2,4-difluorobenzamido and
2,4,6-trifluorobenzamido groups, preferably the benzamido group.
Where R.sup.3 represents an alkoxycarbonylamino group, this may be a
straight or branched chain alkoxycarbonylamino group having from 2 to 5
carbon atoms, that is the alkoxy part has from 1 to 4 carbon atoms, add
examples include the methoxycarbonylamino, ethoxycarbonylamino,
propoxycarbonylamino, isopropoxycarbonylamino, butoxycarbonylamino,
isobutoxycarbonylamino, sec-butoxycarbonylamino and t-butoxycarbonylamino
groups. Of these, we prefer those alkoxycarbonylamino groups having from 1
to 3 carbon atoms in the alkoxy part and the t-butoxycarbonylamino group,
more preferably the methoxycarbonylamino, ethoxycarbonylamino and
t-butoxycarbonylamino groups.
Where R.sup.3 represents an aralkoxycarbonylamino group, the alkoxy part is
an alkoxy group having from 1 to 4, preferably from 1 to 3, carbon atoms,
such as those exemplified above in relation to R.sup.1, especially the
methoxy, ethoxy, propoxy or isopropoxy groups. The aryl part is as defined
above and has from 6 to 10, preferably 6 or 10, ring carbon atoms.
Examples of such aryl groups include the phenyl, 1-naphthyl and 2-naphthyl
groups and such groups which are substituted by one or more of
substituents D, defined above and examples of which have been given in
relation to the same groups and atoms which may be represented by R.sup.1.
The alkoxy part may be substituted by one or more aryl groups, the maximum
being dictated only by the number of substitutable positions and possibly
also by steric constraints; however, from 1 to 3 aryl groups are normally
preferred, 1 or 2 being more preferred and 1 being most preferred.
Specific examples of the aralkyloxycarbonylamino groups include the
benzyloxycarbonylamino, N-(1-naphthylmethoxycarbonyl)amino,
N-(2-naphthylmethoxycarbonyl)amino, phenethyloxycarbonylamino,
N-(.alpha.-methylbenzyloxycarbonyl)amino,
N-(3-phenylpropoxycarbonyl)amino, N-(2-phenylpropoxycarbonyl)amino,
N-(1-phenylpropoxycarbonyl)amino, N-(4-phenylbutoxycarbonyl)amino,
benzhydryloxycarbonylamino and trityloxycarbonylamino groups (of these,
the benzyloxycarbonylamino group is preferred), and such groups which are
substituted by one or more of substituents D.
Y represents a group of formula --NH-- or an oxygen or sulfur atom,
preferably an oxygen or sulfur atom, and more preferably a sulfur atom.
R.sup.3 may be at either the 2- or the 3- position of the
tetrahydropyrrolopyridyl, tetrahydrothienopyridyl or tetrahydrofuropyridyl
group, but is preferably at the 2-position, especially when the Y is an
oxygen or sulfur atom, i.e. on the tetrahydrothienopyridyl or
tetrahydrofuropyridyl group.
In the compounds of the present invention, the carbon atom to which the
group represented by R.sup.2 is attached is an assymetric carbon atom, and
other carbon atoms may be assymetric, and the compounds accordingly form
optical isomers. Although these are all represented herein by a single
molecular formula, the present invention includes both the individual,
isolated isomers and mixtures, including racemates thereof. Where
stereospecific synthesis techniques are employed or optically active
compounds are employed as starting materials, individual isomers may be
prepared directly; on the other hand, if a mixture of isomers is prepared,
the individual isomers may be obtained by conventional resolution
techniques.
In addition, when the compounds of the present invention have one or more
carbon-carbon double bonds or one or more disubstituted cycloalkyl
moieties, they form cis and trans isomers. The present invention includes
both the individual, isolated isomers and mixtures thereof.
The compounds of the present invention can form acid addition salts. There
is no particular restriction on the nature of these salts, provided that,
where they are intended for therapeutic use, they are pharmaceutically
acceptable. Where they are intended for non-therapeutic uses, e.g. as
intermediates in the preparation of other, and possibly more active,
compounds, even this restriction does not apply. Examples of such acid
addition salts include: salts with mineral acids, especially hydrohalic
acids (such as hydrofluoric acid, hydrobromic acid, hydroiodic acid or
hydrochloric acid), nitric acid, carbonic acid, sulfuric acid or
phosphoric acid; salts with lower alkylsulfonic acids, such as
methanesulfonic acid, trifluoromethanesulfonic acid or ethanesulfonic
acid; salts with arylsulfonic acids, such as benzenesulfonic acid or
p-toluenesulfonic acid; and salts with organic carboxylic acids, such as
acetic acid, propionic acid, butyric acid, fumaric acid, tartaric acid,
oxalic acid, malonic acid, maleic acid, malic acid, succinic acid, benzoic
acid, mandelic acid, ascorbic acid, lactic acid, gluconic acid or citric
acid.
The compounds of the present invention may also readily form hydrates and
these, also, form part of the present invention.
Additionally, when R.sup.3 represents an amino group or a substituted amino
group, the resulting compound can form a complex salt with a metal ion,
and such complex salts also form part of the present invention. Examples
of such complex salts include salts with calcium chloride, magnesium
chloride, zinc chloride, ferric chloride, stannic chloride and nickel
chloride.
Preferred classes of compounds of the present invention are those compounds
of formulae (I) and tautomers and salts thereof in which:
(A) R.sup.1 represents a hydrogen atom, an alkyl group having from 1 to 4
carbon atoms, a halogen atom, a fluoroalkyl group having from 1 to 4
carbon atoms and at least one fluorine atom, a hydroxy group, an alkoxy
group having from 1 to 4 carbon atoms, a fluoroalkoxy group having from 1
to 4 carbon atoms and at least one fluorine atom, an alkylthio group
having from 1 to 4 carbon atoms, a fluoroalkylthio group having from 1 to
4 carbon atoms and at least one fluorine atom, an amino group, an alkanoyl
group having from 1 to 5 carbon atoms, a fluoroalkanoyl group having from
2 to 5 carbon atoms and at least one fluorine atom, an alkoxycarbonyl
group having from 2 to 5 carbon atoms, a carbamoyl group, a cyano group, a
nitro group, an alkanesulfonyl group having from 1 to 4 carbon atoms, a
fluoroalkanesulfonyl group having from 1 to 4 carbon atoms and at least
one fluorine atom, or a sulfamoyl group.
(B) R.sup.2 represents an alkanoyl group having from 2 to 6 carbon atoms, a
substituted alkanoyl group which has from 2 to 6 carbon atoms and which is
substituted by at least one substituent selected from the group consisting
of substituents A', defined below, a cycloalkylcarbonyl group having from
4 to 7 carbon atoms, a substituted cycloalkylcarbonyl group which has from
4 to 7 carbon atoms and which is substituted by at least one substituent
selected from the group consisting of substituents A', defined below, a
substituted benzoyl group having at least one fluorine substituent, or a
5,6-dihydro-1,4,2-dioxazin-3-yl group; and
said substituents A' are selected from the group consisting of fluorine
atoms, chlorine atoms, hydroxy groups, methoxy groups, ethoxy groups and
cyano groups.
(C) R.sup.3 represents a hydrogen atom, a hydroxy group, an alkoxy group
having from 1 to 4 carbon atoms, an alkoxymethoxy group in which the
alkoxy part has from 1 to 4 carbon atoms, an alkanoyloxymethoxy group in
which the alkanoyl part has from 1 to 5 carbon atoms, a benzyloxy group
which is unsubstituted or is substituted by at least one substituent
selected from the group consisting of substituents D', defined below, an
alkanoyloxy group having from 1 to 18 carbon atoms, an alkenoyloxy group
having 3 or 4 carbon atoms, a cycloalkylcarbonyloxy group having from 4 to
7 carbon atoms, a benzoyloxy group which is unsubstituted or is
substituted by at least one substituent selected from the group consisting
of substituents D', defined below, an alkoxycarbonyloxy group having from
2 to 5 carbon atoms, a benzyloxycarbonyloxy group which is unsubstituted
or is substituted by at least one substituent selected from the group
consisting of substituents D', defined below, a phthalidyloxy group, a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a
(5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a group of formula
--NR.sup.a R.sup.b
wherein R.sup.a and R.sup.b are independently selected from the group
consisting of hydrogen atoms, methyl and ethyl groups or R.sup.a
represents a hydrogen atom and R.sup.b represents an alkanoyloxymethyl
group in which the alkanoyl part has from 1 to 5 carbon atoms,
a benzylamino group, an alkanoylamino group having from 1 to 18 carbon
atoms, an alkenoylamino group having 3 or 4 carbon atoms, a
cycloalkylcarbonylamino group having 6 or 7 carbon atoms, a benzoylamino
group which is unsubstituted or is substituted by at least one substituent
selected from the group consisting of substituents D', defined below, an
alkoxycarbonylamino group having from 2 to 5 carbon atoms or a
benzyloxycarbonylamino group which is unsubstituted or is substituted by
at least one substituent selected from the group consisting of
substituents D', defined below;
and
said substituents D' are selected from the group consisting of fluorine
atoms, chlorine atoms, methyl groups and methoxy groups.
(D) Y represents an oxygen or sulfur atom.
Of these, we prefer those compounds in which R.sup.1 is as defined in (A)
above, R.sup.2 is as defined in (B) above, R.sup.3 is as defined in (C)
above and Y is as defined in (D) above.
More preferred classes of compounds of the present invention are those
compounds of formulae (I) and tautomers and salts thereof in which:
(E) R.sup.1 represents a hydrogen atom, a methyl group, an ethyl group, a
halogen atom, a methyl group substituted by at least one fluorine atom, a
hydroxy group, a methoxy group, an ethoxy group, a methoxy group
substituted by at least one fluorine atom, a methylthio group, a
methylthio group substituted by at least one fluorine atom, a formyl
group, an acetyl group, an acetyl group substituted by at least one
fluorine atom, an alkoxycarbonyl group having from 2 to 4 carbon atoms, a
carbamoyl group, a cyano group, a nitro group, a methanesulfonyl group, an
ethanesulfonyl group, a methanesulfonyl group substituted by at least one
fluorine atom, or a sulfamoyl group.
(F) R.sup.2 represents an alkanoyl group having from 2 to 6 carbon atoms, a
substituted alkanoyl group which has from 2 to 6 carbon atoms and which is
substituted by at least one fluorine atom, a cycloalkylcarbonyl group
having from 4 to 7 carbon atoms, or a substituted cycloalkylcarbonyl group
which is substituted by at least one fluorine atom.
(G) R.sup.3 represents a hydrogen atom, a hydroxy group, a methoxy group,
an ethoxy group, a t-butoxy group, a methoxymethoxy group, an
alkanoyloxymethoxy group in which the alkanoyl part has from 1 to 5 carbon
atoms, a benzyloxy group, an alkanoyloxy group having from 1 to 12 carbon
atoms, an alkenoyloxy group having 3 or 4 carbon atoms, a
cycloalkylcarbonyloxy group having from 4 to 7 carbon atoms, a benzoyloxy
group, an alkoxycarbonyloxy group having from 2 to 5 carbon atoms, a
benzyloxycarbonyloxy group, a phthalidyloxy group, a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, a
(5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy group, an amino group or a
t-butoxycarbonylamino group.
Of these, we prefer those compounds in which R.sup.1 is as defined in (E)
above, R.sup.2 is as defined in (F) above, R.sup.3 is as defined in (G)
above and Y is as defined in (D) above.
Still more preferred classes of compounds of the present invention are
those compounds of formulae (I) and tautomers and salts thereof in which:
(H) R.sup.1 represents a halogen atom, a trifluoromethyl group, a hydroxy
group, a difluoromethoxy group, a trifluoromethoxy group, a
difluoromethylthio group, a trifluoromethylthio group, a formyl group, an
acetyl group, a trifluoroacetyl group, a cyano group or a nitro group.
(I) R.sup.3 represents a hydrogen atom, a hydroxy group, a
pivaloyloxymethoxy group, an alkanoyloxy group having from 2 to 10 carbon
atoms, an alkoxycarbonyloxy group having from 2 to 5 carbon atoms or a
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy group.
(J) Y represents a sulfur atom.
Of these, we prefer those compounds in which R.sup.1 is as defined in (H)
above, R.sup.2 is as defined in (F) above, R.sup.3 is as defined in (I)
above and Y is as defined in (J) above.
The most preferred classes of compounds of the present invention are those
compounds of formulae (I) and tautomers and salts thereof in which:
(K) R.sup.1 represents a fluorine or chlorine atom.
(L) R.sup.2 represents an acetyl group, a propionyl group, a substituted
acetyl or propionyl group which is substituted by at least one fluorine
atom, a cyclopropylcarbonyl group, cyclobutylcarbonyl group, or a
substituted cyclopropylcarbonyl or cyclobutylcarbonyl group which is
substituted by at least one fluorine atom.
(M) R.sup.3 represents a hydrogen atom, a hydroxy group, a
pivaloyloxymethoxy group, an alkanoyloxy group having from 2 to 6 carbon
atoms or an alkoxycarbonyloxy group having from 2 to 5 carbon atoms.
Of these, we prefer those compounds in which R.sup.1 is as defined in (K)
above, R.sup.2 is as defined in (L) above, R.sup.3 is as defined in (M)
above and Y is as defined in (J) above.
In all of the above classes of compounds, we prefer that n should be from 1
to 3, especially 1 or 2, and most preferably 1.
Specific examples of preferred compounds of the present invention are those
compounds of formula (II) or (IIa), in which R.sup.x, R.sup.2, R.sup.3 /Z
and Y are as defined in the following Table 1. In the column headed
"R.sup.3 /Z", the "R.sup.3 " applies to compounds of formula (II), whilst
"Z" applies to compounds of formula (IIa):
##STR4##
In the Table, the following abbreviations are used to refer to certain
substituent groups:
______________________________________
Ac acetyl
Acr acryloyl
.sub.- tBoc
t-butoxycarbonyl
Boz benzoyl
-cBu cyclobutyl
.sub.- tBu
t-butyl
Bun butenoyl
Byr butyryl
.sub.- iByr
isobutyryl
Bz benzyl
Bzc benzyloxycarbonyl
Car carbamoyl
Dcn decanoyl
Ddoz 5,6-dihydro-1,4,2-dioxazin-3-yl
Et ethyl
Etc ethoxycarbonyl
Fo formyl
-cHp cycloheptyl
-cHx cyclohexyl
Hxn hexanoyl
Lau lauroyl
Me methyl
Mec methoxycarbonyl
Mod (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl
Nnn nonanoyl
Plt palmitoyl
Ph phenyl
Phth phthalidyl
Piv pivaloyl
-cPn cyclopentyl
-cPr cyclopropyl
Prn propionyl
Va valeryl
.sub.- iVa
isovaleryl
______________________________________
TABLE 1
______________________________________
Cpd. For-
No. mula R.sup.x R.sup.2 R.sup.3 /Z
Y
______________________________________
1 (II) Ph Ddoz H S
2 (II) 2-FPh Ddoz H S
3 (II) 2-ClPh Ddoz H S
4 (II) 2-CNPh Ddoz H S
5 (II) 2-NO.sub.2 Ph
Ddoz H S
6 (II) 2-CHF.sub.2 Ph
Ddoz H S
7 (II) 2,6-diFPh Ddoz H S
8 (II) 2-F, 6-ClPh
Ddoz H S
9 (II) 2-FPh Ac H S
10 (II) 2-ClPh Ac H S
11 (II) 2-CNPh Ac H S
12 (II) 2-NO.sub.2 Ph
Ac H S
13 (II) 2-CF.sub.3 Ph
Ac H S
14 (II) 2,6-diFPh Ac H S
15 (II) 2-F, 6-ClPh
Ac H S
16 (II) 2,4-diFPh Ac H S
17 (II) 2-F, 6-CNPh
Ac H S
18 (II) Ph Prn H S
19 (II) 2-FPh Prn H S
20 (II) 2-ClPh Prn H S
21 (II) 2-BrPh Prn H S
22 (II) 2-IPh Prn H S
23 (II) 2-HOPh Prn H S
24 (II) 2-NO.sub.2 Ph
Prn H S
25 (II) 2-Cl, Prn H S
5-NH.sub.2 Ph
26 (II) 2-CNPh Prn H S
27 (II) 2-F, Prn H S
5-HOOCPh
28 (II) 2-F, 4-MePh
Prn H S
29 (II) 2-CF.sub.3 Ph
Prn H S
30 (II) 2-F, Prn H S
4-MeOPh
31 (II) 2-CHF.sub.2 OPh
Prn H S
32 (II) 2-CF.sub.3 OPh
Prn H S
33 (II) 3-CH.sub.2 FOPh
Prn H S
34 (II) 4-MeSPh Prn H S
35 (II) 2-CHF.sub.2 SPh
Prn H S
36 (II) 3-CF.sub.3 SPh
Prn H S
37 (II) 2-MeSO.sub.2 Ph
Prn H S
38 (II) 2-EtSO.sub.2 Ph
Prn H S
39 (II) 2-CF.sub.3 SO.sub.2 Ph
Prn H S
40 (II) 4-CarPh Prn H S
41 (II) 3-NH.sub.2 SO.sub.2 Ph
Prn H S
42 (II) 2-FoPh Prn H S
43 (II) 2-AcPh Prn H S
44 (II) 2-CF.sub.3 COPh
Prn H S
45 (II) 2,6-diFPh Prn H S
46 (II) 2-F, 6-ClPh
Prn H S
47 (II) 2,4,6-triFPh
Prn H S
48 (II) 2,3,4,5,6- Prn H S
pentaFPh
49 (II) 2-F, 6-CNPh
Prn H S
50 (II) 2-F, 6-NO.sub.2 Ph
Prn H S
51 (II) 2,6-diF, Prn H S
4-MePh
52 (II) 2,4-diClPh Prn H S
53 (II) 2-F, 4-HOPh
Prn H S
54 (II) 2-Cl, Prn H S
4-MecPh
55 (II) 2-F, Prn H S
6-CHF.sub.2 OPh
56 (II) 2-Cl, 4-EtPh
Prn H S
57 (II) 2-F, 5-EtOPh
Prn H S
58 (II) Ph -cPrCO H S
59 (II) 2-FPh -cPrCO H S
60 (II) 2-ClPh -cPrCO H S
61 (II) 2-BrPh -cPrCO H S
62 (II) 2-IPh -cPrCO H S
63 (II) 2-HOPh -cPrCO H S
64 (II) 2-NO.sub.2 Ph
-cPrCO H S
65 (II) 2-Cl, -cPrCO H S
5-NH.sub.2 Ph
66 (II) 2-CNPh -cPrCO H S
67 (II) 2-F, -cPrCO H S
5-HOOCPh
68 (II) 2-F, 4-MePh
-cPrCO H S
69 (II) 2-CF.sub.3 Ph
-cPrCO H S
70 (II) 2-F, -cPrCO H S
4-MeOPh
71 (II) 2-CHF.sub.2 OPh
-cPrCO H S
72 (II) 2-CF.sub.3 OPh
-cPrCO H S
73 (II) 3-CH.sub.2 FOPh
-cPrCO H S
74 (II) 4-MeSPh -cPrCO H S
75 (II) 2-CHF.sub.2 SPh
-cPrCO H S
76 (II) 3-CF.sub.3 SPh
-cPrCO H S
77 (II) 2-MeSO.sub.2 Ph
-cPrCO H S
78 (II) 2-EtSO.sub.2 Ph
-cPrCO H S
79 (II) 2-CF.sub.3 SO.sub.2 Ph
-cPrCO H S
80 (II) 4-CarPh -cPrCO H S
81 (II) 3-NH.sub.2 SO.sub.2 Ph
-cPrCO H S
82 (II) 2-FoPh -cPrCO H S
83 (II) 2-AcPh -cPrCO H S
84 (II) 2-CF.sub.3 COPh
-cPrCO H S
85 (II) 2,6-diFPh -cPrCO H S
86 (II) 2-F, 6-ClPh
-cPrCO H S
87 (II) 2,4,6-triFPh
-cPrCO H S
88 (II) 2,3,4,5,6- -cPrCO H S
pentaFPh
89 (II) 2-F, 6-CNPh
-cPrCO H S
90 (II) 2-F, 6-NO.sub.2 Ph
-cPrCO H S
91 (II) 2,6-diF, -cPrCO H S
4-MePh
92 (II) 2,4-diClPh -cPrCO H S
93 (II) 2-F, 4-HOPh
-cPrCO H S
94 (II) 2-Cl, 4-EtcPh
-cPrCO H S
95 (II) 2-F, -cPrCO H S
6-CHF.sub.2 OPh
96 (II) 2-Cl, 4-EtPh
-cPrCO H S
97 (II) 2-F, 5-EtOPh
- cPrCO H S
98 (II) 2-FPh 3-FPrn H S
99 (II) 2-ClPh 3-FPrn H S
100 (II) 2-CNPh 3-FPrn H S
101 (II) 2,6-diFPh 3-FPrn H S
102 (II) 2-F, 6-ClPh
3-FPrn H S
103 (II) 2-F, 6-CNPh
3-FPrn H S
104 (II) 2-NO.sub.2 Ph
3-FPrn H S
105 (II) 2-F, 4-CNPh
3-FPrn H S
106 (II) 2-FPh -cBuCO H S
107 (II) 2-ClPh -cBuCO H S
108 (II) 2-CNPh -cBuCO H S
109 (II) 2-FPh HOCH.sub.2 CO
H S
110 (II) 2-ClPh HOCH.sub.2 CO
H S
111 (II) 2-CNPh CF.sub.3 CO
H S
112 (II) 2-FPh CF.sub.3 CO
H S
113 (II) 2-ClPh CF.sub.3 CO
H S
114 (II) 2-FPh Fo H S
115 (II) 2-ClPh Fo H S
116 (II) 2-FPh Byr H S
117 (II) 2-ClPh Byr H S
118 (II) 2-FPh .sub.- iByr
H S
119 (II) 2-ClPh .sub.- iByr
H S
120 (II) 2-FPh Va H S
121 (II) 2-ClPh Va H S
122 (II) 2-FPh Piv H S
123 (II) 2-F, 6-ClPh
Piv H S
124 (II) 2-FPh .sub.- iVa
H S
125 (II) 2-ClPh Hxn H S
126 (II) 2-FPh Dcn H S
127 (II) 2-ClPh 1-Bun H S
128 (II) 2-FPh -cPnCO H S
129 (II) 2-FPh -cHxCO H S
130 (II) 2-FPh -cHpCO H S
131 (II) 2-FPh CH.sub.2 FCO
H S
132 (II) 2-FPh CHF.sub.2 CO
H S
133 (II) 2-ClPh CHF.sub.2 CO
H S
134 (II) 2-CNPh CHF.sub.2 CO
H S
135 (II) 2-FPh MeO--CH.sub.2 CO
H S
136 (II) 2-ClPh MeO--CH.sub.2 CO
H S
137 (II) 2-FPh NC--CH.sub.2 CO
H S
138 (II) 2-ClPh NC--CH.sub.2 CO
H S
139 (II) 2,6-diFPh NC--CH.sub.2 CO
H S
140 (II) 2-FPh 3-ClPrn H S
141 (II) 2-ClPh 3-ClPrn H S
142 (II) 2-FPh 3-HOPrn H S
143 (II) 2-ClPh 3-HOPrn H S
144 (II) 2-FPh 3-MeOPrn H S
145 (II) 2-FPh 3-CNPrn H S
146 (II) 2-FPh 4-FByr H S
147 (II) 2-ClPh 4-ClByr H S
148 (II) 2-FPh 4-FBoz H S
149 (II) 2-ClPh 4-FBoz H S
150 (II) 2-CNPh 4-FBoz H S
151 (II) 2-FPh 2,4-diFBoz
H S
152 (II) 2-ClPh 2,4-diFBoz
H S
153 (II) 2-NO.sub.2 Ph
2,4-diFBoz
H S
154 (II) 2-FPh 3-BrPrn H S
155 (II) 2-FPh 3-IPrn H S
156 (II) 2-FPh Ac H O
157 (II) 2-ClPh Ac H O
158 (II) 2-CNPh Ac H O
159 (II) 2-NO.sub.2 Ph
Ac H O
160 (II) 2-FPh Prn H O
161 (II) 2-ClPh Prn H O
162 (II) 2-CNPh Prn H O
163 (II) 2-NO.sub.2 Ph
Prn H O
164 (II) 2-FPh 3-FPrn H O
165 (II) 2-ClPh 3-FPrn H O
166 (II) 2-CNPh 3-FPrn H O
167 (II) 2-NO.sub.2 Ph
3-FPrn H O
168 (II) 2-FPh -cPrCO H O
169 (II) 2-ClPh -cPrCO H O
170 (II) 2-CNPh -cPrCO H O
171 (II) 2-NO.sub.2 Ph
-cPrCO H O
172 (II) 2,6-diFPh -cPrCO H O
173 (II) 2-F, 6-ClPh
-cPrCO H O
174 (II) 2,6-diFPh 4-FBoz H S
175 (II) 2-FPh -cPrCO 2-NO.sub.2
S
176 (II) 2-FPh - cPrCO 2-NH.sub.2
O
177 (II) 2-FPh -cPrCO 2-NH.sub.2
S
178 (II) 2-FPh -cPrCO 2-AcNH O
179 (II) 2-FPh -cPrCO 2-AcNH S
180 (II) 2-FPh -cPrCO 2-ByrNH O
181 (II) 2-FPh -cPrCO 2-ByrNH S
182 (II) 2-FPh -cPrCO 2-PivNH S
183 (II) 2-FPh -cPrCO 2- .sub.- tBocNH
O
184 (II) 2-FPh -cPrCO 2- .sub.- tBocNH
S
185 (II) 2-FPh -cPrCO 2-HO O
186 (II) 2-ClPh -cPrCO 2-HO S
187 (II) 2-FPh Prn 2-HO S
188 (II) 2-FPh -cPrCO 2-HO S
189 (II) 2-FPh -cPrCO 2-AcO O
190 (II) 2-FPh -cPrCO 2-AcO S
191 (II) 2-FPh -cPrCO 2-PrnO O
192 (II) 2-FPh -cPrCO 2-PrnO S
193 (II) 2-FPh -cPrCO 2-ByrO O
194 (II) 2-FPh -cPrCO 2-ByrO S
195 (II) 2-FPh - cPrCO 2-PivO O
196 (II) 2-FPh -cPrCO 2-PivO S
197 (II) 2-FPh -cPrCO 2-VaO S
198 (II) 2-FPh -cPrCO 2-HxnO S
199 (II) 2-FPh -cPrCO 2-NnnO S
200 (II) 2-FPh -cPrCO 2-DcnO S
201 (II) 2-FPh -cPrCO 2-PltO S
202 (II) 2-FPh -cPrCO 2-BozO S
203 (II) 2-FPh -cPrCO 2- .sub.- tBocO
S
204 (II) 2-FPh -cPrCO 2- .sub.- tBuO
S
205 (II) 2-FPh -cPrCO 2-BzO S
206 (II) 2-FPh -cPrCO 2-MeOCH.sub.2 O
S
207 (II) 2-FPh -cPrCO 2-PivOCH.sub.2 O
S
208 (II) 2-FPh -cPrCO 2-PhthO S
209 (II) 2-FPh -cPrCO 2-ModO S
210 (II) 2-FPh -cPrCO 2-MeO S
211 (II) 2-FPh -cPrCO 2-EtO S
212 (II) 2-FPh -cPrCO 2-LauO S
213 (II) 2-FPh -cPrCO 2-AcrO S
214 (II) 2-FPh -cPrCO 2- -cHxCOO
S
215 (II) 2-FPh -cPrCO 2-MecO S
216 (II) 2-FPh -cPrCO 2-EtcO S
217 (II) 2-FPh -cPrCO 2-FoNH S
218 (II) 2-FPh -cPrCO 2-PrnNH S
219 (II) 2-FPh -cPrCO 2-MeNH S
220 (II) 2-FPh -cPrCO 2-EtNH S
221 (II) 2-FPh -cPrCO 2-NMe.sub.2
S
222 (II) 2-FPh -cPrCO 2-AcrNH S
223 (II) 2-FPh -cPrCO 2- -cHxCONH
S
224 (II) 2-FPh -cPrCO 2-MecNH S
225 (II) 2-FPh -cPrCO 2-EtcNH S
226 (II) 2-FPh -cPrCO 2-BozNH S
227 (II) 2-FPh -cPrCO 2-BozO O
228 (II) 2-FPh -cPrCO 2- .sub.- tBocO
O
229 (II) 2-FPh Prn 2-NO.sub.2
S
230 (II) 2-FPh -cPrCO 2-BzcO S
231 (II) 2-FPh -cPrCO 2-BzcNH S
232 (IIa) 2-FPh - cPrCO O O
233 (IIa) 2-ClPh -cPrCO O S
234 (IIa) 2-FPh Prn O S
235 (IIa) 2-FPh -cPrCO O S
236 (II) 2-FPh Prn 2-AcO S
237 (II) 2-FPh Prn 2-PrnO S
238 (II) 2-FPh Prn 2-ByrO S
239 (II) 2-FPh Prn 2-PivO S
240 (II) 2-FPh Prn 2-VaO S
241 (II) 2-FPh Prn 2-HxnO S
242 (II) 2-FPh Prn 2-MecO S
243 (II) 2-FPh Prn 2-EtcO S
244 (II) 2-FPh Prn 2- .sub.- tBocO
S
245 (II) 2-FPh Prn 2-BozO S
246 (II) 2-FPh Prn 2-NH.sub.2
S
247 (II) 2-FPh Prn 2-AcNH S
248 (II) 2-FPh Prn 2-PrnNH S
249 (II) 2-FPh Prn 2-ByrNH S
250 (II) 2-FPh Prn 2- .sub.- tBocNH
S
251 (II) 2-FPh Prn 2-BzcNH S
252 (II) 2-ClPh -cPrCO 2-AcO S
253 (II) 2-ClPh -cPrCO 2-PrnO S
254 (II) 2-ClPh -cPrCO 2-ByrO S
255 (II) 2-ClPh -cPrCO 2-PivO S
256 (II) 2-ClPh -cPrCO 2-VaO S
257 (II) 2-ClPh -cPrCO 2-HxnO S
258 (II) 2-ClPh -cPrCO 2-MecO S
259 (II) 2-ClPh -cPrCO 2-EtcO S
260 (II) 2-ClPh -cPrCO 2- .sub.- tBocO
S
261 (II) 2-ClPh -cPrCO 2-BozO S
262 (II) 2-ClPh -cPrCO 2-NH.sub.2
S
263 (II) 2-ClPh -cPrCO 2-AcNH S
264 (II) 2-ClPh -cPrCO 2-PrnNH S
265 (II) 2-ClPh -cPrCO 2-ByrNH S
266 (II) 2-ClPh -cPrCO 2- .sub.- tBocNH
S
267 (II) 2-ClPh -cPrCO 2-BzcNH S
268 (II) 2-FPh -cPrCO 2-MeOCH.sub.2 NH
S
269 (II) 2-FPh -cPrCO 2-PhthNH S
270 (II) 2-FPh -cPrCO 2-ModNH S
271 (II) 2-FPh -cPrCO 2-PivOCH.sub.2 NH
S
272 (II) 2-FPh 2-F -cPrCO
H S
273 (II) 2-FPh 2-F -cPrCO
H O
274 (II) 2-FPh 2-F -cPrCO
2-OH S
275 (IIa) 2-FPh 2-F -cPrCO
O S
276 (II) 2-FPh 2-F - cPrCO
2-AcO S
277 (II) 2-FPh 2-F -cPrCO
2-ByrO S
278 (II) 2-FPh 2-F -cPrCO
2-PivO S
279 (II) 2-FPh 2-F -cPrCO
2-PivOCH.sub.2 O
S
280 (II) 2-ClPh 2-F -cPrCO
H S
281 (II) 2-ClPh 2-F -cPrCO
2-OH S
282 (IIa) 2-ClPh 2-F -cPrCO
O S
283 (II) 2-ClPh 2-F -cPrCO
2-AcO S
284 (II) 2-ClPh 2-F -cPrCO
2-ByrO S
285 (II) 2-ClPh 2-F -cPrCO
2-PivO S
286 (II) 2-ClPh 2-F -cPrCO
2-PivOCH.sub.2 O
S
287 (II) 2-FPh 2,2-diF -cPrCO
H S
288 (II) 2-FPh 2,2-diF -cPrCO
2-OH S
289 (IIa) 2-FPh 2,2-diF -cPrCO
O S
290 (II) 2-FPh 2,2-diF -cPrCO
2-AcO S
291 (II) 2-FPh 2,2-diF -cPrCO
2-ByrO S
______________________________________
Of the compounds listed above, the following are preferred, that is to say
Compounds No. 2, 3, 7, 9, 10, 11, 12, 19, 20, 24, 26, 29, 58. 59, 60, 61,
62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79,
80, 81, 82, 83, 84, 85, 86, 89, 90, 98, 99, 106, 107, 108, 109, 111, 112,
113, 114, 116, 117, 118, 119, 120, 121, 122, 124, 125, 128, 129, 131, 132,
133, 135, 137, 140, 142, 144, 149, 151, 156, 160, 168, 177, 184, 186, 187,
188, 190, 192, 194, 196, 197, 198, 199, 200, 201, 203, 204, 206, 207, 208,
209, 210, 233, 234, 235, 236, 238, 239, 252, 253, 254, 255, 274, 275, 276,
277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289 and 290,
of which Compounds No. 9, 10, 19, 20, 59, 60, 63, 64, 66, 69, 71, 72, 75,
76, 83, 84, 85, 86, 98, 106, 113, 116, 118, 120, 122, 125, 128, 129, 131,
132, 186, 187, 188, 190, 192, 194, 196, 197, 198, 199, 200, 203, 207, 209,
233, 234, 235, 236, 238, 239, 252, 253, 254, 255, 274, 275, 276, 277, 278,
279, 281, 282, 283, 284, 285 and 286 are more preferred.
The most preferred compounds are Compounds No.:
19.
5-(2-Fluoro-.alpha.-propionylbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridi
ne;
59.
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,
2-c]pyridine;
60. 5-(2-Chloro-60
-cyclopropylcarbonylbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine;
190.
2-Acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydr
othieno[3,2-c]pyridine;
192. 5-(-60
Cyclopropylcarbonyl-2-fluorobenzyl)-2-propionyloxy-4,5,6,7-tetrahydrothien
o[3,2-c]pyridine;
194.
2-Butyryloxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrah
ydrothieno[3,2-c]pyridine;
196.
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-2-pivaloyloxy-4,5,6,7-tetra
hydrothieno[3,2-c]pyridine;
197.
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-2-valeryloxy-4,5,6,7-tetrah
ydrothieno[3,2-c]pyridine;
198.
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-2-hexanoyloxy-4,5,6,7-tetra
hydrothieno[3,2-c]pyridine;
203.
2-t-Butoxycarbonyloxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6
,7-tetrahydrothieno[3,2-c]pyridine;
207.
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-2-pivaloyloxymethoxy-4,5,6,
7-tetrahydrothieno[3,2-c]pyridine;
233.
5-(2-Chloro-.alpha.-cyclopropylcarbonylbenzyl)-2-oxo-2,4,5,6,7,7a-hexahydr
othieno[3,2-c]pyridine and its tautomer;
234.
5-(2-Fluoro-.alpha.-propionylbenzyl)-2-oxo-2,4,5,6,7,7a-hexahydrothieno[3,
2-c]pyridine and its tautomer;
235. 5
(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7a-hexahydrot
hieno[3,2-c]pyridine and its tautomer;
252.
2-Acetoxy-5-(2-chloro-.alpha.-cyclopropylcarbonylbenzyl)-4,5,6,7-tetrahydr
othieno[3,2-c]pyridine;
275.
5[.alpha.-(2-Fluorocyclopropylcarbonyl-2-fluorobenzyl]-2-oxo-2,4,5,6,7,7a-
hexahydrothieno[3,2-c]pyridine and its tautomer;
276.
2-Acetoxy-5-[.alpha.-(2-fluorocyclopropylcarbonyl-2-fluorobenzyl]-4,5,6,7-
tetrahydrothieno[3,2-c]pyridine.
The compounds of the present invention can be prepared by a variety of
methods, whose general techniques are known in the art for the preparation
of compounds of this type. For example, they may be prepared by reacting a
compound of formula (III):
##STR5##
(in which R.sup.1, R.sup.2 and n are as defined above and X represents a
halogen atom, for example a fluorine, chlorine, bromine or iodine atom,
preferably a chlorine or bromine atom) with a compound of formula (IV):
##STR6##
(in which Y is as defined above and R.sup.3a represents a hydrogen atom or
a hydroxy or nitro group) to give a compound of formula (Ic):
##STR7##
(in which R.sup.1, R.sup.2, R.sup.3a, n and Y are as defined above).
If required, this compound of formula (Ic) may then be subjected to one or
more appropriate reactions, as explained in more detail hereafter, to
convert the hydroxy or nitro group represented by R.sup.3a to any other
group represented by R.sup.3, as defined above.
These reactions may be summarized in the following Reaction Scheme A:
##STR8##
In the above formulae, R.sup.1, R.sup.2, R.sup.3, R.sup.3a, X, Y and n are
as defined above.
In Step A1 of this Reaction Scheme, the substituted benzyl halide of
formula (III) is reacted with a condensed hydropyridyl compound of formula
(IV), to give the compound of formula (Ic). This reaction may be carried
out in the presence or absence of an inert solvent (preferably in the
presence of an inert solvent) and in the presence or absence of a base
(preferably in the presence of a base).
There is no specific limitation on the nature of the base employed, and any
base known for use in reactions of this type may equally be used here.
Examples of suitable bases include: organic amines, such as triethylamine,
tributylamine, N-methylmorpholine, pyridine, 4-dimethylaminopyridine,
picoline, lutidine, collidine, 1,8-diazabicyclo[5.4.0]undec-7-ene or
1,5-diazabicyclo[4.3.0]non-5-ene; alkali metal alkoxides, such as sodium
methoxide, sodium ethoxide or potassium t-butoxide; alkali metal
carbonates, such as sodium carbonate or potassium carbonate; and alkali
metal hydroxides, such as sodium hydroxide or potassium hydroxide. Of
these, the alkali metal carbonates are preferred. The amount of base
employed is not critical, but we would generally recommend an amount of
base of from an equimolar amount to 5 times the equimolar amount with
respect to the starting material of formula (III). Where an excess of the
starting material of formula (IV) is employed, this may also function as
the base. Also, if an excess of an organic amine is employed as the base,
this may additionally serve as the solvent.
The reaction is normally and preferably effected in the presence of a
solvent. There is no particular restriction on the nature of the solvent
to be employed, provided that it has no adverse effect on the reaction or
on the reagents involved and that it can dissolve the reagents, at least
to some extent. Examples of suitable solvents include: ethers, such as
diethyl ether, tetrahydrofuran or dioxane; ketones, such as acetone or
methyl ethyl ketone; esters, such as ethyl acetate; alcohols, such as
methanol, ethanol, propanol, isopropanol or butanol; nitriles, such as
acetonitrile; amides, such as N,N-dimethylformamide, N,N-dimethyl
acetamide, N-methyl-2-pyrrolidone or hexamethyl phosphoric triamide; and
sulfoxides, such as dimethyl sulfoxide. Of these, the amides or the
sulfoxides are preferred.
The reaction can take place over a wide range of temperatures, and the
precise reaction temperature is not critical to the invention. In general,
we find it convenient to carry out the reaction at a temperature of from
0.degree. C. to 200.degree. C. (more preferably at from about room
temperature to 150.degree. C.). The time required for the reaction may
also vary widely, depending on many factors, notably the reaction
temperature and the nature of the reagents and solvent employed. However,
provided that the reaction is effected under the preferred conditions
outlined above, a period of from 1 to 24 hours (more preferably from 2 to
15 hours) will usually suffice.
After completion of the reaction, the desired compound of formula (Ic) can
be obtained from the reaction mixture by conventional means. For example,
if the compound is produced immediately in the form of crystals, these can
be separated simply by filtration. Alternatively, a suitable recovery
procedure comprises: adding water; neutralizing the mixture, if necessary;
extracting the mixture with a water-immiscible organic solvent; drying the
extract; and distilling the solvent off. If necessary, the product thus
obtained can be further purified by conventional means, such as
recrystallization or the various chromatography techniques, for example
preparative thin layer chromatography or column chromatography, notably
column chromatography.
In the optional second step of this reaction, Step A2, the resulting
compound of formula (Ic) is converted, if desired, to a compound of
formula (I). This reaction may involve any one or more of the following
reactions:
(1) Where R.sup.3a represents a hydroxy group, alkylation, aralkylation or
acylation of this hydroxy group;
(2) Where R.sup.3a represents a nitro group, conversion of this nitro group
to an amino group;
(3) Alkylation, aralkylation or acylation of the amino group obtained as
described in (2) above.
Alkylation, aralkylation or acylation of the hydroxy group in Step A2(1) is
carried out in an inert solvent and in the presence of a base by reacting
a hydroxy compound of formula (Ic) (R.sup.3a represents a hydroxy group)
with a corresponding alkylating, aralkylating or acylating agent, for
example an alkyl halide, aralkyl halide, acyl halide or acid anhydride.
The nature of this compound will, of course, depend on the nature of the
group which it is desired to introduce into the compound of formula (I).
However, examples of suitable compounds are as follows:
alkyl halides having from 1 to 4 carbon atoms, such as methyl iodide, ethyl
bromide, ethyl iodide, propyl chloride, propyl bromide, butyl chloride or
butyl iodide;
aralkyl halides having from 7 to 14 carbon atoms, such as benzyl chloride,
benzyl bromide, p-methylbenzyl chloride, p-methoxybenzyl chloride,
p-chlorobenzyl chloride, p-fluorobenzyl chloride or naphthylmethyl
chloride;
alkyl halides from 1 to 4 carbon atoms which are substituted by an alkoxy
group having from 1 to 4 carbon atoms, by an alkanoyloxy group having from
1 to 6 carbon atoms or by an arylcarbonyloxy group having from 7 to 11
carbon atoms, such as methoxy methyl chloride, 1-methoxyethyl chloride,
2-methoxyethyl chloride, 1-methoxypropyl chloride, 1-methoxybutyl
chloride, ethoxymethyl chloride, propoxymethyl chloride, butoxymethyl
chloride, acetoxymethyl chloride, 1-acetoxyethyl chloride, 2-acetoxyethyl
chloride, 1-acetoxypropyl chloride, 1-acetoxybutyl chloride,
propionyloxymethyl chloride, butyryloxymethyl chloride, valeryloxymethyl
chloride, pivaloyloxymethyl chloride, benzoyloxymethyl cchloride,
1-benzoyloxyethyl chloride, p-methylbenzoyloxymethyl chloride,
p-methoxybenzoyloxymethyl chloride, p-chlorobenzoyloxymethyl chloride,
p-fluorobenzoyloxymethyl chloride or naphthoyloxymethyl chloride;
alkanoyl halides having from 2 to 18 carbon atoms or a mixed acid anhydride
of one such corresponding acid with formic acid, such as acetyl chloride,
propionyl chloride, butyryl chloride, butyryl bromide, valeryl chloride,
isovaleryl chloride, pivaloyl chloride, hexanoyl chloride, nonanoyl
chloride, decanoyl chloride, lauroyl chloride, palmitoyl chloride,
stearoyl chloride, mixed acid anhydride of formic acid and acetic acid,
acetic anhydride, propionic anhydride or butyric anhydride;
alkenoyl chlorides having from 3 to 6 carbon atoms, such as acryloyl
chloride, methacryloyl chloride, crotonoyl chloride or 2-hexenoyl
chloride;
cycloalkanecarbonyl halides having from 3 to 7 carbon atoms in the
cycloalkane part, such as cyclopropanecarbonyl chloride,
cyclobutanecarbonyl chloride, cyclopentanecarbonyl chloride,
cyclohexanecarbonyl chloride or cycloheptanecarbonyl chloride;
arylcarbonyl halides having from 6 to 10 carbon atoms in the aryl part,
such as benzoyl chloride, p-methylbenzoyl chloride, p-methoxybenzoyl
chloride, p-chlorobenzoyl chloride, p-fluorobenzoyl chloride or naphthoyl
chloride;
alkoxycarbonyl halides having from 1 to 4 carbon atoms in the alkoxy part,
or an alkyl carbonate anhydride having from 1 to 4 carbon atoms in the
alkyl part, such as methoxycarbonyl chloride, ethoxycarbonyl chloride,
propoxycarbonyl chloride, isopropoxycarbonyl chloride, butoxycarbonyl
chloride, t-butoxycarbonyl chloride, dimethyl dicarbonate, diethyl
dicarbonate, dipropyl dicarbonate, diisopropyl dicarbonate, dibutyl
dicarbonate or di-t-butyl dicarbonate;
aralkyloxycarbonyl halides having from 7 to 14 carbon atoms in the aralkyl
part, such as benzyl oxycarbonyl chloride, p-methylbenzyloxycarbonyl
chloride, p-methoxybenzyloxycarbonyl chloride, p-chlorobenzyloxycarbonyl
chloride, p-fluorobenzyloxycarbonyl chloride or naphthylmethoxycarbonyl
chloride;
phthalidyl halides, such as phthalidyl chloride; or substituted methyl
halides, such as (5-methyl- or 5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl
chloride.
The base employed is not critical to the invention, provided that it has no
adverse effect on other parts of the molecule, and any base commonly used
in reactions of this type may equally be used here. Examples of suitable
bases include: alkali metal hydrides, such as lithium hydride or sodium
hydride; alkali metal alkoxides, such as sodium methoxide, sodium ethoxide
or potassium t-butoxide; alkali metal carbonates, such as sodium carbonate
or potassium carbonate; and alkali metal hydroxides, such as sodium
hydroxide or potassium hydroxide. Of these, the alkali metal hydrides are
preferred.
The reaction is normally and preferably effected in the presence of a
solvent. There is no particular restriction on the nature of the solvent
to be employed, provided that it has no adverse effect on the reaction or
on the reagents involved and that it can dissolve the reagents, at least
to some extent. Examples of suitable solvents include: ethers, such as
diethyl ether, tetrahydrofuran or dioxane; ketones, such as acetone or
methyl ethyl ketone; esters, such as ethyl acetate; nitriles, such as
acetonitrile; amides, such as N,N-dimethylformamide,
N,N-dimethylacetamide, N-methyl-2-pyrrolidone or hexamethylphosphoric
triamide; and sulfoxides, such as dimethyl sulfoxide. Of these, the amides
are preferred.
The reaction can take place over a wide range of temperatures, and the
precise reaction temperature is not critical to the invention. In general,
we find it convenient to carry out the reaction at a temperature of from
-10.degree. C. to 100.degree. C. (more preferably from 0.degree. C. to
50.degree. C.), although this may vary, depending on the nature of the
compound of formula (Ic) and the solvent. The time required for the
reaction may also vary widely, depending on many factors, notably the
reaction temperature and the nature of the reagents and solvent employed.
However, provided that the reaction is effected under the preferred
conditions outlined above, a period of from 30 minutes to 24 hours (more
preferably from 1 to 10 hours) will usually suffice.
The reaction of Step A2(2), which comprises the conversion of the nitro
group represented by R.sup.3a in the compound of formula (Ic) into an
amino group is preferably effected, in an inert solvent and in the
presence of an acid, by reaction of a nitro compound of formula (Ic) in
which R.sup.3a represents a nitro group with a reducing agent, for example
a metal powder. Suitable reducing metal powders include powders of iron,
tin or zinc. Of these, iron or tin powder is preferred.
Suitable acids include: mineral acids, such as hydrochloric acid or
sulfuric acid; and organic acids, such as acetic acid, trifluoroacetic
acid, methanesulfonic acid or p-toluensulfonic acid. Of these,
hydrochloric acid or acetic acid is preferred.
The reaction is normally and preferably effected in the presence of a
solvent. There is no particular restriction on the nature of the solvent
to be employed, provided that it has no adverse effect on the reaction or
on the reagents involved and that it can dissolve the reagents, at least
to some extent. Examples of suitable solvents include: water; ethers, such
as diethyl ether, tetrahydrofuran or dioxane; alcohols, such as methanol
or ethanol; the acid employed for the reaction, as mentioned above; or a
mixture of any two or more of these solvents. Of these, we prefer to use a
mixture of water with an acid.
The reaction can take place over a wide range of temperatures, and the
precise reaction temperature is not critical to the invention. In general,
we find it convenient to carry out the reaction at a temperature of from
-10.degree. C. to 100.degree. C. (more preferably from 0.degree. C. to
50.degree. C.), although this may vary depending on the nature of the
starting material of formula (Ic) and on the solvent employed. The time
required for the reaction may also vary widely, depending on many factors,
notably the reaction temperature and the nature of the reagents and
solvent employed. However, provided that the reaction is effected under
the preferred conditions outlined above, a period of from 15 minutes to 20
hours (more preferably from 30 minutes to 10 hours) will usually suffice.
If this reaction is carried out in an organic acid and in the presence of
one of the acid anhydrides mentioned later in connection with the reaction
of Step A2(3), this reaction affords an amino-acylated compound.
Conversion of the nitro group into an amino group can be also conducted in
a similar manner to Step C2(4) of Reaction Scheme C as described
hereafter, and, in this case, any nitro group contained in R.sup.1 is
converted into an amino group at the same time.
Alkylation, aralkylation or acylation of the amino group can be conducted
by reacting an amino compound of formula (Ic) in which R.sup.3 represents
an amino group with a corresponding alkyl halide, aralkyl halide, acyl
halide or acid anhydride [for example: an alkyl halide having from 1 to 4
carbon atoms; an alkyl halide having from 1 to 4 carbon atoms which is
substituted by an alkoxy group having from 1 to 4 carbon atoms, by an
alkanoyloxy group having from 1 to 6 carbon atoms or by an arylcarbonyloxy
group having from 6 to 10 carbon atoms in the aryl moiety; an aralkyl
halide having from 7 to 14 carbon atoms; an alkanoyl halide having from 2
to 18 carbon atoms or a mixed acid anhydride of a corresponding acid with
formic acid; an alkenoyl halide having from 3 to 6 carbon atoms; a
cycloalkanecarbonyl halide having from 3 to 7 carbon atoms in the
cycloalkane moiety; an arylcarbonyl halide having from 6 to 10 carbon
atoms in the aryl moiety; an alkoxycarbonyl halide having from 1 to 4
carbon atoms in the alkoxy moiety; an alkyl carbonate anhydride having
from 1 to 4 carbon atoms in the alkyl moiety; an aralkyloxycarbonyl halide
having from 7 to 14 carbon atoms in the aralkyl moiety; a phthalidyl
halide; or a (5-methyl or 5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl halide,
all as exemplified above in relation to Step A2(1)]. This reaction
normally and preferably takes place in an inert solvent and in the
presence of a base. If it is desired to prepare a mono-alkylamino compound
having from 1 to 4 carbon atoms, we prefer to use about an equimolar
amount of an alkyl halide having from 1 to 4 carbon atoms with respect to
the compound of formula (I); on the other hand, the desired compound is a
di-alkylamino compound having from 1 to 4 carbon atoms in each alkyl
moiety, it is preferred to use more than about 2 moles of an alkyl halide
having from 1 to 4 carbon atoms per mole of the compound of formula (I).
The reaction is essentially the same as that employed in Step A1, and may
be carried out using the the reaction conditions, base and solvent as
described above in relation to that reaction.
After completion of the reaction or any of the reactions described above,
the desired compound can be obtained from the reaction mixture by
conventional means. For example, one suitable recovery procedure
comprises: filtering off any insoluble matter; adding water to the
filtrate; if necessary, neutralizing the resulting mixture; extracting it
with a water-immiscible organic solvent, such as ethyl acetate; drying it;
and distilling off the solvent. If necessary, the product thus obtained
can be further purified by conventional means, such as recrystallization
or the various chromatography techniques, for example preparative thin
layer chromatography or column chromatography, notably column
chromatography.
A salt of the compound of formula (I) can be prepared by conventional
means, as is well known in the art. For example, the compound of formula
(I) is treated with an acid, such as hydrochloric acid or maleic acid, in
an inert solvent, such as diethyl ether or diisopropyl ether, and the
separated crystals are recovered by filtration.
An optically active compound of formula (I) can be prepared by using a
corresponding optically active benzyl halide of formula (II) as the
starting material, or by optical resolution of a racemic compound of
formula (I) by conventional means, such as fractional crystallization or
liquid chromatography.
The condensed hydropyridyl compound of formula (IV), used as one of the
starting materials, is known or may easily be prepared by any known method
[for example, M. Podesta et al., Eur. J. Med. Chem. - Chim. Ther. 9 (5),
487-490 (1974); and Japanese Patent Kokai Application No. Sho 61-246186].
Compounds of formula (IV) having a nitro group as the group R.sup.3a are
known or can be prepared as follows:
The imino group in a compound corresponding to the compound of formula
(IV), but in which the group R.sup.3a is a hydrogen atom [which can easily
be prepared by any known method (for example as described in Japanese
Patent Kokai Application No. Sho 62-103088)]is protected. The protecting
reaction can be conducted in a similar way to that described in Step A2(3)
of Reaction Scheme A, above. The protecting group may be, for example, an
acyl group, such as an alkanoyl group having from 1 to 18 carbon atoms as
exemplified above. The protected compound is then allowed to react in an
inert solvent (which may be, for example, a fatty acid, such as acetic
acid or propionic acid, or acid anhydride, such as acetic anhydride or
propionic anhydride, or a mixture of any two or more thereof) with a
nitrating agent (such as fuming nitric acid or anhydrous nitric acid) at a
suitable temperature, for example from 0.degree. C. to 50.degree. C., for
a period of, for example, from 15 minutes to 5 hours, and is finally
treated with an acid (such as aqueous hydrochloric acid or aqueous
sulfuric acid) at a suitable temperature, for example from 20.degree. C.
to 100.degree. C., for a period of, for example, from 15 minutes to 5
hours to remove the protecting group.
The compound of formula (III), which is the other starting material, can
easily be prepared, for example by the processes shown below in Reaction
Schemes B, C, D and E.
##STR9##
In these formulae, R.sup.1, X and n are as defined above.
R.sup.1a represents a hydrogen atom, an alkyl group having from 1 to 4
carbon atoms, a halogen atom, a haloalkyl group having from 1 to 4 carbon
atoms and at least one halogen atom, a hydroxy group, an alkoxy group
having from 1 to 4 carbon atoms, a haloalkoxy group having from 1 to 4
carbon atoms and at least one halogen atom, an alkylthio group having from
1 to 4 carbon atoms, a haloalkylthio group having from 1 to 4 carbon atoms
and at least one halogen atom, an amino group, an protected alkanoyl group
having from 1 to 5 carbon atoms in the alkanoyl part, a protected
haloalkanoyl group having from 2 to 5 carbon atoms and at least one
halogen atom in the haloalkanoyl part, a carbamoyl group, a nitro group,
an alkanesulfonyl group having from 1 to 4 carbon atoms, a
haloalkanesulfonyl group having from 1 to 4 carbon atoms and at least one
halogen atom, or a sulfamoyl group. That is, it represents the same groups
as does R.sup.1, other than the cyano, carboxy and alkoxy. carbonyl, and
the alkanoyl groups and the haloalkanoyl groups are protected.
R.sup.1b represents a hydrogen atom, an alkyl group having from 1 to 4
carbon atoms, a halogen atom, a haloalkyl group having from 1 to 4 carbon
atoms and at least one halogen atom, a protected hydroxy group, an alkoxy
group having from 1 to 4 carbon atoms, a haloalkoxy group having from 1 to
4 carbon atoms and at least one halogen atom, an alkylthio group having
from 1 to 4 carbon atoms, a haloalkylthio group having from 1 to 4 carbon
atoms and at least one halogen atom, an protected alkanoyl group having
from 1 to 5 carbon atoms in the alkanoyl part, a protected haloalkanoyl
group having from 2 to 5 carbon atoms and at least one halogen atom in the
haloalkanoyl part, a nitro group, an alkanesulfonyl group having from 1 to
4 carbon atoms, or a haloalkanesulfonyl group having from 1 to 4 carbon
atoms and at least one halogen atom. That is, it represents the same
groups as does R.sup.1, other than the amino, cyano, carboxy, carbamoyl,
sulfamoyl and alkoxycarbonyl groups, and the alkanoyl groups, the
haloalkanoyl groups and the hydroxy groups are protected.
R.sup.1c represents the same groups as are defined above for R.sup.1,
except that the alkanoyl group having from 1 to 5 carbon atoms and the
haloalkanoyl group having from 2 to 5 carbon atoms are protected.
R.sup.2 a represents the same groups as are defined above for R.sup.2,
other than the dihydrodioxazinyl group.
R.sup.4 represents an alkyl group having from 1 to 4 carbon atoms.
R.sup.5 represents a hydrogen atom, an alkyl group having from 1 to 9
carbon atoms, a substituted alkyl group which has from 1 to 9 carbon atoms
and which is substituted by at least one substituent selected from the
group consisting of substituents A, defined above, an alkenyl group having
from 2 to 5 carbon atoms, a substituted alkenyl group which has from 2 to
5 carbon atoms and which is substituted by at least one substituent
selected from the group consisting of substituents A, defined above, a
cycloalkyl group having from 3 to 7 carbon atoms, a substituted cycloalkyl
group which has from 3 to 7 carbon atoms and which is substituted by at
least one substituent selected from the group consisting of substituents
A, defined above, or a substituted phenyl group having at least one
substituent selected from the group consisting of substituents B, defined
above, and provided that any hydroxy group in substituents A is protected.
That is, it represents any of the groups (other than the dihydrodioxazinyl
group) defined above for R.sup.2, but without the terminal carbonyl group.
R.sup.5a represents any of the groups represented by R.sup.5, except that
the hydroxy group of substituent A need not be protected.
There is no particular limitation on the nature of the protecting group for
the alkanoyl group having from 1 to 5 carbon atoms or the haloalkanoyl
group having from 2 to 5 carbon atoms, and any such group commonly used
for the protection of aldehydes and ketones in the field of organic
chemistry. Examples include an acetal or ketal containing a carbonyl
moiety as shown in the following formula:
##STR10##
in which R.sup.6 and R.sup.7 are the same or different and each represents
an alkyl group having from 1 to 4 carbon atoms (such as a methyl, ethyl,
propyl, isopropyl or butyl group) or R.sup.6 and R.sup.7 together form an
alkylene group having 2 or 3 carbon atoms (such as an ethylene or
trimethylene group). We prefer an acetal or ketal in which R.sup.6 and
R.sup.7 are each a methyl or ethyl group, or R.sup.6 and R.sup.7 together
form an ethylene or trimethylene group.
The nature of the hydroxy-protecting groups which may be employed in this
reaction is not critical and any hydroxy-protecting group known for use in
this type of reaction may equally be employed here. Examples of such
groups include groups derived from the cyclic ethers, such as the
tetrahydropyranyl or tetrahydrofuranyl group.
In Reaction Scheme B, a compound of formula (IIIa) is prepared; this is a
compound of formula (III) in which R.sup.2 is a dihydrodioxazinyl group.
In Step B1 of this Reaction Scheme, a compound of formula (VI) is prepared
by reacting a compound of formula (V) with hydroxylamine or with a mineral
acid salt of hydroxylamine (such as the hydrochloride or the sulfate) in
an inert solvent (for example, an alcohol such as methanol or ethanol) and
in the presence of a base (for example, an alkali metal alkoxide such as
sodium methoxide, sodium ethoxide or potassium t-butoxide) at a suitable
temperature, preferably from 0.degree. C. to 150.degree. C. (more
preferably from about room temperature to 100.degree. C.) for a suitable
period, preferably from 1 to 24 hours (more preferably from 2 to 15
hours).
In Step B2 of this Reaction Scheme, a compound of formula (VII) is prepared
by reacting a compound of formula (VI) with a compound of formula (XVIII):
X.sup.a CH.sub.2 CH.sub.2 X.sup.b (XVIII)
in which X.sup.a and X.sup.b are the same or different and each represents
a halogen atom. The reaction is normally and preferably effected in the
presence of a solvent. There is no particular restriction on the nature of
the solvent to be employed, provided that it has no adverse effect on the
reaction or on the reagents involved, and that it can dissolve the
reagents, at least to some extent. Examples of suitable solvents include:
water, and alcohols, such as methanol or ethanol. The reaction is also
preferably effected in the presence of a base, the nature of which is also
not critical to the present invention. Examples of such bases include:
alkali metal carbonates, such as sodium carbonate or potassium carbonate;
and alkali metal hydroxides, such as sodium hydroxide or potassium
hydroxide. The reaction can take place over a wide range of temperatures,
and the precise reaction temperature is not critical to the present
invention. In general, we find it convenient to carry out the reaction at
a temperature of from 0.degree. C. to 200.degree. C. (more preferably at a
temperature from about room temperature to 150.degree. C.). The time
required for the reaction may also vary widely, depending on many factors,
notably the reaction temperature and the nature of the reagents and
solvent employed. However, provided that the reaction is effected under
the preferred conditions outlined above, a period of from 1 to 24 hours
(more preferably from 2 to 15 hours) will usually suffice.
Step B3 of this Reaction Scheme is optional to give a compound of formula
(VIII), and may consist of one or more of the following reactions:
(1) Removal of the alkanoyl or haloalkanoyl-protecting group contained in
R.sup.1a ;
(2) Conversion of the halogen atom contained in R.sup.1a into a cyano
group;
(3) Conversion of the halogen atom contained in R.sup.1a into a carboxy
group, followed, if desired, by conversion of the carboxy group into an
alkoxycarbonyl group having from 1 to 4 carbon atoms in the alkoxy moiety.
In Step B3(1) of this Reaction Scheme, removal of the alkanoyl- or
haloalkanoyl-protecting group can be effected by conventional means
commonly employed in the field of organic chemistry. For example, if the
protecting group is an acetal or a ketal, a corresponding compound of
formula (VII) is reacted with an acid (for example, a mineral acid, such
as hydrochloric acid, sulfuric acid or nitric acid; or an organic acid,
such as acetic acid, trifluoroacetic acid, methanesulfonic acid or
p-toluenesulfonic acid). The reaction is normally and preferably effected
in the presence of a solvent. There is no particular restriction on the
nature of the solvent to be employed, provided that it has no adverse
effect on the reaction or on the reagents involved and that it can
dissolve the reagents, at least to some extent. Examples of suitable
solvents include: water and alcohols, such as methanol or ethanol. The
reaction can take place over a wide range of temperatures, and the precise
reaction temperature is not critical to the invention. In general, we find
it convenient to carry out the reaction at a temperature of from 0.degree.
C. to 100.degree. C. (more preferably at a temperature from about room
temperature to 50.degree. C.). The time required for the reaction may also
vary widely, depending on many factors, notably the reaction temperature
and the nature of the reagents and solvent employed. However, provided
that the reaction is effected under the preferred conditions outlined
above, a period of from 10 minutes to 5 hours (more preferably from 30
minutes to 2 hours) will usually suffice.
Conversion of a halogen atom into a cyano group in Step B3(2) of this
Reaction Scheme is preferably effected by reacting the corresponding
compound of formula (VII) with a metal cyanide, such as sodium cyanide,
potassium cyanide or copper cyanide. The reaction is normally and
preferably effected in the presence of a solvent. There is no particular
restriction on the nature of the solvent to be employed, provided that it
has no adverse effect on the reaction or on the reagents involved and that
it can dissolve the reagents, at least to some extent. Examples of
suitable solvents include: amides, such as dimethylformamide or
dimethylacetamide; and ethers, such as diethyl ether or tetrahydrofuran.
The reaction can take place over a wide range of temperatures, and the
precise reaction temperature is not critical to the invention. In general,
we find it convenient to carry out the reaction at a temperature of from
0.degree. C. to 200.degree. C. (more preferably at a temperature from
about room temperature to 150.degree. C.). The time required for the
reaction may also vary widely, depending on many factors, notably the
reaction temperature and the nature of the reagents and solvent employed.
However, provided that the reaction is effected under the preferred
conditions outlined above, a period of from 1 to 24 hours (more preferably
from 2 to 15 hours) will usually suffice.
Conversion of the halogen atom into a carboxy group in Step B3(3) of this
Reaction Scheme is preferably effected by reacting the corresponding
compound of formula (VII) with magnesium. The reaction is normally and
preferably effected in the presence of a solvent. There is no particular
restriction on the nature of the solvent to be employed, provided that it
has no adverse effect on the reaction or on the reagents involved and that
it can dissolve the reagents, at least to some extent. Examples of
suitable solvents include: ethers, such as diethyl ether or
tetrahydrofuran. The reaction can take place over a wide range of
temperatures, and the precise reaction temperature is not critical to the
invention. In general, we find it convenient to carry out the reaction at
a temperature of from 0.degree. C. to 150.degree. C. (more preferably at a
temperature from about room temperature to 100.degree. C.). The time
required for the reaction may also vary widely, depending on many factors,
notably the reaction temperature and the nature of the reagents and
solvent employed. However, provided that the reaction is effected under
the preferred conditions outlined above, a period of from 30 minutes to 24
hours (more preferably from 1 to 10 hours) will usually suffice. The
resulting Grignard reagent is then reacted with carbon dioxide gas at a
temperature from, for example, 0.degree. C. to 150.degree. C. (more
preferably at a temperature from about room temperature to 100.degree. C.)
for a suitable period, for example from 30 minutes to 24 hours (more
preferably from 1 to 10 hours).
Conversion of the resulting carboxy group into an alkoxycarbonyl group
having from 1 to 4 carbon atoms can, if desired, be conducted by reacting
the corresponding carboxylic acid with an alcohol having from 1 to 4
carbon atoms, such as methanol, ethanol, propanol, isopropanol or butanol,
in the presence of an acid (for example, a mineral acid, such as
hydrochloric acid, sulfuric acid or nitric acid; or an organic acid, such
as acetic acid, trifluoroacetic acid, methane. sulfonic acid or
p-toluensulfonic acid). The reaction can take place over a wide range of
temperatures, and the precise reaction temperature is not critical to the
invention. In general, we find it convenient to carry out the reaction at
a temperature of from 0.degree. C. to 100.degree. C. (more preferably at a
temperature from about room temperature to 50.degree. C.). The time
required for the reaction may also vary widely, depending on many factors,
notably the reaction temperature and the nature of the reagents and
solvent employed. However, provided that the reaction is effected under
the preferred conditions outlined above, a period of from 30 minutes to 5
hours (preferably from 1 to 2 hours) will usually suffice. Rather than
using any additional solvent, this reaction is usually carried out by
using as the solvent a large excess of the alcohol having from 1 to 4
carbon atoms, which is one of the reagents.
In Step B4, a compound of formula (IIIa) is prepared by reacting a compound
of formula (VIII) with a haloimide, such as N-chlorosuccimide,
N-bromosuccimide or N-iodosuccimide in the presence of a radical
initiator, such as benzoyl peroxide, or by reacting said compound of
formula (VIII) with a halogen, such as chlorine, bromine or iodine, in an
inert solvent (for example, a halogenated hydrocarbon, preferably a
halogenated aliphatic hydrocarbon, such as methylene chloride, chloroform
or carbon tetrachloride). The reaction can take place over a wide range of
temperatures, and the precise reaction temperature is not critical to the
invention. In general, we find it convenient to carry out the reaction at
a temperature of from 0.degree. C. to 100.degree. C. (more preferably at a
temperature from about room temperature to 50.degree. C.). The time
required for the reaction may also vary widely, depending on many factors,
notably the reaction temperature and the nature of the reagents and
solvent employed. However, provided that the reaction is effected under
the preferred conditions outlined above, a period of from 30 minutes to 20
hours (more preferably from 1 to 15 hours) will usually suffice.
In Reaction Scheme C, a compound of formula (IIIb) is prepared. This is a
compound of formula (III) in which R.sup.2 is replaced by R.sup.2a, that
is any of the groups defined above for R.sup.2 except a dihydrodioxazinyl
group.
In Step C1 of this Reaction Scheme, a compound of formula (X) is prepared
by reacting a compound of formula (IX) with magnesium in an inert solvent
(for example, an ether, such as diethyl ether or tetrahydrofuran), to give
a Grignard reagent. The reaction can take place over a wide range of
temperatures, and the precise reaction temperature is not critical to the
invention. In general, we find it convenient to carry out the reaction at
a temperature of from 0.degree. C. to 150.degree. C. (more preferably at a
temperature from about room temperature to 100.degree. C.). The time
required for the reaction may also vary widely, depending on many factors,
notably the reaction temperature and the nature of the reagents and
solvent employed. However, provided that the reaction is effected under
the preferred conditions outlined above, a period of from 30 minutes to 24
hours (more preferably from 1 to 10 hours) will usually suffice. The
resulting Grignard reagent is then reacted with a compound of formula
(XIX), (XX) or (XXI):
R.sup.5b --CN (XIX)
R.sup.5c --COX (XX)
or
R.sup.5 --CO--O--CO--R.sup.5c (XXI)
in which R.sup.5 and X are as defined above; R.sup.5b represents any of the
groups defined for R.sup.5, except a group having a cyano substituent; and
R.sup.5c represents any of the groups defined for R.sup.5, except a
hydrogen atom. The reaction can take place over a wide range of
temperatures, and the precise reaction temperature is not critical to the
invention. In general, we find it convenient to carry out the reaction at
a temperature of from 0.degree. C. to 150.degree. C. (more preferably at a
temperature from about room temperature to 100.degree. C.). The time
required for the reaction may also vary widely, depending on many factors,
notably the reaction temperature and the nature of the reagents and
solvent employed. However, provided that the reaction is effected under
the preferred conditions outlined above, a period of from 30 minutes to 24
hours (more preferably from 1 to 10 hours) will usually suffice.
Step C2 of Reaction Scheme C comprises one or more of the following
optional reactions:
(1) Removal of the alkanoyl or haloalkanoyl-protecting group contained in
R.sup.1b ;
(2) Removal of the hydroxy-protecting group contained in R.sup.1b, R.sup.5
etc;
(3) Conversion of the halogen atom contained in R.sup.1b into a cyano
group, and then optionally into a carbamoyl group, and then optionally
into a carboxy, and finally optionally into an alkoxycarbonyl group having
from 1 to 4 carbon atoms in the alkoxy moiety;
(4) Conversion of the nitro group contained in R.sup.1b into an amino
group; and
(5) Conversion of the alkylthio group contained in R.sup.1b into a
sulfamoyl group.
Removal of the alkanoyl or haloalkanoyl-protecting group in Step C2(1) and
removal of the hydroxy-protecting cyclic ether group in Step C2(2) can be
conducted in a similar way to that in Step B3(1) of Reaction Scheme B, as
described above.
Conversion of the halogen atom into a cyano group in Step C2(3) can be
conducted in a similar way to that in Step B3(2) of Reaction Scheme B, as
described above. In this reaction, it is preferred not to use as the
starting material a compound of formula (X) containing a halogen atom in
the substituent of R.sup.5. If a compound containing a halogen atom in the
substituent R.sup.5 is used, conversion of this halogen atom into a cyano
group is also possible.
Successive conversion of the cyano group into carbamoyl and carboxy groups
can be conducted by reaction of a corresponding compound of formula (X)
with an aqueous mineral acid (such as aqueous sulfuric acid, aqueous
hydrochloric acid or aqueous nitric acid). The reaction can take place
over a wide range of temperatures, and the precise reaction temperature is
not critical to the invention. In general, we find it convenient to carry
out the reaction at a temperature of from 0.degree. C. to 200.degree. C.
(more preferably at a temperature from about room temperature to
100.degree. C.). The time required for the reaction may also vary widely,
depending on many factors, notably the reaction temperature and the nature
of the reagents and solvent employed. However, provided that the reaction
is effected under the preferred conditions outlined above, a period of
from 1 to 24 hours (more preferably from 2 to 15 hours) will usually
suffice. In this reaction, it is possible to choose whether the carbamoyl
or the carboxy compound will be obtained by adjusting the acid
concentration. For example, the carbamoyl compound can be obtained by
reaction in about 90% sulfuric acid, and then it can be converted into the
carboxy compound by reaction in about 60% sulfuric acid.
Conversion of the carboxy group into an alkoxycarbonyl group having from 1
to 4 carbon atoms in the alkoxy moiety can be conducted in a similar way
to that described in Step B3(3) of Reaction Scheme B, as described above.
Conversion of the nitro group into an amino group in Step C2(4) can be
conducted by reacting the corresponding compound of formula (X) with
hydrogen gas (preferably at from 1 atmosphere to 5 atmospheres) in an
inert solvent (for example, an alcohol, such as methanol or ethanol) and
in the presence of a reducing catalyst (such as Raney-nickel,
palladium-on-carbon or platinum oxide). The reaction can take place over a
wide range of temperatures, and the precise reaction temperature is not
critical to the invention. In general, we find it convenient to carry out
the reaction at a temperature of from 0.degree. C. to 150.degree. C.
(preferably at room temperature to 100.degree. C.). The time required for
the reaction may also vary widely, depending on many factors, notably the
reaction temperature and the nature of the reagents and solvent employed.
However, provided that the reaction is effected under the preferred
conditions outlined above, a period of from 30 minutes to 24 hours (more
preferably from I to 10 hours) will usually suffice.
Conversion of the alkylthio group into a sulfamoyl group in Step C2(5) can
be conducted by reacting a corresponding compound of formula (X) with a
halogenating agent (such as chlorine or bromine) in an inert solvent (for
example, water, an organic acid, such as acetic acid or propionic acid or
a mixture of any two or more thereof), to give a sulfonyl halide. The
reaction can take place over a wide range of temperatures, and the precise
reaction temperature is not critical to the invention. In general, we find
it convenient to carry out the reaction at a temperature of from
-10.degree. C. to 100.degree. C. (more preferably at from 5.degree. C. to
50.degree. C.). The time required for the reaction may also vary widely,
depending on many factors, notably the reaction temperature and the nature
of the reagents and solvent employed. However, provided that the reaction
is effected under the preferred conditions outlined above, a period of
from 30 minutes to 24 hours (more preferably from 1 to 10 hours) will
usually suffice. The resulting sulfonyl halide is then reacted with
ammonia in an inert solvent (for example, water or an alcohol, such as
methanol or ethanol) at, for example, from 0.degree. C. to 100.degree. C.
(more preferably at room temperature to 50.degree. C.) for a suitable
period, for example from 30 minutes to 24 hours (more preferably from 1 to
10 hours).
In Step C3 of Reaction Scheme C, a compound of formula (IIIb) is prepared
by halogenation of the compound of formula (XI) prepared in Step C2. This
reaction is essentially the same as that described in Step B4 of Reaction
Scheme B, and may be carried out using the same reagents and reaction
conditions.
Reaction Scheme D provides an alternative route for preparing the compound
of formula (XI), which is also prepared in Step C2 of Reaction Scheme C.
In Step D1 of Reaction Scheme D, a compound of formula (XIII) is prepared
by reacting a compound of formula (XII) with a compound of formula (XXII):
O.sub.2 N--CH.sub.2 --R.sup.5a (XXII)
in which R.sup.5a is as defined above. The reaction is normally and
preferably effected in the presence of a solvent. There is no particular
restriction on the nature of the solvent to be employed, provided that it
has no adverse effect on the reaction or on the reagents involved and that
it can dissolve the reagents, at least to some extent. Examples of
suitable solvents include organic acids, such as acetic acid or propionic
acid. The reaction is also normally and preferably effected and in the
presence of a base, for example, an ammonium salt of an organic acid, such
as ammonium acetate, ammonium propionate or ammonium benzoate. The
reaction can take place over a wide range of temperatures, and the precise
reaction temperature is not critical to the invention. In general, we find
it convenient to carry out the reaction at a temperature of from about
room temperature to 200.degree. C. (more preferably at from 50.degree. C.
to 150.degree. C.). The time required for the reaction may also vary
widely, depending on many factors, notably the reaction temperature and
the nature of the reagents and solvent employed. However, provided that
the reaction is effected under the preferred conditions outlined above, a
period of from 1 to 24 hours (more preferably from 2 to 15 hours) will
usually suffice.
In Step D2 of Reaction Scheme D, a compound of formula (XIV) is prepared by
reacting a compound of formula (XIII) with a reducing agent (such as zinc
or iron) in an inert solvent (for example, an organic acid, such as acetic
acid or propionic acid) and in the presence of water. The reaction can
take place over a wide range of temperatures, and the precise reaction
temperature is not critical to the invention. In general, we find it
convenient to carry out the reaction at a temperature of from about room
temperature to 250.degree. C. (more preferably at from 50.degree. C. to
150.degree. C.). The time required for the reaction may also vary widely,
depending on many factors, notably the reaction temperature and the nature
of the reagents and solvent employed. However, provided that the reaction
is effected under the preferred conditions outlined above, a period of
from 30 minutes to 24 hours (more preferably from 1 to 10 hours) will
usually suffice.
Step D3 of this Reaction Scheme is optional and comprises removal of the
alkanoyl- or haloalkanoyl protecting group contained in R.sup.1c. The
removal reaction is essentially the same reaction as that employed in Step
B3 of Reaction Scheme B, and may be carried out employing the same
reagents and reaction conditions.
Reaction Scheme E provides an alternative route for preparing a compound of
formula (XI), which is also prepared in Step C2 of Reaction Scheme C, when
R.sup.2a in the compound of formula (XI) is a formyl group, that is a
compound of formula (XIa).
In Step E1 of Reaction Scheme E, a compound of formula (XVI) is prepared by
reacting a compound of formula (XV) with a reducing agent [for example, an
aluminum hydride, such as lithium tri(t-butoxy)aluminum hydride or lithium
aluminum hydride]. The reaction is normally and preferably effected in the
presence of a solvent. There is no particular restriction on the nature of
the solvent to be employed, provided that it has no adverse effect on the
reaction or on the reagents involved and that it can dissolve the
reagents, at least to some extent. Examples of suitable solvents include
ethers, such as diethyl ether or tetrahydrofuran. The reaction can take
place over a wide range of temperatures, and the precise reaction
temperature is not critical to the invention. In general, we find it
convenient to carry out the reaction at a temperature of from -30.degree.
C. to 50.degree. C. (more preferably at from 0.degree. C. to room
temperature). The time required for the reaction may also vary widely,
depending on many factors, notably the reaction temperature and the nature
of the reagents and solvent employed. However, provided that the reaction
is effected under the preferred conditions outlined above, a period of
from 1 to 24 hours (more preferably from 2 to 15 hours) will usually
suffice.
Step E2 of Reaction Scheme E is optional and comprises one or more of the
following reactions:
(1) Removal of the alkanoyl or haloalkanoyl-protecting group contained in
R.sup.1a ;
(2) Conversion of the halogen atom contained in R.sup.1a into a cyano
group, which may then, if desired, be converted into a carboxy group,
which finally may, if desired, be converted into an alkoxycarbonyl group.
These reactions are essentially the same as those described above in
relation to Step C2 of Reaction Scheme C, and may be carried out employing
the same reagents and reaction conditions.
After completion of any of these reactions, the desired compound can be
recovered from the reaction mixture by conventional means. For example,
insoluble matter, if any, is filtered off, and, if the reaction solution
is acidic or alkaline, the solution is neutralized. The desired product
can then be recovered by distilling off the solvent, or by adding water,
extracting the resulting mixture with a water-immiscible organic solvent,
such as ethyl acetate, drying the extract, and then distilling off the
solvent. If necessary, the product thus obtained can be further purified
by conventional means, such as recrystallization or the various
chromatography techniques, for example preparative thin layer
chromatography or column chromatography, notably column chromatography.
Alternatively, when the desired compound is a carboxylic acid derivative,
it may be recovered from the reaction medium by the following procedure:
making the reaction solution alkaline; extracting the resulting mixture
with a water-immiscible organic solvent, such as ethyl acetate;
neutralizing the aqueous layer; extracting the desired compound with a
water-immiscible organic solvent, such as ethyl acetate; drying the
extract; and then distilling off the solvent.
The compounds of the present invention prepared as described above may be
converted to acid addition salts and/or to complexes with metal ions by
methods well known in the art.
BIOLOGICAL ACTIVITY
The compounds of formula (I) and their tautomers, salts and complexes of
the present invention have an excellent inhibitory activity against blood
platelet aggregation, and are therefore very useful for prevention and
therapy of thrombosis and embolism. These activities are demonstrated by
the following Test Examples, which employ techniques well recognized in
the art to provide a model of such activity in humans and other mammals.
TEST EXAMPLE 1
Prolongation of Bleeding Time in mice
Male mice of the ICR strain (supplied by Japan Charles River Inc.) were
divided into groups of 10 each for the test. A sample of the drug to be
tested was suspended in a 5% w/v aqueous solution of gum arabic, and
administered orally to the mice at a dose of 3 mg/kg for 3 successive
days, namely 48 hours, 24 hours and 4 hours before the bleeding test. For
the test, each of the mice was fixed by use of conventional apparatus, and
the tail was cut 5 mm from the end. The last 2 cm of the tail was soaked
in physiological saline kept warm at 37.degree. C. The time at which
bleeding was observed to cease for a successive 15 seconds was regarded as
the point at which bleeding stopped, and the time between cutting the tail
until the point when bleeding stopped was recorded as the bleeding time.
The bleeding time was observed for a maximum of 5 minutes, and, even if
bleeding continued for longer than 5 minutes, the bleeding time was
reported as 5 minutes (300 seconds). The results are shown in Table 2. The
test was carried out using certain of the compounds of the present
invention, as well as with two prior art compounds.
Each of the compounds of the present invention is identified in the Table
by the number assigned to it in the foregoing Table 1 and by the number of
the Example hereafter which illustrates its preparation. The prior art
compounds are identified as follows:
Compound A: 5 (2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine;
Compound B: 5-(2-chloro-.alpha.-methoxycarbonylbenzyl)
4,5,6,7-tetrahydrothieno[3,2-c]pyridine.
TEST EXAMPLE 2
Inhibition of Blood Platelet Aggregation
Female rats of the SD strain (supplied by Japan Charles River Inc.) were
divided into groups of 4 each for the test. A sample of the drug to be
tested was suspended in a 5% w/v aqueous solution of gum arabic, and
administered orally to the rats 4 hours before the test. As a control, a
5% w/v aqueous solution of gum arabic was administered to a control group
of rats, without any test drug. Blood platelet aggregation was tested
according to the method of P. Lumley and P. P. A. Humphrey [J. Pharmacol.
Methods 6, 153-166 (1981)]with a partial modification. From the abdominal
aorta of the anesthetized rat, 5.4 ml of a blood sample was taken in 0.6
ml of a 3.8% (w/v) sodium citrate solution serving as an anticoagulant.
The resulting citrate-containing blood samples were poured into cuvettes,
with 1.2 ml in each cuvette, and stirred (1000 rpm) at 37.degree. C. After
preliminary heating for 2 minutes, 0.3 ml of the blood sample was taken
out of each of the cuvettes, and the blood platelet count was measured by
means of an automatic blood cell counter (E-4000, Sysmex); this was
regarded as the blood platelet count before addition. 0.9 ml of the blood
sample in the cuvette was then mixed with 0.1 ml of a 0.05M adenosine
diphosphate (ADP) solution or with 0.1 ml of a collagen suspension (0.06
mg/ml), to induce blood platelet aggregation. Two minutes after addition
of the ADP, or 4 minutes after addition of the collagen, 0.3 ml of the
blood sample was taken and the blood platelet count was measured; this was
regarded as the blood platelet count after addition. The blood platelet
aggregation rate was calculated from the following equation.
100.times. (blood platelet count before addition-blood platelet count after
addition)/blood platelet count before addition
The inhibitory effect was calculated as the percent inhibition of the
treated groups as compared with the control groups. The results are
reported in Table 2.
TABLE 2
______________________________________
Test Ex. 1
Bleeding time
Test Ex. 2
Ex. Cpd. (hours), % Inhibition
No. No. 3 mg/kg 1 mg/kg
3 mg/kb 10 mg/kg
______________________________________
5 60 2.20 -- 74.2 100
6 19 2.13 -- 29.3 97.8
12 59 >2.75 57.1 98.1 --
20 235 >2.75 98.8 -- --
22 233 2.30 -- -- 98.9
23 190 >2.75 100 -- --
25 194 >2.75 100 -- --
26 196 >2.75 97.6 -- --
Compound A
1.00 -- -- 3.7*
Compound B
1.80 -- 25.7 98.8
______________________________________
*at a dose of 30 mg/kg.
For therapeutic or prophylactic use, the compounds of the present invention
may be administered by themselves or in admixture with any one or more
conventional carriers, diluents or additives. Administration may be by any
convenient route, for example orally or parenterally, and the formulation
will be chosen having regard to the intended route of administration. The
compounds may, for example, be administered in the form of powders,
granules, tablets, capsules and injections. The dosage may vary depending
upon the severity and nature of the disorder, as well as the symptoms, age
and body weight of the patient and the chosen route of administration;
however, in the case of oral administration, we would normally suggest a
dose of from 1 to 1000 mg, more preferably from 10 to 500 mg, if
administered orally, or a dose of from 0.5 to 500 mg, more preferably from
5 to 250 mg, if administered intravenously. The compound may be
administered in single or divided doses, e.g. from 1 to 3 times a day
depending on the symptoms.
The preparation of the compounds of the present invention is further
illustrated by the following non-limiting Examples, whilst the preparation
of certain of the starting materials used in these Examples is illustrated
by the subsequent Preparations.
EXAMPLE 1
5-(2-Chloro-.alpha.-trifluoroacetylbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]p
yridine (Compound No. 113)
10 ml of methylene chloride were added to 0.39 g (2.6 mmole) of
4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride and 0.28 g (2.6
mmole) of sodium carbonate, and then a solution of 0.67 g (2.2 mmole) of
2-chloro-.alpha.-trifluoroacetylbenzyl bromide in 10 ml of methylene
chloride was slowly added to the resulting mixture, whilst stirring at
room temperature. The mixture was then stirred at room temperature for 3
hours. At the end of this time, 200 ml of ethyl acetate were added to the
reaction mixture, and the organic layer was separated, washed with a
saturated aqueous solution of sodium chloride and dried over anhydrous
magnesium sulfate. The solvent was removed by distillation under reduced
pressure, and the resulting residue was subjected to silica gel column
chromatography, using a 100:4 by volume mixture of toluene and ethyl
acetate as the eluent, to give 0.31 g of the title compound as a colorless
oil.
Infrared Absorption Spectrum (thin film) .nu..sub.max cm.sup.-1 : 1685,
1705.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 2.90-3.04
(2H, multiplet); 3.90 (1H, triplet, J=6.0 Hz); 4.01 (1H, triplet, J=6.0
Hz); 5.51 (1H, doublet, J=7.3 Hz); 5.58 (1H, doublet, J=7.3 Hz); 6.82 (1H,
doublet, J=5.4 Hz); 7.19 (2H, doublet, J=5.4 Hz); 7.36-7.58 (4H,
multiplet).
Mass spectrum (CI, m/z): 360 (M.sup.+ +1). Here and hereafter, in the mass
spectra, "CI" means "chemical ionization".
EXAMPLE 2
5-[2-Chloro-.alpha.-(5,6-dihydro-1,4,2-dioxazin-3-yl)
benzyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its hydrochloride
(Compound No. 3)
2(a) Following a procedure similar to that described in Example 1, except
that an equivalent amount of
2-chloro-.alpha.-(5,6-dihydro-1,4,2-dioxazin-3-yl)benzyl bromide (prepared
as described in Preparation 18) was used in place of the
2-chloro-.alpha.-trifluoroacetylbenzyl bromide, the title compound was
obtained as a colorless oil in a yield of 77%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 2.77-2.94
(4H, multiplet); 3.63 (1H, doublet, J=14.4 Hz); 3.79 (1H, doublet, J=14.4
Hz); 3.96-4.02 (1H, multiplet); 4.08-4.14 (1H, multiplet); 4.27-4.32 (1H,
multiplet); 4.36-4.42 (1H, multiplet); 4.75 (1H, singlet); 6.70 (1H,
doublet, J=5.4 Hz); 7.07 (1H, doublet, J=5.4 Hz); 7.20-7.90 (4H,
multiplet).
Mass spectrum (CI, m/z): 349 (M.sup.+ +1).
2(b) 2.7 g of the title compound obtained as described in step (a) above
were dissolved in 100 ml of diethyl ether, and hydrogen chloride gas was
blown into the resulting solution at room temperature. The crystals which
precipitated were collected to obtain 2.3 g of the hydrochloride of the
title compound as a colorless powder, melting at 104.degree.-107.degree.
C.
Elemental analysis: Calculated for C.sub.17 H.sub.17 C1N.sub.2 O.sub.2
S.HCl.3/2H.sub.2 O: C, 49.52%; H, 5.13%; N, 6.80%., Found: C, 49.81%; H,
4.73%; N, 6.56%.
EXAMPLE 3
5-[2-Fluoro-.alpha.-(5,6-dihydro-1,4,2-dioxazin-3-yl)benzyl]-4,5,6,7-tetrah
ydrothieno]3,2-c]pyridine and its hydrochloride (Compound No. 2)
3(a) Following a procedure similar to that described in Example 1, except
that an equivalent amount of
2-fluoro-(5,6-dihydro-1,4,2-dioxazin-3-yl)benzyl bromide (prepared as
described in Preparation 19) was used in place of the
2-chloro-.alpha.-trifluoroacetylbenzyl bromide, the title compound was
obtained as a colorless oil in a yield of 50%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 2.73-2.98
(4H, multiplet); 3.63 (1H, doublet, J=13.8 Hz); 3.79 (1H, doublet, J=13.8
Hz); 3.95-4.18 (2H, multiplet); 4.23-4.45 (H, multiplet); 4.61 (1H,
singlet); 6.70 (1H, doublet, J .TM.5.4 Hz); 7.09 (1H, doublet, J=5.4 Hz);
7.20-7.80 (4H, multiplet).
Mass spectrum (CI, m/z) : 333 (M.sup.+ +1).
3(b) The procedure described in Example 2(b) was repeated, using the title
compound as prepared in step (a) above, to obtain the hydrochloride of the
title compound as a colorless powder, melting at 108.degree.-112.degree.
C., in a yield of 81%.
Elemental analysis: Calculated for C.sub.17 H.sub.17 FN.sub.2 O.sub.2 S
HCl.H.sub.2 O: C, 52 78%; H, 5.21%; N, 7.24%, Found: C, 53.19%; H, 4.99%;
N, 7.16%.
EXAMPLE 4
5-[2,6-Difluoro-.alpha.-(5,6-dihydro-1,4,2-dioxazin-3-yl)benzyl]-4,5,6,7-te
trahydrothieno[3,2-c]pyridine (Compound No. 7)
Following a procedure similar to that described in Example 1, except that
an equivalent amount of 2,6-difluoro-.alpha.- 5,6-dihydro
1,4,2-dioxazin-3-yl)benzyl bromide (prepared as described in Preparation
20) was used in place of the 2-chloro-.alpha.-trifluoroacetylbenzyl
bromide, the title compound was obtained as a colorless powder, melting at
151.degree.-153.degree. C., in a yield of 8%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 2.81-2.93
(4H, multiplet); 3.62 (1H, doublet, J=14.0 Hz); 3.79 (1H, doublet, J=14.0
Hz); 4.00-4.10 (2H, multiplet); 4.26-4.36 (2H, multiplet); 4.59 (1H,
singlet); 6.70 (1H, doublet, J=5.4 Hz); 7.08 (1H, doublet, J=5.4 Hz);
7.20-7.80 (4H, multiplet).
Mass spectrum (CI, m/z) : 351 (M.sup.+ +1).
Elemental analysis: Calculated for C.sub.17 H.sub.16 F.sub.2 N.sub.2
O.sub.2 S: C, 58.27%; H, 4.60%; N, 8.00%; Found: C, 58.22%; H, 4.61%; N,
7.79%.
EXAMPLE 5
5-(2-Chloro-.alpha.-cyclopropylcarbonylbenzyl)-4,5,6,7-tetrahydrothieno[3,2
-c]pyridine and its sulfate (Compound No. 60)
5(a) Following a procedure similar to that described in Example 1, except
that an equivalent amount of 2-chloro-.alpha.-cyclopropylcarbonylbenzyl
bromide was used in place of the 2-chloro-.alpha.-trifluoroacetylbenzyl
bromide, the title compound was obtained as a yellow oil in yield of 66%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.78-0.90
(2H, multiplet); 0.96-1.06 (2H, multiplet); 2.15-2.29 (1H, multiplet);
2.83-2.94 (4H, multiplet); 3.56 (1H, doublet, J=4.3 Hz); 3.72 (1H,
doublet, J=4.3 Hz); 5.06 (1H, singlet); 6.68 (1H, doublet, J=4.9 Hz); 7.06
(1H, doublet, J=4.9 Hz): 7.10-7.70 (4H, multiplet).
Mass spectrum (CI, m/z) : 332 (M.sup.+ +1), 262.
5(b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound as prepared in step (a) above, except that
concentrated sulfuric acid was added in place of blowing hydrogen chloride
gas through the mixture, to obtain the sulfate of the title compound as
white crystals, melting at 184.degree.-186.degree. C., in a yield of 70%.
Elemental analysis: Calculated for C.sub.18 H.sub.18 ClNOS.H.sub.2 SO.sub.4
: C, 50.28%; H, 4.69%; N, 3.26%.; Found: C, 50.43%; H, 4.53%; N, 2.87%.
EXAMPLE 6
5-(2-Fluoro-.alpha.-propionylbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin
e and its maleate (Compound No. 19)
6(a) 1.85 g 11.13 mmole) of 1-(2-fluorophenyl)-2-butanone (prepared as
described in Preparation 9) were dissolved in 30 ml of carbon
tetrachloride, and then a solution of 1.78 g of bromine in 15 ml of carbon
tetrachloride was added dropwise to the resulting solution at room
temperature over a period of 30 minutes. The resulting mixture was then
stirred at room temperature for 5 hours, after which water was added to
the reaction mixture. The reaction mixture was then extracted with
chloroform, and the extract was dried over anhydrous magnesium sulfate. A
crude 2-fluoro-.alpha.-propionylbenzyl bromide was obtained from this
extract by removal of the solvent by evaporation under reduced pressure
1.95 g (11.13 mmole) of 4,5,6,7-tetrahydrothieno[3,2-c]pyridine
hydrochloride, 3.38 g (24.45 mmole) of anhydrous potassium carbonate and
30 ml of dimethylformamide were added to the crude product thus obtained,
and the resulting mixture was stirred at room temperature for 5 hours. At
the end of this time, toluene was added to the reaction mixture, and after
the insolubles had been removed by filtration, the filtrate was
concentrated by evaporation under reduced pressure. The resulting residue
was subjected to silica gel column chromatography, using a 19:1 by volume
mixture of toluene and ethyl acetate as the eluent, to give 1.17 g of the
title compound as a pale yellow oil.
Infrared Absorption Spectrum (thin film) .nu..sub.max cm.sup.-1 : 1715.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 1.03 (3H,
triplet, J=7.0 Hz); 2.50 (2H, quartet, J=7.0 Hz); 2.80-2.95 (4H,
multiplet); 3.53 (1H, doublet, J=11.0 Hz); 3.63 (1H, doublet, J=11.0 Hz);
4.75 (1H, singlet); 6.67 (1H, doublet, J=5.7 Hz); 7.05 (1H, doublet, J=5.7
Hz); 7.10-7.55 (4H, multiplet).
Mass spectrum (CI, m/z) : 304 (M.sup.+ +1), 246.
6(b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound prepared as described in step (a) above, except
that maleic acid was added in place of blowing hydrogen chloride gas
through the reaction mixture, to obtain the maleate of the title compound
as a colorless powder, melting at 101.degree.-103.degree. C., in a yield
of 54%.
Elemental analysis: Calculated for C.sub.17 H.sub.18 FNOS.C.sub.4 H.sub.4
O.sub.4.1/2H.sub.2 O: C, 58.86%; H, 5.4I%; N, 3.27%; Found: C, 59.19%; H,
5.33%; N, 3.19%.
EXAMPLE 7
5-(.alpha.-Acetyl-2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
and its hydrochloride (Compound No. 10)
7(a) Following a procedure similar to that described in Example 6, except
that an equivalent amount of 1-(2-chlorophenyl)-2-propanone (prepared as
described in Preparation 10) was used in place of the
1-(2-fluorophenyl)-2-butanone, the title compound was obtained as a pale
yellow oil in a yield of 44%.
Infrared Absorption Spectrum (thin film) .nu..sub.max cm.sup.-1 : 1715.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 2.13 (3H,
singlet); 2.70-2.95 (4H, multiplet); 3.50 (1H, doublet, J=10.0 Hz); 3.70
(1H, doublet, J=10.0 Hz); 4.93 (1H, singlet); 6.65 (1H, doublet, J=5.7
Hz); 7.05 (1H, doublet, J=5.7 Hz); 7.10-7.75 (4H, multiplet).
Mass spectrum (CI, m/z) : 306 (M.sup.+ +1), 262.
7(b) A procedure similar to that described in Example (b) was repeated,
using the title compound prepared as described in step (a) above, to
obtain the hydrochloride of the title compound as a pale yellow powder,
melting at 98.degree.-101.degree. C., in a yield of 70%.
Elemental analysis: Calculated for C.sub.16 H.sub.16 ClNOS.HCl.1/2H.sub.2
O: C, 54.70%; H, 5.16%; N, 3.98%; Found: C, 55.09%; H, 4.97%; N, 3.80%.
EXAMPLE 8
5-(2-Chloro-.alpha.-propionylbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin
e and its hydrochloride (Compound No. 20)
8(a) Following a procedure similar to that described in Example 6, except
that an equivalent amount of (2-chlorophenyl)-2-butanone (prepared as
described in Preparation 11) was used in place of the
1-(2-fluorophenyl)-2-butanone, the title compound was obtained as a pale
yellow oil in a yield of 32%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 1.05 (3H,
triplet, J=6.5 Hz); 2.31-2.58 (2H, multiplet); 2.75-3.00 (4H, multiplet);
3.48 (1H, doublet, J=14.5 Hz); 3.68 (1H, doublet, J=14.5 Hz); 4.97 (1H,
singlet); 6.65 (1H, doublet, J=6.0 Hz); 7.05 (1H, doublet, J=6.0 Hz);
7.10-7.65 (4H, multiplet).
Mass spectrum (CI, m/z) : 320 (M.sup.+ +1).
8(b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound prepared as described in step (a) above, to
obtain the hydrochloride of the title compound as a pale yellow powder,
melting at 110.degree.-115.degree. C., in a yield of 25%.
Elemental analysis: Calculated for C.sub.17 H.sub.18 ClNOS.HCl.H.sub.2 O:
C, 54.55%; H, 5.92%; N, 3.74%; Found: C, 54.39%; H, 5.59%; N, 3.73%.
EXAMPLE 9
5-(2-Chloro-.alpha.-hexanoylbenzyl)-4,5,6,7,-tetrahydrothieno[3,2-c]pyridin
e (Compound No. 125)
Following a procedure similar to that described in Example 6, except that
an equivalent amount of 1-(2-chlorophenyl)-2-heptanone (prepared as
described in Preparation 12) was used in place of the
1-(2-fluorophenyl)-2-butanone, the title compound was obtained as a yellow
oil in a yield of 10%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.90 (3H,
triplet, J=7.6 Hz); 1.10-1.60 (6H, multiplet); 2.40 (2H, triplet, J=8.0
Hz); 2.75-3.00 (4H, multiplet); 3.50 (1H, doublet, J=14.5 Hz); 3.70 (1H,
doublet, J=14.5 Hz); 5.00 (1H, singlet); 6.65 (1H, doublet, J=6.0 Hz);
7.05 (1H, doublet, J=6.0 Hz); 7.10-7.60 (4H, multiplet).
Mass spectrum (CI, m/z) : 362 (M.sup.+ +1), 262.
EXAMPLE 10
5-(.alpha.-Acetyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
and its maleate (Compound No. 9)
10(a) Following a procedure similar to that described in Example 6, except
that an equivalent amount of 1-(2-fluorophenyl)-2-propanone was used in
place of the 1-(2-fluorophenyl)-2-butanone, the title compound was
obtained as a pale yellow oil in a yield of 55%.
Infrared Absorption Spectrum (thin film) .nu..sub.max cm.sup.-1 : 1715.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 2.18 (3H,
singlet); 2 80-2.95 (4H, multiplet); 3.55 (1H, doublet, J=12.0 Hz); 3.65
(1H, doublet, J=12.0 Hz); 4.72 (1H, singlet); 6.65 (1H, doublet, J=5.5
Hz); 7.05 (1H, doublet, J=5.5 Hz); 7.10-7.55 (4H, multiplet).
Mass spectrum (CI, m/z) : 290 (M.sup.+ +1), 246.
10(b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound prepared as described in step (a) above, except
that maleic acid was added in place of blowing hydrogen chloride gas
through the mixture, to obtain the maleate of the title compound as a pale
yellow powder, melting at 104.degree.-106.degree. C., in a yield of 61%.
Elemental analysis: Calculated for C.sub.16 H.sub.16 FNOS.C.sub.4 H.sub.4
O.sub.4.1/2H.sub.2 O: C, 57.96%; H, 5.10%; N, 3.38%; Found: C, 58.36%; H,
4.94%; N, 3.39%.
EXAMPLE 11
5-(.alpha.-Cyclobutylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-
c]pyridine and its maleate (Compound No. 106)
11(a) Following a procedure similar to that described in Example 6, except
that an equivalent amount of cyclobutyl-2-fluorobenzyl ketone (prepared as
described in Preparation 13 was used in place of the
1-(2-fluorophenyl)-2-butanone, the title compound was obtained as a pale
yellow oil in a yield of 24%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 1.70-2.55
(6H, multiplet); 2.80-3.00 (4H, multiplet); 3.50 (1H, doublet, J=11.0 Hz);
3.62 (1H, doublet, J=11.0 Hz); 3.70-3.90 (1H, multiplet); 4.73 (1H,
singlet); 6.65 (1H, doublet, J=6.0 Hz): 7.05 (1H, doublet, J=6.0 Hz);
7.10-7.50 (4H, multiplet).
Mass spectrum (CI, m/z) : 330 (M.sup.+ +1), 246.
11(b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound prepared as described in step (a) above, except
that maleic acid was added in place of blowing hydrogen chloride gas
through the mixture, to obtain the maleate of the title compound as a
colorless powder, melting at 99.degree.-104.degree. C., in a yield of 57%.
Elemental analysis: Calculated for C.sub.16 H.sub.16 FNOS.C.sub.4 H.sub.4
O.sub.4.1/2H.sub.2 O: C, 60.78%; H, 5.54%; N, 3.08%; Found: C, 60.97%; H,
5.48%; N, 2.94%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 1.70-2.30
(6H, multiplet); 3.10-3.30 (4H, multiplet); 3.68-3.82 (1H, multiplet);
4.30 (2H, broad singlet); 5.55 (1H, singlet); 6.30 (2H, singlet); 6.72
(1H, doublet, J=6.5 Hz); 7.20 (1H, doublet, J=6.5 Hz); 7.25-7.60 (4H,
multiplet).
EXAMPLE 12
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2
-c]pyridine and its hydrochloride (Compound No. 59)
12(a) Following a procedure similar to that described in Example 6, except
that an equivalent amount of cyclopropyl 2-fluorobenzyl ketone (prepared
as described in Preparation 8) was used in place of the
1-(2-fluorophenyl)-2-butanone, the title compound was obtained as a
colorless oil in a yield of 69%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.78-0.90
(2H, multiplet); 0.98-1.11 (2H, multiplet); 2.22-2.34 (1H, multiplet);
2.72-2.98 (4H, multiplet); 3.58 (1H, doublet, J=4.2 Hz); 3.68 (1H,
doublet, J=4.2 Hz); 4.85 (1H, singlet); 6.68 (1H, doublet, J=4.9 Hz); 7.06
(1H, doublet, J=4.9 Hz); 7.20-7.60 (4H, multiplet).
Mass spectrum (CI, m/z) : 316 (M.sup.+ +1), 246.
12(b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound prepared as described in step (a) above, to
obtain the hydrochloride of the title compound as white crystals, melting
at 171.degree.-173.degree. C., in a yield of 75%.
Elemental analysis: Calculated for C.sub.18 H.sub.18 FNOS.HCl: C, 61.44%;
H, 5.44%; N, 3.98%, Found: C, 61.37%; H, 5.74%; N, 3.85%.
EXAMPLE 13
5-(.alpha.-Butyryl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
and its maleate (Compound No. 116)
13(a) Following a procedure similar to that described in Example 6, except
that an equivalent amount of 1-(2-fluorophenyl)-2-pentanone (prepared as
described in Preparation 5) was used in place of the
1-(2-fluorophenyl)-2-butanone, the title compound was obtained as a pale
yellow oil in a yield of 41%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.82 (3H,
triplet, J=9.5 Hz); 1.45-1.70 (2H, multiplet); 2.41 (2H, triplet, J=8.0
Hz); 2.75-2.95 (4H, multiplet); 3.55 (1H, doublet, J=13.0 Hz); 3.62 (1H,
doublet, J=13.0 Hz); 4.75 (1H, singlet); 6.65 (1H, doublet, J=6.0 Hz);
7.05 (1H, doublet, J=6.0 Hz): 7.10-7.55 (4H, multiplet).
Mass spectrum (CI, m/z) : 318 (M.sup.+ +1), 246.
13(b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound prepared as described in step (a) above, except
that maleic acid was added in place of blowing hydrogen chloride gas
through the mixture, to obtain the maleate of the title compound as a
colorless powder, melting at 89.degree.-90.degree. C., in a yield of 36%.
Elemental analysis: Calculated for C.sub.18 H.sub.20 FNOS.C.sub.4 H.sub.4
O.sub.4 : C, 60.96%; H, 5.58%; N, 3.23%; Found: C, 60.69%; H, 5.43%; N,
3.01%.
EXAMPLE 14
5-(2-Fluoro-.alpha.-valerylbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
and its maleate (Compound No. 120)
14(a) Following a procedure similar to that described in Example 6, except
that an equivalent amount of 1-(2-fluorophenyl)-2-hexanone (prepared as
described in Preparation 6) was used in place of the
1-(2-fluorophenyl)-2-butanone, the title compound was obtained as a pale
yellow oil in a yield of 46%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.83 (3H,
triplet, J=8.0 Hz); 1.12-1.35 (2H, multiplet); 1.40-1.70 (2H, multiplet);
2.45 (2H, triplet, J=8.2 Hz); 2.60-2.90 (4H, multiplet); 3.52 (1H,
doublet, J=14.0 Hz); 3.65 (1H, doublet, J=14.0 Hz); 4.75 (1H, singlet);
6.65 (1H, doublet, J=6.0 Hz); 7.05 (1H, doublet, J=6.0 Hz); 7.10-7.50 (4H,
multiplet).
Mass Spectrum (CI, m/z) : 332 (M.sup.+ +1), 246.
14(b) A procedure similar to that described in Example (b) was repeated,
using the title compound prepared as described in step (a) above, except
that maleic acid was added in place of blowing hydrogen chloride gas
through the mixture, to obtain the maleate of the title compound as a
colorless powder, melting at 92.degree.-93.degree. C., in a yield of 26%.
Elemental analysis: Calculated for C.sub.19 H.sub.22 FNOS.C.sub.4 H.sub.4
O.sub.4 : C, 61.73%; H, 5.86%; N, 3.13%; Found: C, 61.38%; H, 5.88%; N,
2.59%.
EXAMPLE 15
5-(2-Fluoro-.alpha.-pivaloylbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
and its hydrochloride (Compound No. 122)
15(a) Following a procedure similar to that described in Example 6, except
that an equivalent amount of 1-(2-fluorophenyl)-3,3-dimethyl-2-butanone
(prepared as described in Preparation 7) was used in place of the
1-(2-fluorophenyl)-2-butanone, the title compound was obtained as a pale
yellow oil in a yield of 87%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub. 3) .delta. ppm: 1.10 (9H,
singlet); 2.74-3.00 (4H, multiplet); 3.55 (1H, doublet, J=15.0 Hz); 3.66
(1H, doublet, J=15.0 Hz); 5.23 (1H, singlet); 6.63 (1H, doublet, J=6.0
Hz); 7.03 (1H, doublet, J=6.0 Hz); 7 10-7.55 (4H, multiplet).
Mass spectrum (CI, m/z) : 332 (M.sup.+ +1), 246.
15(b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound prepared as described in step (a) above, to
obtain the hydrochloride of the title compound as a pale yellow powder,
melting at 85.degree.-90.degree. C., in a yield of 34%.
Elemental analysis: Calculated for C.sub.19 H.sub.22 FNOS.HCl.H.sub.2 O: C,
59.14%; H, 6.23%; N, 3.63%; Found: C, 58.99%; H, 6.57%; N, 3.17%.
EXAMPLE 16
5-[2-Chloro-.alpha.-(4-fluorobenzoyl)benzyl]-4,5,6,7-tetrahydrothieno[3,2-c
]pyridine and its hydrochloride (Compound No. 149)
16(a) Following a procedure similar to that described in Example 6, except
that an equivalent amount of 2-chlorobenzyl 4-fluorophenyl ketone
(prepared as described in Preparation 22) was used in place of the
1-(2-fluorophenyl)-2-butanone, the title compound was obtained as a pale
yellow oil in a yield of 58%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 2 80-3.00
(4H, multiplet); 3.63 (1H, doublet, J=16.0 Hz); 3.80 (1H, doublet, J=16.0
Hz); 5.80 (1H, singlet); 6.63 (1H, doublet, J=6.0 Hz); 7.00-7.60 (6H,
multiplet); 7.95-8.15 (2H, multiplet).
Mass spectrum (CI, m/z) : 386 (M.sup.+ +1), 262.
16(b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound prepared as described in step (a) above, to
obtain the hydrochloride of the title compound as a yellowish brown
powder, melting at 121.degree.-130.degree. C., in a yield of 40%.
Elemental analysis: Calculated for C.sub.21 H.sub.17 ClFNOS.HCl.1/2H.sub.2
O: C, 58.47%; H, 4.44%; N, 3.25%; Found: C, 58.25%; H, 4.86%; N, 3.48%.
EXAMPLE 17
5-(2-Fluoro-.alpha.-isobutyrylbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridi
ne and its maleate (Compound No. 118)
17(a) Following a procedure similar to that described in Example 6, except
that an equivalent amount of 2-fluorobenzyl isopropyl ketone (prepared as
described in Preparation 23) was used in place of the
1-(2-fluorophenyl)-2-butanone, the title compound was obtained as a yellow
oil in a yield of 44%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.95 (3H,
doublet, J=7.0 Hz); 1.10 (3H, doublet, J=7.0 Hz); 2.60-2.80 (1H,
multiplet); 2.80-2.95 (4H, multiplet); 3.50 (1H, doublet, J=11.0 Hz); 3.65
(1H, doublet, J=11.0 Hz); 4.90 (1H, singlet); 6.65 (1H, doublet, J=5.7
Hz); 7.05 (1H, doublet, J=5.7 Hz); 7.10-7.50 (4H, multiplet).
Mass spectrum (CI, m/z) : 318 (M.sup.+ +1), 246.
17(b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound prepared as described in step (a) above, except
that maleic acid was added in place of blowing hydrogen chloride gas
through the mixture, to obtain the maleate of the title compound as a
colorless powder, melting at 96.degree.-98.degree. C., in a yield of 42%.
Elemental analysis: Calculated for C.sub.18 H.sub.20 FNOS.C.sub.4 H.sub.4
O.sub.4 : C, 61.02%; H, 5.59%; N, 3.23%; Found: C, 60.74%; H, 5.52%; N,
3.23%.
EXAMPLE 18
5(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-2nitro-4,5,6,7-tetrahydrothie
no[3,2-c]pyridine and its hydrochloride (Compound No. 175)
18(a) Following a procedure similar to that described in Example 6, except
that an equivalent amount of cyclopropyl 2-fluorobenzyl ketone (prepared
as described in Preparation 8) was used in place of the
1-(2-fluorophenyl)-2-butanone and that
2-nitro-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (prepared as
described in Preparation 24) was used in place of the
4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride, the title compound
was obtained as a brown oil in a yield of 72%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.82-0.92
(2H, multiplet); 1.01-1.11 (2H, multiplet); 2.00-2.20 (1H, multiplet);
2.75-3.05 (4H, multiplet); 3.61 (2H, singlet); 4.91 (1H, singlet);
7.10-7.45 (4H, multiplet); 7.55 (1H, singlet).
Mass spectrum (CI, m/z) : 361 (M.sup.+ +1), 291.
18(b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound prepared as described in step (a) above, to
obtain the hydrochloride of the title compound as white crystals, melting
at 161.degree.-168.degree. C., in a yield of 79%.
Elemental analysis: Calculated for C.sub.18 H.sub.17 FN.sub.2 O.sub.3
S.HCl: C, 54.47%; H, 4.57%; N, 7.06%. Found: C, 54.47%; H, 4.63%; N,
6.89%.
EXAMPLE 19
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrofuro[3,2-c
]pyridine and its hydrochloride (Compound No. 168)
19(a) Following a procedure similar to that described in Example 12, except
that an equivalent amount of 4,5,6,7-tetrahydrofuro[3,2.-c]pyridine
(prepared as described in Preparation 25) was used in place of the
4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride, the title compound
was obtained as a brown oil in a yield of 21%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.75-0.95
(2H, multiplet); 0.98-1.10 (2H, multiplet); 2.15-2.31 (1H, multiplet);
2.65-3.05 (4H, multiplet); 3.40-3.60 (2H, multiplet); 4.90 (1H, singlet);
6.15 (1H, doublet, J=5.0 Hz); 7.05-7.55 (5H, multiplet).
Mass spectrum (CI, m/z) : 300 (M.sup.+ +1), 230.
19(b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound prepared as described in step (a) above, to
obtain the hydrochloride of the title compound as white crystals, melting
at 154.degree.-155.degree. C., in a yield of 39%.
Elemental analysis: Calculated for C.sub.18 H.sub.18 FNO.sub.2.HCl: C,
64.38%; H, 5.70%; N, 4.17%; Found: C, 64.37%; H, 5.80%; N, 4.19%.
EXAMPLE 20
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7a-hexahydro
thieno[3,2-c]pyridine and its hydrochloride (Compound No. 235)
20(a) Following a procedure similar to that described in Example 12, except
that an equivalent amount of
2-oxo-2,4,5,6,7,7a-hexahydrothieno[3,2.-c]pyridine hydrochloride was used
in place of the 4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride, the
title compound was obtained as a brown oil in a yield of 32%. Diisopropyl
ether was added to this compound to cause crystallization, yielding white
crystals, melting at 123.degree.-125.degree. C.
The resulting
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7a-hexahydr
othieno[3,2-c]pyridine (Compound No. 235) is believed to contain a small
quantity of the tautomeric
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-hydroxy-4,5,6,7-tetrahydr
othieno[3,2-c ]pyridine (Compound No. 188), from which it was not
separated.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.75-0.96
(2H, multiplet); 0.99-1.14 (2H, multiplet); 1.83-2.01 (1H, multiplet);
2.02-2.17 (1H, multiplet); 2.25-2.45 & 2.47-2.62 (together 2H, each
multiplet); 2.85 & 3.10 (together 2H, each doublet, J=12.0 Hz); 3.88-4.01
& 4.03-4.16 (together 2H, each multiplet); 4.85 & 4.89 (together 1H, each
singlet); 6.03 & 6.06 (together 1H, each singlet); 7.10-7.45 (4H,
multiplet).
Mass spectrum (CI, m/z) : 332 (M.sup.+ +1), 262.
Elemental analysis: Calculated for C.sub.18 H.sub.18 FNO.sub.2 S: C,
65.23%; H, 5.48%; N, 4.23%; Found: C, 65.09%; H, 5.55%; N, 4.20%.
20 (b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound prepared as described in step (a) above, to
obtain the hydrochloride of the title compound as white crystals, melting
at 104.degree.-109.degree. C., in a yield of 46%.
EXAMPLE 21
5-(2-Fluoro-.alpha.-propionylbenzyl)-2-oxo-2,4,5,6,7,7a-hexahydrothieno[3,2
-c]pyridine and its hydrochloride (Compound No. 234)
21(a) Following a procedure similar to that described in Example 20, except
that an equivalent amount of 1-(2-fluorophenyl)-2-butanone (prepared as
described in Preparation 9) was used in place of the cyclopropyl
2-fluorobenzyl ketone, the title compound was obtained as a brown oil in a
yield of 36%.
The resulting
5-(2-fluoro-.alpha.-propionylbenzyl)-2-oxo-2,4,5,6,7,7a-hexahydrothieno[3,
2-c]pyridine (Compound No. 234) is believed to contain a small quantity of
the tautomeric
5-(2-fluoro-.alpha.-propionylbenzyl)-2-hydroxy-4,5,6,7-tetrahydrothieno[3,
2-c]pyridine (Compound No. 187).
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 1.00 (3H,
triplet, J=9.1 Hz); 1.82-1.98 (1H, multiplet); 2.25-2.50 (4H, multiplet);
2.85 & 3.05 (together 2H, each doublet, J=14.0 Hz); 3.84-3.95 & 4.04-4.17
(together 2H, each multiplet); 4.72 & 4.76 (together 1H, each singlet);
6.03 & 6.07 (together 1H, each singlet); 7.15-7.40 (4H, multiplet).
Mass spectrum (CI, m/z) : 320 (M.sup.+ +1), 262.
21(b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound prepared as described in step (a) above, to
obtain the hydrochloride of the title compound as white crystals, melting
at 110.degree.-115.degree. C. in a yield of 78%.
EXAMPLE 22
5-(2-Chloro-.alpha.-cyclopropylcarbonylbenzyl)-2-oxo-2,4,5,6,7,7a-hexahydro
thieno[3,2-c]pyridine (Compound No. 233)
Following a procedure similar to that described in Example 5, except that
an equivalent amount of 2-oxo-2,4,5,6,7,7a-hexahydrothieno[3,2-c]pyridine
hydrochloride was used in place of the
4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride, a yellow oil was
obtained. The oil was crystallized from diisopropyl ether to give the
title compound as pale brown crystals, melting at 119.degree.-123.degree.
C. in a yield of 8%.
The resulting
5-(2-chloro-.alpha.-cyclopropylcarbonylbenzyl)-2-oxo-2,4,5,6,7,7a-hexahydr
othieno[3,2-c]pyridine (Compound No. 233) is believed to contain a small
quantity of the tautomeric
5-(2-chloro-.alpha.-cyclopropylcarbonylbenzyl)-2-hydroxy-4,5,6,7-tetrahydr
othieno[3,2-c ]pyridine (Compound No. 186).
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.75-1.10
(4H, multiplet); 175-2.10 (2H, multiplet); 2.25-2.70 (2H, multiplet);
2.90-3.30 (2H, multiplet); 3.75-4.20 (2H, multiplet); 5.09 & 5.10
(together 1H, each singlet); 5.98 & 6.07 (together 1H, each singlet);
7.10-7.50 (4H, multiplet).
Mass spectrum (CI, m/z) : 348 (M.sup.+ +1), 278.
EXAMPLE 23
2-Acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)4,5,6,7-tetrahydrot
hieno[3,2-c]pyridine (Compound No. 190)
2.6 g (7.8 mmole) of
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7a-hexahydr
othieno[3,2-c]pyridine pyridine (prepared as described in Example 20) were
dissolved in a mixture of 10 ml of dimethylformamide and 5 ml of acetic
anhydride, and then 0.35 g (8.6 mmole) of a 60% w/w dispersion of sodium
hydride in mineral oil was added to the resulting solution, whilst
ice-cooling; the mixture was then stirred for 20 minutes at the same
temperature, after which it was stirred for a further 3 hours at room
temperature. At the end of this time, 300 ml of ethyl acetate were added
to the mixture, which was then washed four times, each time with 50 ml of
a saturated aqueous solution of sodium chloride The organic layer was
separated and dried over anhydrous sodium sulfate, and the solvent was
removed by evaporation under reduced pressure. The resulting residue was
subjected to silica gel column chromatography, using a 100:3 by volume
mixture of toluene and ethyl acetate as the eluent, to give a yellow oil.
This oil was crystallized from diisopropyl ether, to obtain the title
compound as white crystals, melting at 120.degree.-121.5.degree. C., in a
yield of 65%.
Infrared Absorption Spectrum (KBr) .nu..sub.max cm.sup.-1 : 1758, 1704.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.80-0.95
(2H, multiplet); 0.99-1.16 (2H, multiplet); 2.27 (3H, singlet); 2.21-2.34
(1H, multiplet); 2.70-2.95 (4H, multiplet); 3.47 (1H, doublet, J=15.0 Hz);
3.57 (1H, doublet, J=15.0 Hz); 4.83 (1H, singlet); 6.27 (1H, singlet);
7.10-7.55 (4H, multiplet).
Mass spectrum (CI, m/z) : 374 (M.sup.+ +1), 304.
Elemental analysis: Calculated for C.sub.20 H.sub.20 FNO.sub.3 S: C,
64.32%; H, 5.40%; N, 3.75%; Found: C, 64.46%; H, 5.39%; N, 3.73%.
EXAMPLE 24
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-2-propionyloxy-4,5,6,7-tetra
hydrothieno[3,2-c]pyridine (Compound No. 192)
Following a procedure similar to that described in Example 23, except that
an equivalent amount of propionic anhydride was used in place of the
acetic anhydride, the title compound was obtained as white crystals,
melting at 101.degree.-102.degree. C., in a yield of 16%.
Infrared Absorption Spectrum (KBr) .nu..sub.max cm.sup.-1 : 1705, 1760.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.75-0.90
(2H, multiplet); 0.90-1.10 (2H, multiplet); 1.21 (3H, triplet, J=6.7 Hz);
2.15-2.37 (1H, multiplet); 2.55 (2H, quartet, J=6.7 Hz); 2.65-2.95 (4H,
multiplet); 3.40-3.60 (2H, multiplet); 4.80 (1H, singlet); 6.25 (1H,
singlet); 7.05-7.55 (4H, multiplet).
Mass spectrum (CI, m/z) : 388 (M.sup.+ +1), 318.
Elemental analysis: Calculated for C.sub.21 H.sub.22 FNO.sub.3 S: C,
65.10%; H, 5.72%; N, 3.61%; Found: C, 64.80%; H, 5.72%; N, 3.61%.
EXAMPLE 25
2-Butyryloxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)4,5,6,7-tetrahyd
rothieno[3,2-c]pyridine (Compound No. 194)
Following a procedure similar to that described in Example 23, except that
an equivalent amount of butyric anhydride was used in place of the acetic
anhydride, the title compound was obtained as white crystals, melting at
84.degree.-85.degree. C., in a yield of 39%.
Infrared Absorption Spectrum (KBr) .nu..sub.max cm.sup.-1 : 1756, 1706.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.75-1.10
(7H, multiplet); 165-1.85 (2H, multiplet); 2.21-2.34 (1H, multiplet); 2.49
(2H, triplet, J=7.0 Hz); 2.70-3.00 (4H, multiplet); 3.52 (2H, broad
triplet, J=16.0 Hz); 4.82 (1H, singlet); 6.25 (1H, singlet): 7.05-7.55
(4H, multiplet).
Mass spectrum (CI, m/z) : 402 (M.sup.+ +1), 332.
Elemental analysis: Calculated for C.sub.22 H.sub.24 FNO.sub.3 S: C,
65.81%; H, 6.03%; N, 3.49%. Found: C, 65.92%; H, 5.91%; N, 3.41%.
EXAMPLE 26
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-2-pivaloyloxy-4,5,6,7-tetrah
ydrothieno[3,2-c]pyridine (Compound No. 196)
Following a procedure similar to that described in Example 23, except that
an equivalent amount of pivalic anhydride was used in place of the acetic
anhydride, the title compound was obtained as white crystals, melting at
91.degree.-94.degree. C., in a yield of 44%.
Infrared Absorption Spectrum (KBr) .nu..sub.max cm.sup.-1 : 1749, 1700.
Nuclear Magnetic Resonance Spectrum (CDC;.sub.3) .delta. ppm: 0.79-0.92
(2H, multiplet); 0.98-1.09 (2H, multiplet); 1.31 (9H, singlet); 2.23-2.36
(1H, multiplet); 2.70-2.95 (4H, multiplet); 3.47 (1H, doublet, J=14.5 Hz);
3.58 (1H, doublet, J=14.5 Hz); 4.83 (1H, singlet); 6.26 (1H, singlet);
7.05-7.55 (4H, multiplet).
Mass spectrum (CI, m/z) : 416 (M.sup.+ +1), 346.
Elemental analysis: Calculated for C.sub.23 H.sub.26 FNO.sub.3 S: C,
66.48%; H, 6.31%; N, 3.37%; Found: C, 66.21%; H, 6.40%; N, 3.38%.
EXAMPLE 27
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-2-nonanoyloxy-4,5,6,7-tetrah
ydrothieno[3,2-c]pyridine (Compound No. 199)
1.0 g (3.0 mmole) of
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7a-hexahydr
othieno[3,2-c]pyridine (prepared as described in Example 20) was dissolved
in 15 ml of dimethylformamide, and then 0.18 g (4.5 mmole) of a 60% w/w
dispersion of sodium hydride in mineral oil and 0.82 ml (4.5 mmole) of
nonanoyl chloride were added, in that order, to the resulting mixture,
whilst ice-cooling. The resulting reaction mixture was then stirred at the
same temperature for 30 minutes, after which it was stirred at room
temperature for a further 5 hours. 300 ml of ethyl acetate were then added
to the mixture, which was then washed with a saturated aqueous solution of
sodium hydrogencarbonate and with a saturated aqueous solution of sodium
chloride, in that order. The organic layer was separated and dried over
anhydrous sodium sulfate, and the solvent was removed by evaporation under
reduced pressure. The resulting residue was subjected to silica gel column
chromatography, using a 100:2 by volume mixture of toluene and ethyl
acetate as the eluent, to give a yellow oil. The oil was crystallized from
petroleum ether to obtain the title compound as white crystals, melting at
45.degree.-48.degree. C., in a yield of 40%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub. 3) .delta. ppm: 0.80-1.80
(19H, multiplet); 2.21-2.32 (1H, multiplet); 2.53 (2H, triplet, J=7.5 Hz);
2.70-2.95 (4H, multiplet); 3.48 (1H, doublet, J=15.0 Hz); 3.57 (1H,
doublet, J=15.0 Hz); 4.84 (1H, singlet); 6.27 (1H, singlet); 7.05-7.55
(4H, multiplet).
Mass spectrum (CI, m/z) : 472 (M.sup.+ +1), 402.
Elemental analysis: Calculated for C.sub.27 H.sub.34 FNO.sub.3 S: C,
68.76%; H, 7.27%; N, 2.97%.: Found: C, 68.56%; H, 7.49%; N, 2.97%.
EXAMPLE 28
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-2-decanoyloxy-4,5,6,7-tetrah
ydrothieno[3,2-c]pyridine and its hydrochloride (Compound No. 200)
28(a) Following a procedure similar to that described in Example 27, except
that an equivalent amount of decanoyl chloride was used in place of the
nonanoyl chloride, the title compound was obtained as a yellow oil in a
yield of 40%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.80-1.80
(21H, multiplet); 2.18-2.32 (1H, multiplet); 2.52 (2H, triplet, J=7.5 Hz);
2.70-2.97 (4H, multiplet); 3.50 (1H, doublet, J=14.5 Hz); 3.59 (1H,
doublet, J=14.5 Hz); 4.85 (1H, singlet); 6.26 (1H, singlet); 7.20-7.55
(4H, multiplet).
Mass spectrum (CI, m/z) : 486 (M.sup.+ +1), 416.
28(b) A procedure similar to that described in Example 2(b) was repeated,
using the title compound prepared as described in step (a) above, except
that diisopropyl ether was used as a solvent in place of the diethyl
ether, to give the hydrochloride of the title compound as yellow crystals,
melting at 62.degree.-64.degree. C., in a yield of 81%
Elemental analysis: Calculated for C.sub.28 H.sub.36 FNO.sub.3 S.HCl: C,
64.41%; H, 7.14%; N, 2.68%; Found: C, 64.12%; H, 7.05%; N, 2.63%.
EXAMPLE 29
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-2-palmitoyloxy-4,5,6,7-tetra
hydrothieno[3,2-c]pyridine (Compound No. 201)
Following a procedure similar to that described in Example 27, except that
an equivalent amount of palmitoyl chloride was used in place of the
nonanoyl chloride, the title compound was obtained as white crystals,
melting at 6620 -68.degree. C., in a yield of 21%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.80-1.80
(33H, multiplet); 2.20-2.32 (1H, multiplet); 2.51 (2H, triplet, J=7.5 Hz);
2.70-2.95 (4H, multiplet); 3.48 (1H, doublet, J=15.0 Hz); 3.58 (1H,
doublet, J=15.0 Hz); 4.84 (1H, singlet); 6.26 (1H, singlet); 7.10-7.55
(4H, multiplet).
Mass spectrum (CI, m/z) : 570 (M.sup.+ +1), 500.
Elemental analysis: Calculated for C.sub.34 H.sub.48 FNO.sub.3 S: C,
71.66%; H, 8.49%; N, 2.46%; Found: C, 71.72%; H, 8.62%; N, 2.43%.
EXAMPLE 30
2-t-Butoxycarbonyloxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,
7-tetrahydrothieno[3,2-c]pyridine (Compound No. 203)
Following a procedure similar to that described in Example 23, except that
an equivalent amount of di-t-butyl dicarbonate was used in place of the
acetic anhydride, the title compound was obtained as white crystals,
melting at 98.degree.-99.degree. C., in a yield of 15%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.80-0.90
(2H, multiplet); 0.98-1.09 (2H, multiplet); 1.55 (9H, singlet); 2.20-2.34
(1H, multiplet); 2.70-2.95 (4H, multiplet); 3.40-3.60 (2H, multiplet);
4.83 (1H, singlet); 6.27 (1H, singlet); 7.07-7.52 (4H, multiplet).
Mass spectrum (CI, m/z) : 432 (M.sup.+ +1), 362.
Elemental analysis: Calculated for C.sub.23 H.sub.26 FNO.sub.4 S: C,
64.02%; H, 6.07%; N, 3.25%; Found: C, 63.57%; H, 6.03%; N, 3.27%.
EXAMPLE 31
2-Amino-5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)4,5,6,7-tetrahydrothi
eno[3,2-c]pyridine (Compound No. 177)
5 ml of hydrochloric acid were added to 0.4 g of
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-nitro-4,5,6,7-tetrahydrot
hieno[3,2-c]pyridine hydrochloride (prepared as described in Example 18),
and then 0.23 g of tin powder was added to the resulting mixture, whilst
stirring, after which the mixture was stirred at room temperature for a
further hour. 10 ml of water were added to the reaction mixture, which was
then extracted with methylene chloride. The methylene chloride layer was
removed, and the aqueous layer was concentrated to dryness by evaporation
under reduced pressure, and then crystallized from diethyl ether, to give
a complex of the title compound with stannic chloride as a pale yellow
powder in a yield of 72%.
Nuclear Magnetic Resonance Spectrum (CD.sub.3 OD) .delta. ppm: 0.95-1.05
(2H, multiplet); 1.20-1.35 (2H, multiplet); 1.85-1.99 (1H, multiplet);
3.60-3.80 (2H, multiplet); 6.07 (1H, singlet); 7.35-7.80 (4H, multiplet).
EXAMPLE 32
2-Acetylamino-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrah
ydrothieno[3,2-c]pyridine (Compound No. 179)
1.85 g (5.13 mmole) of
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-nitro-4,5,6,7-tetrahydrot
hieno[3,2-c]pyridine (prepared as described in Example 18) were dissolved
in a mixture of 20 ml of acetic acid and 2 ml of acetic anhydride, and
then 1.85 g of iron powder were added to the solution, whilst stirring at
room temperature; the mixture was then stirred at the same temperature for
90 minutes. At the end of this time, water and chloroform were added to
the reaction mixture, and the mixture was neutralized with sodium
carbonate. The inorganic salt thus precipitated was filtered off, the
remaining organic layer was separated and the aqueous layer was extracted
with chloroform. The organic layer and the extract were combined and dried
over anhydrous magnesium sulfate, and then the solvent was removed by
distillation under reduced pressure. The resulting residue was then
subjected to silica gel column chromatography, using a 6:4 by volume
mixture of toluene and ethyl acetate as the eluent, to give 1.86 g of the
title compound. This was crystallized from diisopropyl ether to obtain
1.37 g of the title compound as white crystals, melting at
155.degree.-159.degree. C.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.78-0.94
(2H, multiplet); 0.98-1.12 (2H, multiplet); 2.17 (3H, singlet); 2.15-2.32
(1H, multiplet); 2.70-2.99 (4H, multiplet); 3.50 (1H, doublet, J=11.4 Hz);
3.60 (1H, doublet, J=11.4 Hz); 4.86 (1H, singlet); 6.27 (1H, singlet);
7.10-7.5S (4H, multiplet); 7.80-8.00 (1H, broad singlet).
Mass spectrum (CI, m/z) : 373 (M.sup.+ +1), 303.
Elemental analysis: Calculated for C.sub.20 H.sub.21 FN.sub.2 O.sub.2 S: C,
64.49%; H, 5.68%; N, 7.52%.; Found: C, 64.38%; H, 5.50%; N, 7.38%.
EXAMPLE 33
2-Butyrylamino-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetra
hydrothieno[3,2-c]pyridine (Compound No. 181)
Following a procedure similar to that described in Example 32, except that
equivalent amounts of butyric acid and butyric anhydride were used in
place of the acetic acid and acetic anhydride, the title compound was
obtained as white crystals, melting at 154.degree.-157.degree. C., in a
yield of 61%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.78-0.94
(2H, multiplet); 0.90-1.10 (5H, multiplet); 1.65-1.82 (2H, multiplet);
2.21-2.39 (3H, multiplet); 2.69-2.95 (4H, multiplet); 3.47 (1H, doublet,
J=11.4 Hz); 3.56 (1H, doublet, J=11.4 Hz); 4.81 (1H, singlet); 6.25 (1H,
singlet); 7.10-7.60 (4H, multiplet); 7.70 (1H, singlet).
Mass spectrum (CI, m/z) : 401 (M.sup.+ +1), 331.
Elemental analysis: Calculated for C.sub.22 H.sub.25 FN.sub.2 O.sub.2 : C,
65.97%; H, 6.29%; N, 6.99%; Found: C, 65.95%; H, 6.36%; N, 6.95%.
EXAMPLE 34
Optically active
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,
2-c]pyridine (Compound No. 59)
0.3 g of
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,
2-c]pyridine (prepared as described in Example 12) was separated into
fractions by liquid chromatography [column: DAICEL CHIRALPAC AD (trade
name), 1 cm.times.25 cm); eluent: a 1000:40:1 by volume mixture of hexane,
isopropanol and diethylamine; column temperature: 35.degree. C.; flow
rate: 4 ml/minute], to obtain an optically active isomer A [retention
time: 8.3 minutes; specific rotation angle [.alpha.].sub.D.sup.25 :
109.4.degree. (C=1.80, CHCl.sub.3)] and an isomer B [retention time: 9.9
minutes; specific rotation angle [.alpha.].sub.D.sup.25 :100.1.degree.
(C=1.90, CHCl.sub.3)].
Isomers A and B were separately dissolved in diethyl ether, and then
hydrogen chloride gas was allowed to act upon the resulting solutions to
obtain 0.13 g and 0.12 g of the hydrochlorides of isomer A and isomer B,
respectively, as white crystals.
Hydrochloride of isomer A
melting at 106.degree.-110.degree. C.
Elemental analysis: Calculated for C.sub.18 H.sub.18 FNOS.HCl.3/4H.sub.2 O:
C, 59.17%; H, 5.65%; N, 3.83%; Found: C, 59.06%; H, 5.74%; N, 3.90%.
Hydrochloride of isomer B
melting at 105.degree.-110.degree. C.
Elemental analysis: Calculated for C.sub.18 H.sub.18 FNOS.HCl.1/2H.sub.2 O:
C, 59.91%; H, 5.59%; N, 3.88%; Found: C, 59.80%; H, 5.84%; N, 3.79%.
EXAMPLE 35
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-2-pivaloyloxymethoxy-4,5,6,7
-tetrahydrothieno[3,2c]pyridine (Compound No. 207)
1.0 g (3.0 mmole) of
5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7a-hexahydr
othieno [3,2-c]pyridine (prepared as described in Example 20) was dissolved
in 20 ml of dimethylformamide, and then 100 mg (0.6 mmole) of potassium
iodide and 0.13 g (3.3 mmole) of a 60% dispersion of sodium hydride in
mineral oil were added to the solution at room temperature; the mixture
was then stirred at the same temperature for 10 minutes. At the end of
this time, a solution of 0.43 ml (3.0 mmole) of pivaloyloxymethyl chloride
in 5 ml of dimethylformamide was added dropwise to the resulting mixture
over a period of 10 minutes, and the resulting mixture was stirred at room
temperature for 30 minutes. 300 ml of ethyl acetate were added to the
reaction mixture, and the mixture was washed three times, each time with
50 ml of a saturated aqueous solution of sodium hydrogen. carbonate. The
organic layer was dried over anhydrous sodium sulfate, and the solvent was
removed by evaporation under reduced pressure. The resulting residue was
subjected to silica gel column chromatography, using a 100:3 by volume
mixture of toluene and ethyl acetate as the eluent, to give the title
compound as a colorless oil in a yield of 15%.
Infrared Absorption Spectrum (thin film) .nu..sub.max cm.sup.-1 : 1715,
1702.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.79-0.93
(2H, multiplet); 0.99-1.14 (2H, multiplet); 1.22 (9H, singlet); 2.18-2.31
(1H, multiplet); 2.65-2.95 (4H, multiplet); 3.44 (1H, doublet, J=15.5 Hz);
3.55 (1H, doublet, J=15.5 Hz); 4.84 (1H, singlet); 5.57 (2H, singlet);
6.04 (1H, singlet); 7.05-7.50 (4H, multiplet).
Mass spectrum (CI, m/z) : 446 (M.sup.+ +1), 376.
EXAMPLE 36
5-(.alpha.-Cyclopropylcarbonyl-2-fluorobenzyl)-2-methoxy-4,5,6,7-tetrahydro
thieno[3,2c]pyridine and its hydrochloride (Compound No. 210)
36(a) A procedure similar to that described in Example 35 was repeated,
except that an equivalent amount of methyl iodide was used in place of the
pivaloyloxymethyl chloride and potassium iodide, to give the title
compound as a yellow oil in a yield of 45%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.80-0.92
(2H, multiplet); 1.00-1.10 (2H, multiplet); 2.20-2.36 (1H, multiplet);
2.65-2.96 (4H, multiplet); 3.42 (1H, doublet, J=14.5 Hz); 3.55 (1H,
doublet, J=14.5 Hz); 3.80 (3H, singlet); 4.82 (1H, singlet); 5.80 (1H,
singlet);
7.10-7.60 (4H, multiplet).
Mass spectrum (CI, m/z) : 346 (M.sup.+ +1), 276.
36(b) Following a procedure similar to that described in Example 2(b),
using the whole of the title compound prepared as described in step (a)
above, the hydrochloride of the title compound was obtained as white
crystals, melting at 102.degree.-106.degree. C., in a yield of 78%.
Elemental analysis:
Calculated for C.sub.19 H.sub.20 FNO.sub.2 S.HCl.1/2H.sub.2 O: C, 58.38%;
H, 5.67%; N, 3.58%.; Found: C, 58.08%; H, 5.77%; N, 3.53%.
EXAMPLE 37
5-[.alpha.-(2-Fluorocyclopropylcarbonyl-2-fluorobenzyl]-2-oxo-2,4,5,6,7,7a-
hexahydrothieno[3,2-c]pyridine (Compound No. 275)
Following a procedure similar to that described in Example 1, except that
equivalent amounts of 2-oxo2,4,5,6,7,7a-hexahydrothieno[3,2-c]pyridine
hydrochloride and 2-fluoro-.alpha.-(2-fluorocyclopropylcarbonyl)benzyl
bromide (prepared as described in Preparation 27) were used in place of
the 4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride and
2-chloro-.alpha.-trifluoroacetylbenzyl bromide, the title compound was
obtained as a yellow oil in a yield of 31%.
The resulting
5-[.alpha.-(2-fluorocyclopropylcarbonyl-2-fluorobenzyl]-2-oxo-2,4,5,6,7,7a
-hexahydrothieno[3,2-c]pyridine (Compound No. 275) is believed to contain a
small quantity of the tautomeric
5-[.alpha.-(2-fluorocyclopropylcarbonyl-2-fluorobenzyl]-2-hydroxy-4,5,6,7-
tetrahydrothieno[3,2-c]pyridine (Compound No. 274), from which it was not
separated.
Infrared Absorption Spectrum (thin film) .nu..sub.max cm.sup.-1 : 1680.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 1.48-1.55
(2H, multiplet); 1.85-2.01 (1H, multiplet); 2.30-2.51 (2H, multiplet);
2.53-2.90 (1H, multiplet); 3.00-3.20 (2H, multiplet); 3.83-4.01 &
4.03-4.18 (together 2H, each multiplet); 4.46-4.60 & 4.79-4.92 (together
2H, each multiplet); 6.05 & 6.09 (together 1H, each singlet); 7.10-7.45
(4H, multiplet). Mass spectrum (CI, m/z) : 350 (M.sup.+ +1), 262.
PREPARATION 1
3-(2-Chlorobenzyl)-5,6-dihydro-1,4,2-dioxazine
A solution of 5.0 g (29.3 mmole) of o-chlorophenylacetic acid and 0.3 g of
p-toluenesulfonic acid monohydrate in 50 ml of methanol was heated under
reflux for 6 hours. At the end of this time, 3.1 g (44 mmole) of
hydroxylamine hydrochloride were added to the reaction mixture, followed
by 2.1 g of sodium methoxide. The resulting reaction mixture was then
heated under reflux for 10 hours. 14.2 g (103 mmole) of potassium
carbonate and 5.1 ml of 1,2-dibromoethane were then added to the resulting
reaction mixture, followed by 15 ml of water. The reaction mixture was
then heated under reflux for a further 10 hours. At the end of this time,
200 ml of ethyl acetate were added to the reaction mixture, and the
organic layer was separated, washed with a saturated aqueous solution of
sodium hydrogencarbonate and dried over anhydrous sodium sulfate; the
solvent was then removed by distillation under reduced pressure. The
residue thus obtained was subjected to silica gel column chromatography,
using a 9:1 by volume mixture of toluene and ethyl acetate as the eluent,
to give 4.9 g of the title compound as an oil.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 3.67 (2H,
singlet); 4.05 (2H, triplet, J=4.2 Hz); 4.29 (2H, triplet, J=4.2 Hz);
7.10-7.40 (4H, multiplet). Mass spectrum (CI, m/z) : 212 (M.sup.+ +1),
176.
PREPARATION 2
3-(2-Fluorobenzyl)-5,6-dihydro-1,4,2-dioxazine
A procedure similar to that described in Preparation 1 was repeated, except
that an equivalent amount of o-fluorophenylacetic acid was used in place
of the o-chlorophenylacetic acid, to give the title compound as a
colorless oil in a yield of 45%.
Mass spectrum (CI, m/z) : 196 (M.sup.+ +1), 109.
PREPARATION 3
3-(2,6-Difluorobenzyl)-5,6-dihydro-1,4,2-dioxazine
A procedure similar to that described in Preparation 1 was repeated, except
that an equivalent amount of 2,6-difluorophenylacetic acid was used in
place of the o-chlorophenylacetic acid, to give the title compound as a
colorless oil in a yield of 45%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 3.61 (2H,
singlet); 4.04 (2H, triplet, J=4.1 Hz); 4.30 (2H, triplet, J=4.1 Hz);
6.80-7.30 (4H, multiplet).
Mass spectrum (CI, m/z) : 214 (M.sup.+ +1), 127.
PREPARATION 4
2-Chlorobenzyl cyclopropyl ketone
10 ml of anhydrous diethyl ether were added to 0.45 g (18.5 mmole) of
metallic magnesium, and then a solution of 2.0 ml (15.4 mmole) of
2-chlorobenzyl bromide in 10 ml of diethyl ether was slowly added dropwise
to the resulting mixture, whilst stirring; the mixture was then stirred at
room temperature for one hour. The resulting solution was slowly added
dropwise to a solution of 1.1 ml of cyclopropyl cyanide in 10 ml of
diethyl ether over a period of 30 minutes, and then the mixture was
stirred at room temperature for 2 hours. At the end of this time, a
saturated aqueous solution of ammonium chloride was added to the reaction
mixture, and the mixture was stirred at room temperature for 15 minutes.
200 ml of ethyl acetate were then added to the reaction mixture, and the
organic layer was separated, washed with water, with a saturated aqueous
solution of sodium hydrogencarbonate and with a saturated aqueous solution
of sodium chloride, in that order, and dried over anhydrous sodium
sulfate; the solvent was then removed by distillation under reduced
pressure. The residue thus obtained was subjected to silica gel column
chromatography, using a 9:1 by volume mixture of toluene and ethyl acetate
as the eluent, to give 2.0 g of the title compound as a colorless oil.
Infrared Absorption Spectrum (thin film) .nu..sub.max cm.sup.-1 : 1695.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.86-0.92
(2H, multiplet); 1.06-1.12 (2H, multiplet); 1.96-2.02 (1H, multiplet);
3.98 (2H, singlet); 7.10-7.50 (4H, multiplet).
Mass spectrum (CI, m/z) : 195 (M.sup.+ +1), 159.
PREPARATION 5
1-(2-Fluorophenyl)-2-pentanone
A procedure similar to that described in Preparation 4 was repeated, except
that equivalent amounts of 2-fluorobenzyl bromide and butyl cyanide were
used in place of the 2-chlorobenzyl bromide and cyclopropyl cyanide, to
give the title compound as a colorless oil in a yield of 36%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.90 (3H,
triplet, J=8.0 Hz); 1.52-1.73 (2H, multiplet); 2.45 (2H, triplet, J=8.0
Hz); 3.70 (2H, singlet); 7.00-7.30 (4H, multiplet).
Mass spectrum (CI, m/z) : 181 (M.sup.+ +1), 109.
PREPARATION 6
1-(2-Fluorophenyl)-2-hexanone
A procedure similar to that described in Preparation 4 was repeated, except
that equivalent amounts of 2-fluorobenzyl bromide and pentyl cyanide were
used in place of the 2-chlorobenzyl bromide and cyclopropyl cyanide, to
give the title compound as a colorless oil in a yield of 46%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.90 (3H,
triplet, J=8.0 Hz); 1.20-1.39 (2H, multiplet); 1.50-1.65 (2H, multiplet);
2.50 (2H, triplet, J=8.0 Hz); 3.70 (2H, singlet); 7.00-7.30 (4H,
multiplet).
Mass spectrum (CI, m/z) : 195 (M.sup.+ +1), 109.
PREPARATION 7
1-(2-Fluorophenyl)-3,3-dimethyl-2-butanone
A procedure similar to that described in Preparation 4 was repeated, except
that equivalent amounts of 2-fluorobenzyl bromide and t-butyl cyanide were
used in place of the 2-chlorobenzyl bromide and cyclopropyl cyanide, to
give the title compound as a colorless oil in a yield of 42%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 1.25 (9H,
singlet); 3.80 (2H, singlet); 7.00-7.30 (4H, multiplet).
Mass spectrum (CI, m/z) : 195 (M.sup.+ +1), 109.
PREPARATION 8
Cyclopropyl 2-fluorobenzyl ketone
A procedure similar to that described in Preparation 4 was repeated, except
that equivalent amounts of 2-fluorobenzyl bromide and cyclopropyl cyanide
were used in place of the 2-chlorobenzyl bromide and cyclopropyl cyanide,
to give the title compound as a colorless oil in a yield of 70%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.82-0.98
(2H, multiplet); 1.03-1.17 (2H, multiplet); 1.92-2.06 (1H, multiplet);
3.86 (2H, singlet); 7.10-7.30 (4H, multiplet).
Mass spectrum (CI, m/z) : 179 (M.sup.+ +1).
PREPARATION 9
1-(2-Fluorophenyl)-2-butanone
(a) 1-(2-Fluorophenyl)-2-nitro-1-butene 30 ml of acetic acid were added to
4.73 g (38.11 mmole) of 2-fluorobenzaldehyde, 4.41 g (49.49 mmole) of
nitropropane and 3.23 g (41.90 mmole) of ammonium acetate, and the
resulting mixture was heated under reflux, whilst stirring, for 4 hours.
At the end of this time, the reaction mixture was cooled to room
temperature, neutralized with an aqueous solution of sodium
hydrogencarbonate and extracted with diethyl ether. The extract was dried
over anhydrous magnesium sulfate, and then xylene was added to the
solution. The mixture was concentrated by evaporation under reduced
pressure, to give 7.4 g of the title compound as a pale yellow oil.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 1.25 (3H,
triplet, J=6.5 Hz); 2.80 (2H, quartet, J=6.5 Hz); 7.00-7.60 (4H,
multiplet); 8.03 (1H, singlet).
Mass spectrum (CI, m/z) : 196 (M.sup.+ +1), 149.
9(b) 1-(2-Fluorophenyl)-2-butanone
100 ml of 90% v/v aqueous acetic acid were added to 7.4 g of
1-(2-fluorophenyl)-2-nitro-1-butene [prepared as described in step (a)
above], and then 12.11 g (190 mmole) of a zinc powder were added in
portions to the resulting solution, whilst heating. The mixture was then
heated under reflux, whilst stirring, for 4 hours. At the end of this
time, the reaction mixture was left to stand overnight, and then the
crystals which had precipitated were filtered off and washed with toluene.
The filtrate was combined with the toluene washings, and the mixture was
concentrated by evaporation under reduced pressure. The residue thus
obtained was subjected to silica gel column chromatography, using toluene
as the eluent, to give 1.85 g of the title compound as a pale brown oil.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 1.05 (3H,
triplet, J=7.0 Hz); 2.53 (2H, quartet, J=7.0 Hz); 3.73 (2H, singlet);
7.00-7.40 (4H, multiplet).
Mass spectrum (CI, m/z) : 167 (M.sup.+ +1), 109.
PREPARATION 10
1-(2-Chlorophenyl)-2-propanone
Following a procedure similar to that described in Preparation 9, except
that equivalent amounts of 2-chlorobenzaldehyde and nitroethane were used
in place of the 2-fluorobenzaldehyde and nitropropane, the title compound
was obtained as a brown oil in a yield of 27%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 2.20 (3H,
singlet); 3.85 (2H, singlet); 7.15-7.45 (4H, multiplet).
Mass spectrum (CI, m/z) : 169 (M.sup.+ +1), 125.
PREPARATION 11
1-(2-chlorophenyl)-2-butanone
Following a procedure similar to that described in Preparation 9, except
that an equivalent amount of 2-chlorobenzaldehyde was used in place of the
2-fluorobenzaldehyde, the title compound was obtained as a pale yellow oil
in a yield of 17%.
Mass spectrum (CI, m/z) : 183 (M.sup.+ +1), 125.
PREPARATION 12
1-(2-Chlorophenyl)-2-heptanone
Following a procedure similar to that described in Preparation 9, except
that equivalent amounts of 2-chlorobenzaldehyde and nitrohexane were used
in place of the 2-fluorobenzaldehyde and nitropropane, the title compound
was obtained as a pale yellow oil in a yield of 17%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.90 (3H,
triplet, J=8.0 Hz); 1.20-1.40 (4H, multiplet); 1.50-1.70 (2H, multiplet);
2.50 (2H, triplet, J=10.0 Hz); 3.80 (2H, singlet); 7.20-7.60 (4H,
multiplet).
Mass spectrum (CI, m/z) : 225 (M.sup.+ +1), 125.
PREPARATION 13
Cyclobutyl 2-fluorobenzyl ketone
20 ml of anhydrous diethyl ether were added to 1.06 g (44 mmole) of
metallic magnesium, and then a solution of 7.56 g (40 mmole) of
2-fluorobenzyl bromide in 10 ml of diethyl ether was slowly added dropwise
to the resulting mixture, whilst stirring; the mixture was then stirred at
room temperature for 1 hour. The resulting solution was slowly added
dropwise to a solution of 4.74 g (40 mmole) of cyclobutanecarbonyl
chloride in 30 ml of tetrahydrofuran, whilst cooling in a methanol-dry ice
bath, over a period of 2 hours, and then the mixture was allowed to return
to room temperature, whilst stirring, over a period of 2 hours. At the end
of this time, 100 ml of water and 150 ml of diethyl ether were added to
the reaction mixture, and the organic layer was separated, dried over
anhydrous magnesium sulfate and concentrated by evaporation under reduced
pressure. The residue thus obtained was subjected to silica gel column
chromatography, using a 9:1 by volume mixture of toluene and hexane as the
eluent, to give 2.97 g of the title compound as a pale yellow oil.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 1.65-2.40
(6H, multiplet); 3.31-3.48 (1H, multiplet); 3.67 (2H, singlet); 7.00-7 30
(4H, multiplet).
Mass spectrum (CI, m/z) : 193 (M.sup.+ +1), 137.
PREPARATION 14
5-Chloro-1-(2-chlorophenyl)-2-pentanone
Following a procedure similar to that described in Preparation 13, except
that equivalent amounts of 2-chlorobenzyl bromide and 4-chlorobutyryl
chloride were used in place of the 2 fluorobenzyl bromide and
cyclobutanecarbonyl chloride, the title compound was obtained as a yellow
oil in a yield of 79%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 1.96-2.15
(2H, multiplet); 2.69 (2H, triplet, J=7.7 Hz); 3.56 (2H, triplet, J=7.7
Hz); 3.86 (2H, singlet); 7.10-7.50 (4H, multiplet).
PREPARATION 15
1-(2-Chlorophenyl)-3,3,3-trifluoro-2-propanone
10 ml of anhydrous diethyl ether were added to 0.9 g (37.0 mmole) of
metallic magnesium, and then a solution of 3.9 ml (30.8 mmole) of
2-chlorobenzyl chloride in 10 ml of diethyl ether was slowly added
dropwise to the resulting mixture, with vigorous stirring, over a period
of 30 minutes; the mixture was then stirred at room temperature for 1
hour. The resulting solution was slowly added dropwise to a solution of
4.3 ml (30.8 mmole) of trifluoroacetic anhydride in 40 ml of
tetrahydrofuran, whilst cooling to about -70.degree. C., and then the
mixture was allowed to return to room temperature, whilst stirring, over a
period of about 1 hour; after this, the mixture was left to stand
overnight. At the end of this time, 200 ml of ethyl acetate were added to
the resulting reaction mixture, and the organic layer was separated,
washed with IN aqueous hydrochloric acid and with a saturated aqueous
solution of sodium chloride, in that order, dried over anhydrous sodium
sulfate and concentrated by evaporation under reduced pressure. The
residue thus obtained was subjected to silica gel column chromatography,
using a 10:2 by volume mixture of toluene and ethyl acetate as the eluent,
to give 5.7 g of the title compound as a yellow oil.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 4.16 (2H,
singlet); 7.10-7.50 (4H, multiplet).
Mass spectrum (CI, m/z) : 223 (M.sup.+ +1), 125.
PREPARATION 16
2-Chloro-.alpha.-trifluoroacetylbenzyl bromide
2.0 g (9.0 mmole) of 1-(2-chlorophenyl)-3,3,3-trifluoro-2-propanone were
dissolved in 30 ml of carbon tetrachloride, and then 0.46 ml (9.0 mmole)
of bromine was added to the solution, which was then stirred at room
temperature for 10 hours. At the end of this time, sodium hydrogensulfite
was added to the reaction mixture, and the mixture was stirred at room
temperature for 15 minutes, after which insolubles were removed by
filtration. The filtrate was concentrated by evaporation under reduced
pressure, and the residue was subjected to silica gel column
chromatography, using a 10:2 by volume mixture of toluene and ethyl
acetate as the eluent, to give 0.87 g of the title compound as a yellow
oil.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 6.39 (1H,
singlet); 7.30 7.70 (4H, multiplet).
Mass spectrum (CI, m/z) : 302 (M.sup.+ +2), 300 (M.sup.+), 221.
PREPARATION 17
2-Chloro-.alpha.-(4-chlorobutyryl)benzyl bromide
Following a procedure similar to that described in Preparation 16, except
that an equivalent amount of 1-(2-chlorophenyl)-5-chloro-2-pentanone was
used in place of the 1-(2-chlorophenyl)-3,3,3-trifluoro-2-propanone, the
title compound was obtained as a yellow oil in a yield of 72%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 2.01-2.14
(2H, multiplet); 2.40-2.90 (2H, multiplet); 3.49-3.61 (2H, multiplet);
5.98 (1H, singlet); 7.20-7.60 (4H, multiplet).
Mass spectrum (CI, m/z) : 311 (M.sup.+ +1), 231.
PREPARATION 18
2-Chloro-.alpha.-(5,6-dihydro-1,4,2-dioxazin-3-yl)benzyl bromide
4.0 g (19 mmole) of 3-(2-chlorobenzyl)-5,6-dihydro-1,4,2-dioxazine
(prepared as described in Preparation 1) were dissolved in 40 ml of carbon
tetrachloride, and then 4.1 g (23 mmole) of N-bromosuccinimide and 0.2 g
of benzoyl peroxide were added to the solution, which was then stirred,
whilst heating, for 8 hours. At the end of this time, 100 ml of ethyl
acetate and 100 ml of hexane were added to the solution, and the mixture
was stirred at room temperature for 30 minutes; insolubles were then
removed by filtration. The filtrate was concentrated by evaporation under
reduced pressure, to give 4.8 g of the title compound as a yellow oil.
Mass spectrum (CI, m/z) : 292 (M.sup.+ +3), 290 (M.sup.+ +1), 212.
PREPARATION 19
2-Fluoro-.alpha.-(5,6-dihydro-1,4,2-dioxazin-3-yl)benzyl bromide
Following a procedure similar to that described in Preparation 18, except
that an equivalent amount of
3-(2-fluorobenzyl)-5,6-dihydro-1,4,2-dioxazine (prepared as described in
Preparation 2) was used in place of the
3-(2-chlorobenzyl)-5,6-dihydro-1,4,2-dioxazine, the title compound was
obtained as a red oil in a yield of 98%.
Mass spectrum (CI, m/z) : 276 (M.sup.+ +3), 194.
PREPARATION 20
2,6-Difluoro-.alpha.-(5,6-dihydro-1,4,2-dioxazin-3-yl)benzyl bromide
Following a procedure similar to that described in Preparation 18, except
that an equivalent amount of
3-(2,6-difluorobenzyl)-5,6-dihydro-1,4,2-dioxazine (prepared as described
in Preparation 3) was used in place of the
3-(2-chlorobenzyl)-5,6-dihydro-1,4,2-dioxazine, the title compound was
obtained as a red oil in a yield of 57%.
Mass spectrum (CI, m/z) : 294 (M.sup.+ +3), 214.
PREPARATION 21
2-Chloro-.alpha.-cyclopropylcarbonylbenzyl bromide
Following a procedure similar to that described in Preparation 18, except
that an equivalent amount of 2-chlorobenzyl cyclopropyl ketone (prepared
as described in Preparation 4) was used in place of the
3-(2-chlorobenzyl)-5,6-dihydro-1,4,2-dioxazine, the title compound was
obtained as a red oil in a yield of 83%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 0.80-1.20
(4H, multiplet); 2.04-2.16 (1H, multiplet); 6.18 (1H, singlet); 7.20-7.60
(4H, multiplet).
Mass spectrum (CI, m/z) : 275 (M.sup.+ +3), 193.
PREPARATION 22
2-Chlorobenzyl 4-fluorophenyl ketone
Following a procedure similar to that described in Preparation 13, except
that equivalent amounts of 2-chlorobenzyl bromide and 4-fluorobenzoyl
chloride were used in place of the 2-fluorobenzyl bromide and
cyclobutanecarbonyl chloride, the title compound was obtained as a
colorless powder in a yield of 34%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 4.40 (2H,
singlet); 7.10-7.45 (6H, multiplet); 8.04-8.10 (2H, multiplet).
Mass spectrum (CI, m/z) : 249 (M.sup.+ +1), 213.
PREPARATION 23
2-Fluorobenzyl isopropyl ketone
Following a procedure similar to that described in Preparation 4, except
that equivalent amounts of 2-fluorobenzyl chloride and isobutyronitrile
were used in place of the 2-chlorobenzyl bromide and cyclopropyl cyanide,
the title compound was obtained as a colorless oil in a yield of 25%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 1.15 (6H,
doublet, J=7.5 Hz); 2.75 (1H, septet, J=7.5 Hz); 3.78 (2H, singlet);
6.97-7.30 (4H, multiplet).
Mass spectrum (CI, m/z) : 181 (M.sup.+ +1), 109.
PREPARATION 24
2-Nitro-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride
24(a) 5-Acetyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
35.1 g (200 mmole) of 4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride
and 38.57 g (200 mmole) of 28% w/v sodium methoxide in methanol were added
to 200 ml of ethanol, and the resulting mixture was stirred at room
temperature for 1 hour. The inorganic salt thus precipitated was filtered
off, and the filtrate was concentrated to dryness by evaporation under
reduced pressure. 50 ml of acetic anhydride were added all at once, whilst
stirring, to the residue, and the resulting mixture was stirred at room
temperature for 1 hour. The reaction mixture was then concentrated to
dryness by evaporation under reduced pressure, and the residue thus
obtained was subjected to silica gel column chromatography, using a 6:4 by
volume mixture of toluene and ethyl acetate as the eluent, to give 29.32 g
of the title compound as a yellow oil.
24(b) 5-Acetyl2-nitro-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
20 ml of an acetic anhydride solution containing 5.43 g (30 mmole) of
5-acetyl-4,5,6,7-tetrahydrothieno.[3,2-c]pyridine [prepared as described
in step (a) above] were added dropwise at 10.degree. to 18.degree. C. over
a period of one hour to 30 ml of an acetic acid solution containing 4.2 g
(60 mmole) of 90% fuming nitric acid, and the mixture was then stirred at
a temperature not greater than 18.degree. C. for 1 hour. The reaction
mixture was then poured into ice-water and extracted with methylene
chloride. The organic layer was separated, washed with a saturated aqueous
solution of sodium hydrogencarbonate and with water, in that order, and
dried over anhydrous magnesium sulfate. The solvent was then removed by
distillation under reduced pressure, and the resulting residue was
crystallized from a mixture of hexane and toluene, to give 4.46 g of the
title compound as yellow crystals.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 2.19 & 2.21
(together 3H, each singlet); 2.82-3.05 (2H, multiplet); 3.80 & 3.95
(together 2H, each triplet, J=5.7 Hz); 4.55 & 4.66 (together 2H, each
singlet); 7.66 (1H, singlet).
Mass spectrum (CI, m/z) : 227 (M.sup.+ +1).
24(c) 2-Nitro-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride 2.38 g
(10.53 mmole) of 5-acetyl-2-nitro-4,5,6,7-tetrahydrothieno[3,2-c]pyridine
[prepared as described in step (b) above] were heated under reflux for 2
hours in 60 ml of 10% w/v aqueous hydrochloric acid. The reaction mixture
was then concentrated to dryness by evaporation under reduced pressure, to
give 2.19 g of the title compound as brown crystals.
Nuclear Magnetic Resonance Spectrum (CD.sub.3 OD) .delta. ppm: 3.22 (2H,
triplet, J=6.2 Hz); 3.60 (2H, triplet, J=6.2 Hz); 4.31 (2H, singlet); 7.87
(1H, singlet).
Mass spectrum (CI, m/z) : 185 (M.sup.+ +1).
PREPARATION 25
4,5,6,7-Tetrahydrofuro[3,2-c]pyridine
3.7 g (46 mmole) of a 37% aqueous formaldehyde solution were added dropwise
at room temperature to 5.1 g (46 mmole) of 2-furylethylamine [the compound
described, for example, in Brit., J. Pharmacol., 9, 376 (1954)], and the
resulting mixture was stirred for about 15 minutes, after which it was
extracted with diethyl ether. The organic extract was washed with water
and dried over anhydrous sodium sulfate, and then the diethyl ether was
removed by distillation under reduced pressure. 5 ml of dimethylformamide
were added to the residue, and the resulting solution was added dropwise
to 15 ml of dimethylformamide containing 3.6 g (100 mmole) of dry hydrogen
chloride at room temperature. The resulting mixture was then stirred for 3
hours. At the end of this time, the greater part of the dimethylformamide
was removed by distillation under reduced pressure, and then water and a
0.1N aqueous solution of sodium hydroxide were added to the residue so as
to adjust its pH to a value of about 11; the mixture was then extracted
with chloroform. The organic extract was washed with water and dried over
anhydrous sodium sulfate. The chloroform was then removed by evaporation
under reduced pressure, and the resulting residue was purified by silica
gel column chromatography, using a 50:1 by volume mixture of chloroform
and methanol as the eluent, to give the title compound as a brown oil in a
yield of 27%.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 3.10-3.20
(4H, multiplet); 3.70-3.80 (2H, multiplet); 6.20 (1H, singlet); 7.27 (1H,
singlet).
Mass spectrum (CI, m/z) : 124 (M.sup.+ +1).
PREPARATION 26
2-Fluorobenzyl 2-fluorocyclopropyl ketone
A procedure similar to that described in Preparation was repeated, except
that an equivalent amount of 2-fluorocyclopropylcarbonyl chloride was used
in place of the cyclobutylcarbonyl chloride, to give the title compound as
a colorless oil in a yield of 27 %.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 1.38-1.58
(2H, multiplet); 2.34-2.56 (1H, multiplet); 3.90 (2H, singlet); 4.54-4.61
& 4.86-4.93 (together 1H, each multiplet); 7.05-7.35 (4H, multiplet).
Mass spectrum (CI, m/z) : 197 (M.sup.+ +1), 109.
PREPARATION 27
2-Fluoro-.alpha.-(2-fluorocyclopropylcarbonyl)benzyl bromide
A procedure similar to that described in Preparation 18 was repeated,
except that an equivalent amount of 2-fluorobenzyl 2-fluorocyclopropyl
ketone was used in place of the
3-(2-chlorobenzyl)-5,6-dihydro-1,4,2-dioxazine, to give the title compound
as a colorless oil in a yield of 76 %.
Nuclear Magnetic Resonance Spectrum (CDCl.sub.3) .delta. ppm: 1.44-1.73
(2H, multiplet); 2.54-2.76 (1H, multiplet); 4.54-4.68 & 4.85-4.99
(together 1H, each multiplet); 5.93 (1H, singlet); 7.05-7.60 (4H,
multiplet).
Mass spectrum (CI, m/z) : 277 (M.sup.+ +2), 275 (M.sup.+), 195.
Top